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ABSTRACT 
 
Background: The Peripheral Benzodiazepine Receptor (PBR) can be classified as a distinct 
receptor from the central benzodiazepine receptor. The PBR gene has been located to 
chromosome 22q13.31 in humans and has been found to consist of four exons, with the first 
and half of the fourth exon being untranslated to form the PBR protein. PBR is involved in 
numerous biological conditions including the regulation of cellular proliferation and 
apoptosis, steroidogenesis, heme biosynthesis, anion and porphyrin transport and 
mitochondrial functions such as oxidative phosphorylation and translocation of cholesterol 
from the outer to the inner mitochondrial membrane. Recent studies showed that the 
expression of PBR correlated with tumour malignancy and patient survival. 
 
Aim: The objectives of this research were to determine the expression pattern and level of 
PBR mRNA in various types of human normal and cancer tissues and to isolate the PBR 
protein. 
 
Materials and Methods: Tissue arrays of multiple organs containing normal and diseased 
tumour tissues that were formalin-fixed were purchased from Cybrdi Inc. (Frederick, 
Maryland, USA). Sense and anti-sense RNA probes were synthesised by in vitro transcription 
and labelled with digoxigenin (DIG). Anti-sense RNA probe complimentary to the PBR 
mRNA was used to localise the PBR mRNA transcript in tissue sections during colorimetric 
and fluorescent in situ hybridisation (ISH and FISH). Human normal and various human 
cancerous cell lines purchased from Highveld Biological (Pty) Ltd (Johannesburg, South 
Africa) were used for relative quantitative real-time PCR in order to determine the expression 
levels of PBR mRNA in the various cell lines. PBR was ligated into the pGEX-6P-2 
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expression vector, which formed a gluthathione-S-transferase (GST) fusion protein when 
induced with isopropyl--D-thiogalactopyranoside (IPTG). 
 
Results: Increase levels of PBR mRNA were seen in Grade II and Grade III liver 
hepatocellular carcinoma, Grade I colonic adenocarcinoma, Grade III stomach squamous cell 
carcinoma, Grade II and Grade III prostate adenocarcinoma of the peripheral duct and acini, 
Grade III breast invasive ductal carcinoma (NST), Grade III lung squamous cell carcinoma, 
kidney chromophobe renal cell carcinoma, kidney clear cell carcinoma, Grade II brain diffuse 
fibrillary astrocytoma, brain primary central nervous system lymphoma and brain 
ependymoma while the expression of PBR mRNA decreased in Grade II and Grade III 
colonic adenocarcinoma, Grade III lung adenocarcinoma and lung small cell carcinoma when 
compared to their normal counterparts. In liver hepatocellular carcinoma, it was found that 
PBR mRNA expression levels decreased as tumours became more invasive while in prostate 
adenocarcinoma of the peripheral duct and acini PBR mRNA expression increased as tumour 
invasion increased. Relative quantitative real-time PCR showed that the expression of PBR 
mRNA decreased in lung adenocarcinoma when compared to lung normal and in the 
cancerous cell lines the concentration of PBR mRNA increases as follows: liver 
hepatocellular carcinoma > cervical carcinoma  lung adenocarcinoma. 
 
Conclusion: PBR mRNA is expressed in most types of human cancer tissues. It is highly 
expressed in most cancerous tissues when compared to its normal counterparts. Expression of 
PBR mRNA varies with tumour malignancy grade. In most cells PBR mRNA is expressed 
cytoplasmically, however, nuclear localisation has been seen in some cells. Determination of 
PBR mRNA expression in the various types of cancer tissues serves as the preliminary step to 
future studies that will elucidate the role of PBR in the development of cancer. 
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1. INTRODUCTION 
 
1.1. Cancer  
1.1.1. Introduction 
Cancer is one of the most important medico-biological problems that still remain unsolved 
(Lokitnov, 2004) and can be seen as a disease involving dynamic changes at multiple sites in 
the genome, which include the discovery of mutations that produce oncogenes that have a 
dominant gain of function and tumour suppressor genes that have a recessive loss of function 
(Hanahan, et al., 2000, Karpinets, et al., 2004). Furthermore, these mutations can be as subtle 
as point mutations and obvious as changes in chromosome complement (Hanahan, et al., 
2000). Thus, it is thought that cancer progression can be seen as analogous to Darwinian 
evolution where a succession of genetic changes that confer some form of growth advantage 
to environmental stresses result in cell survival and genomic instability leading to the 
progressive conversion of normal human cells into cancer cells (Hanahan, et al., 2000, 
Karpinets, et al., 2004, Vineis, 2003). Thus, this conversion of normal cells to cancer cells 
occurs where natural selection occurs through several sequential steps to direct mutations to 
adaptation (Karpinets, et al., 2004, Vineis, 2003). 
 
Normal cells have exquisite machinery that governs cellular fates in response to external 
stimuli (Huang, et al., 2004). The tumour tissue grows as an abnormal analogue of the tissue 
of origin as it is influenced and often governed by the interplay of multiple basically normal 
physiological processes and corresponding regulatory mechanisms, which are not necessarily 
damaged but deregulated or taken out of their physiological context in such a manner that the 
beneficial role in normal cells is now distorted (Lokitnov, 2004). Normal cells are 
transformed into immortal and malignant when there is a loss of control of cell proliferation, 
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differentiation and cell death (Decaudin, et al., 2002, Huang, et al., 2004). Deregulated cell 
proliferation is caused by a loss of balance between cell proliferation and apoptosis at certain 
stages during tumour development (Hsu, et al., 2004).  
 
Numerous genetic factors involved in the pathogenesis of neoplastic growth have been 
identified but the complex mechanism by which it occurs is still not completely understood 
(Lokitnov, 2004). Neoplastic growth should not be regarded as a cell-autonomous process 
intrinsic to the cancer cell because cancer development depends on the changes in interactions 
between malignant cells and their normal neighbours (Lokitnov, 2004). It is usually triggered 
by genetic damage, which causes chromosomal aberrations and somatic mutations and the 
accumulation of these mutations in many genes encoding crucial proteins or oncoproteins that 
control cell growth and apoptosis leads to malignant transformation that occurs as a result of 
loss of cell multiplication and death control (Hsu, et al., 2004, Lokitnov, 2004). These genes 
include those coding for cell cycle regulators such as cyclins, cyclin-dependent kinases 
(CDKs), CDK inhibitors (CDKIs), mainly from the first growth gap (G1) phase of the cell 
cycle and Retinoblastoma (Rb) (Deane, et al., 2005, Reynolds, et al., 1995, Sutter, et al., 
2003), pro-survival genes encoding telomerase, growth factors or their receptors, inhibitors of 
apoptotic proteins such as nuclear factor (NF)-kappa () B, B-cell lymphoma/leukaemia 
(Bcl)-2 and Bcl-XL, the pro-apoptosis genes encoding caspases, Bcl-associated X protein 
(Bax), Bak, Bcl-2-interacting domain death agonist (Bid), fibroblast-associated (Fas), 
receptors for tumour necrosis factor (TNF) alpha () and genes encoding key transcription 
factors or elements for signal transduction lead to apoptosis/survival (Hsu, et al., 2004).  
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Hallmarks to the development of cancer include evasion of apoptosis and uncontrolled cell 
proliferation (Hanahan, et al., 2000, Huang, et al., 2005, Lokitnov, 2004). It is now believed 
that most types of cancers even though they have different manifestations, etiology and 
clinical features share a relatively small number of molecular, biochemical and cellular traits, 
also known as acquired capabilities at the level of development and progression and at the 
level of function of an individual cancer cell since nearly all mammalian cells carry similar 
molecular machinery that regulates cell proliferation, differentiation and cell death (Hanahan, 
et al., 2000, Karpinets, et al., 2004, Lokitnov, 2004). 
 
1.1.2. Carcinogenesis 
Tumorigenesis is characterised by the outgrowth of abnormal cells that is controlled at the 
cellular level (Huang, et al., 2000, Lokitnov, 2004) and can be defined as a multistep process 
that reflect the genetic alterations that drives the progressive transformation of normal human 
cells into a highly malignant derivative (Hanahan, et al., 2000). This progression of the cell 
evolves from normal to malignant to invasive to metastatic cancers (Lokitnov, 2004, 
Hanahan, et al., 2000). Hanahan and Weinberg have suggested that the factors relevant for 
malignancy include: self-sufficiency in growth signals, insensitivity to growth-inhibitory 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, tissue 
invasion and metastasis (Hanahan, et al., 2004, Lokitnov, 2004). Each of these physiological 
factors are acquired during tumour development and can be seen as a successful breaching of 
anticancer defence mechanisms that is hardwired into cells (Hanahan, et al., 2000). Advanced 
stages of neoplasia are characterised by the progressive failure of protective mechanisms 
against tumour growth and spread (Lokitnov, 2004). 
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1.1.2.1. Evasion of Apoptosis 
Tumour cell growth is determined by the rate of cell proliferation and the rate of cell death, 
principally by apoptosis (Hanahan, et al., 2000). Cancer cells have acquired the ability to 
resist apoptosis through a variety of strategies with the most common been the loss of a 
proapoptotic regulator through mutation of the p53 tumour suppressor gene, which results in 
the inactivation of its product that results in the loss of a checkpoint control, which results in 
cells with damaged genomes not undergoing apoptosis and thus allows for defective genomes 
to persist and replicate in daughter cells (Hanahan, et al., 2000, Hsu, et al., 2004). In addition, 
apoptosis can be evaded by tumour cells expressing a non-signalling decoy receptor in order 
to sequester the death factor or by stimulation of survival signal pathways (Herzig, et al., 
2002). 
 
1.1.2.2. Limitless Replicative Potential 
In addition to acquired disruption in cell-to-cell signalling through growth signal autonomy, 
insensitivity to antigrowth signals and resistance to apoptosis, the cell autonomous program 
found in all mammalian cells, which limits multiplication, must also be disrupted (Hanahan, 
et al., 2000). Thus, in order to disrupt any process that places cells in senescence, the Rb and 
p53 tumour suppressor proteins must be disabled, which allows cells to continue to replicate 
without limit known as immortalisation (Hanahan, et al., 2000). Rb and p53 are two 
regulatory proteins that control two major interconnected signalling pathways and when they 
undergo genetic alterations play a role as tumour suppressors in cancer (Deane, et al., 2005, 
Lokitnov, 2004). These two proteins function in the early stage of cancer progression 
(Lokitnov, 2004).  
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Genomic instability that is observed in many types of cancers may occur through 
chromosome missegregation during mitosis. Normally, if this occurs, a checkpoint that 
monitors the proper separation of chromosomes during mitosis results in cell cycle arrest. 
However, a loss of this checkpoint results in accumulation of chromosome missegregation 
(Herzig, et al., 2002). 
 
1.2. Cell Proliferation and the Cell Cycle 
1.2.1. Cell Proliferation 
Cell proliferation can be defined as the expansion of cell populations that is driven by stem 
cell replication that is a major characteristic of developing embryos and young organisms 
(Deane, et al., 2005). In adult organisms, cells are in quiescence but a few exceptions do 
occur such as the epithelia of the gastrointestinal system, which is a continuously renewing 
organ system, and the hepatobillary system, which is a senescent organ system (Deane, et al., 
2005).  
 
During the early phases of cell growth, cells are uncommitted having the capacity to either 
continue their proliferative cycle or to exit the cell cycle and enter differentiation, which is 
dependent on tissue-specific gene expression and extracellular signals derived from the 
microenvironment such as growth factors and cell-cell or cell-matrix contact interactions 
(Deane, et al., 2005, Reynolds, et al., 1995). These extracellular signals include epidermal 
growth factor ligands such as epidermal growth factor (EGF), transforming growth factor 
alpha (TGF), amphiregulin, the “wingless” (Wnt) protein, TGF beta (TGF), platelet derived 
growth factor, fibroblast growth factor, erythropoietin, insulin-like growth factor and large 
families of integrins, interleukins, tumour necrosis factors, interferons, and colon-stimulating 
growth factors (Deane, et al., 2005). Extracellular ligands function in the induction or 
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repression of gene transcription, stabilisation of mRNA transcripts, rate of protein translation 
and posttranslational modification of proteins that includes protein degradation. Furthermore, 
the overall result of all the signalling pathways activated by extracellular growth factors and 
ligands results in either the activation or cessation of the regulatory machinery of the cell 
cycle and thus subsequently controls development and homeostasis (Deane, et al., 2005). 
 
An imbalance of growth inhibitory and growth-promoting effects of factors influencing cell 
cycle, coupled with the lack of accurate positional information can have dire consequences for 
the organism in the form of cancer (Deane, et al., 2005, Reynolds, et al., 1995). 
 
1.2.2. The Cell Cycle 
1.2.2.1. Phases of the Cell Cycle 
The cell cycle or the cell division cycle is the process by which DNA is replicated and a cell 
divided in a series of coordinated events (Collins, et al., 1997). It can be divided into five 
different stages including G0, G1, the S phase, G2 and the M phase (Figure 1-1) (Deane, et al., 
2005). In the G0 phase the cell is in quiescence or in the resting state where it is uncommitted 
having the capacity to enter the cell cycle and undergo proliferation or enter the 
differentiation process (Deane, et al., 2005, Reynolds, et al., 1995). During this state, the cell 
cycle machinery may be partially dismantled (Reynolds, et al., 1995). G1 is the first growth 
gap phase where newly generated cells will typically spend most of their lives (Deane, et al., 
2005, Reynolds, et al., 1995). An additional point located in this phase is known as the 
restriction point. Prior to the restriction point, the cell remains sensitive to a variety of 
negative regulatory signals that counter the effect of mitogenic signals allowing the cell to 
enter and remain in the G0 phase. However, once the cell passes this restriction point, it 
becomes committed to continuing through the rest of the cell cycle (Reynolds, et al., 1995). 
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The S phase is the DNA synthesis phase where DNA replication occurs resulting in the entire 
genome been duplicated (Deane, et al., 2005, Reynolds, et al., 1995). G2 is the second growth 
gap phase where the cell continues to grow in preparation for the M phase (Deane, et al., 
2005, Reynolds, et al., 1995). The M phase is the phase at which mitosis occurs, that is the 
phase at which the duplicated chromosomes split into single chromosomes and nuclear and 
cell division occurs (Deane, et al., 2005, Reynolds, et al., 1995). 
 
 
Figure 1-1: The Cell Cycle  
(Reference: Reynolds, et al., 1995) 
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1.2.2.2. Cell Cycle Control Mechanisms 
Eukaryotic cells have evolved signalling pathways to coordinate cell-cycle transitions and 
ensure faithful replication of the genome before cell division (Stewart, et al., 2003). There are 
at least two types of cell cycle control mechanisms that are recognised: (i) a cascade of 
protein phosphorylations that coveys a cell from one stage to the next and (ii) a set of 
checkpoints that monitor completion of critical events if necessary (Collins, et al., 1997).  
 
Proteins involved in the cell cycle include cyclin proteins, cyclin-dependent kinases (CDKs), 
CDK inhibitors (CDKIs), master regulatory proteins Rb and p53 and the E2F transcription 
factor that are usually activated by extracellular signals (Deane, et al., 2005). They function in 
guiding the cell through the different distinct and sequential replicative stages of the cell cycle 
(Deane, et al., 2005, Reynolds, et al., 1995). 
 
1.2.2.2.1. Cascade of Protein Phosphorylations 
This control mechanism involves a highly regulated protein kinase family known as cyclins, 
whose expression is restricted by transcriptional regulation of cyclin-encoding genes and by 
ubiquitin-mediated degradation. Cyclins are a family of proteins that are highly conserved in 
evolution and are so named because their expression levels are cyclic, that is each cyclin is 
synthesised at a unique and discrete point in the cell cycle and degraded at a second relatively 
discrete point, which is coincidental with the different stages of the cell cycle (Deane, et al., 
2005, Reynolds, et al., 1995).  
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Activation of this kinase family requires association with a second subunit of catalytic 
proteins that is expressed constitutively at the appropriate period of the cell cycle and is 
known as the cyclin-dependent kinases (CDKs) resulting in the formation of an active 
complex with an unique substrate specificity (Collins, et al., 1997, Deane, et al., 2005, 
Stewart, et al., 2003). Regulation by phosphorylation and dephosphorylation perfects the 
activity of the CDK-cyclin complexes, thus ensuring well-delineated transitions between cell 
cycle stages (Collins, et al., 1997, Stewart, et al., 2003). These activated complexes then 
trigger the activation of the downstream phases of the cell cycle (Deane, et al., 2005). 
 
The complexes cyclin D-CDK4, cyclin D-CDK6 and cyclin E-CDK2 regulates the 
progression of the cell from the G1 phase to the S phase (Figure 1-1). Activation of cyclin D-
CDK4/6 results in the progression of the cell through the G1 checkpoint after which it is 
degraded and cyclin E-CDK2 is activated resulting in the transition of the cell from the G1 to 
S phase of the cell cycle (Deane, et al., 2005, Reynolds, et al., 1995, Stewart, et al., 2003).  
 
Rb is a crucial substrate of activated cyclin-CDK complexes in G1 phase. It is sequentially 
phosphorylated by cyclin D-CDK4/6 and cyclin E-CDK2 during G1 phase progression and 
either represses or activates transcription depending on its phosphorylation state and 
associated proteins. Hypophosphorylated Rb and Rb-related “pocket” proteins such as p107 
and p130 binds to and inactivates members of the E2F family of transcription factors and 
arrests cells in the G1 phase (Deane, et al., 1995, Stewart, et al., 2003). E2F family members 
mediate transcription of genes required for DNA synthesis. (Stewart, et al., 2003). During G1 
phase progression, CDK-mediated hyperphosphorylation of Rb and its cousins results in the 
dissociation of Rb and E2F, which enters into the nucleus where it acts as a transcription 
factor functioning in the expression of genes whose products are required for and results in 
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the entry of the cell into the S phase (Deane, et al., 2005, Reynolds, et al., 1995, Stewart, et 
al., 2003).  
 
The rest of the phases of the cell cycle consists of a sequential activation of proteins such as 
the cyclin/CDK complexes that are exquisitely sensitive to cellular integrity and is essentially 
protected from extracellular influences (Deane, et al., 2005, Reynolds, et al., 1995). Thus, the 
late phases of the cell cycle have been described as a cell autonomous process (Deane, et al., 
2005). In the S phase, cyclin D-CDK4/6 and cyclin-E-CDK2 is degraded prior to DNA 
synthesis and replication and cyclin A-CDK2 forms resulting in the progression of the cell 
through the S phase and in the initiation of DNA and histone biosynthesis (Deane, et al., 
2005, Reynolds, et al., 1995). Once successful DNA replication has occurred, cyclin A-CDK2 
levels are decreased and the cell enters into the G2 phase where the cyclin B-CDK1 complex, 
also known as the mitosis promoting factor accumulates and functions in regulating the 
progression of the cell from G2 to the M phase (Deane, et al., 2005, Stewart, et al., 2003). 
After mitosis, cyclin B is degraded rapidly to prevent a second round of division. (Deane, et 
al., 2005). 
 
During the G2 phase, inactive cyclin B-CDK1 complexes accumulate through the 
phosphorylation of CDK1 by Wee1 and Myt1 resulting in its inhibition. In order for the cell 
to enter the M phase, the cyclin B-CDK1 complexes are activated by cell division cycle (Cdc) 
25C phosphatase, which functions in the dephosphorylation of CDK1 while termination of the 
M phase occurs after ubiquitination and proteolytic degradation of cyclin B by the anaphase-
promoting complex (APC), which results in the inactivation of CDK1 (Stewart, et al., 2003). 
Cyclin B-CDK1 is a complex that is regulated at many levels especially through p53 activity, 
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which blocks M phase entry when DNA is damaged, causing the cell to undergo apoptosis 
(Deane, et al., 2005).  
 
1.2.2.2.2. Cell Cycle Checkpoints 
The cell cycle is regulated by a checkpoint control that has a more supervisory role and does 
not form an essential part of the cycle progression machinery (Collins, et al., 1997). These 
cell cycle checkpoints are control mechanisms developed by eukaryotic cells that function in 
sensing flaws during critical events such as DNA replication and chromosome segregation 
and in response to stress (Collins, et al., 1997, Stewart, et al., 2003). The checkpoint control 
consists of three elements; (i) stimuli such as under replicated or damaged DNA that activate 
the checkpoints, (ii) signal transduction machinery are relayed to (iii) the cell-cycle 
progression machinery, that is the different basal cell cycle regulators forming the targets 
(Samuel, et al., 2002). These signals cause a delay in cycle progression, until the danger of 
mutation has been averted, thus resulting in the repair of cellular damage (Collins, et al., 
1997, Stewart, et al., 2003). Thus, a DNA damage checkpoint can be regarded as a coherent 
signal transduction system that allows for the transfer of information from a DNA lesion to 
the cell cycle (Samuel, et al., 2002). However, if the damage is irreparable, the checkpoint 
signalling can activate pathways that result in apoptosis (Stewart, et al., 2003). Thus, it should 
be noted that a loss of checkpoint integrity allows for the accumulation of DNA lesions that 
results in permanent genomic alteration (Stewart, et al., 2003). 
 
CDKs are negatively regulated by a group of functionally related proteins called CDKIs, 
which can be divided into two families: (i) the inhibitor of CDKs (INK) 4 family, which 
consists of four members including the p16INK4a, p15INK4b, p18INK4c and p19INK4d and (ii) the 
cyclin-dependent kinase inhibitor protein (CIP/KIP) family, which consists of three members 
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including the p21Waf1/Cip1, p27Kip1 and p57Kip2 (Deane, et al., 2005, Stewart, et al., 2003). The 
INK4 family of inhibitors inhibit CDK4 and CDK6 during the G1 phase of the cell cycle 
while the CIP/KIP family of inhibitors inhibit CDK activity during all phases of the cell cycle 
(Deane, et al., 2005, Stewart, et al., 2003). The presence of CDKI in the cell is regulated at 
several levels including imprinting programs for p57Kip2, transcriptional activation through Rb 
for p16INK4a or p53 for p21Waf1, TGF signalling for p15INK4b, p21Waf1 and p27Kip1 and 
posttranslational mechanisms such as ubiquitin-mediated proteolysis for p27Kip1 (Deane, et 
al., 2005). Interaction of CDKIs with cyclin/CDK complexes is stochastic and dose dependent 
having implications in both cell cycle activation and apoptosis, thus the cellular processes that 
trigger the production and degradation of the cyclins or CDKIs regulate cell proliferation 
(Deane, et al., 2005). 
 
Different types of checkpoints exist throughout the cell cycle monitoring different aspects of 
DNA replication and chromosome segregation and regulation of different phases of the cell 
cycle. These include the: (i) G1 checkpoint that controls entry into S phases and protects 
against DNA damage, (ii) the G2 checkpoint that monitors the completion of DNA 
replication, chromosomal damage and entry into the M phase and (iii) the M checkpoint, 
which arrests mitosis if chromosomes are not properly aligned along the mitotic spindle 
(Figure 1-1) (Reynolds, et al., 1995). 
 
1.2.2.2.2.1. The G1 and G2 Checkpoints 
The G1 checkpoint and the G2 checkpoint are sensory states that are controlled by the Rb and 
p53 respectively (Deane, et al., 2005). These checkpoints function in surveying the cell for 
deviations from the normal proliferation program. These deviations include imbalances of 
cellular proteins and/or the coincident activation of conflicting signalling cascades (Deane, et 
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al., 2005, Reynolds, et al., 1995). However, when these deviations do occur Rb and p53 
mediate the cessation of proliferation and the induction of apoptosis or it slows down the 
progression of the cell through the cell cycle allowing the damaged DNA to be repaired and 
thus prevents the propagation of genetic mutations and aberrant, unregulated growth (Deane, 
et al., 2005, Reynolds, et al., 1995). 
 
1.2.2.2.2.1.1. The G1 Checkpoint 
The G1 checkpoint functions in the inhibition of cyclin-CDK complexes activated during the 
G1 phase (Stewart, et al., 2003). Exposure of normal cells to genotoxic agents results in the 
activation of p53, which in turn results in the transcription of p21Waf1/Cip1. This protein binds 
to and inactivates cyclin D-CDK4/6 and cyclin E-CDK2 complexes resulting in Rb 
hypophosphorylation and cell cycle arrest during the G1 phase (Stewart, et al., 2003). 
 
1.2.2.2.2.1.2. The G2 Checkpoint 
The G2 checkpoint, which is also known as the G2/M checkpoint functions in preventing the 
initiation of mitosis when the cell has been exposed to DNA damage during G2 or when the 
cell has progressed into G2 with unrepaired damage acquired during the previous phases of 
the cell cycle (Kastan, et al., 2004). Cell cycle arrest is initiated in the G2 phase via 
checkpoint pathways that are triggered by genotoxic stress (Stewart, et al., 2003). For 
example, DNA damage triggers the activation of two phosphatidylinositol-3-kinase (PI-3K)-
related proteins ataxia telengiectasia mutated (ATM)- and ATM and Rad3-related (ATR)- 
dependent signalling, which induces G2 cell cycle arrest via the inhibition of CDK1 (Samuel, 
et al., 2002, Stewart, et al., 2003). Cells that are exposed to ionising radiation result in the 
activation of the ATM pathway, which in turn activates human checkpoint kinase (Chk)2 
while cells that are exposed to ultraviolet radiation results in the activation of the ATR 
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pathway, which in turn activates Chk1. Thereafter, both Chk1 and Chk2 trigger the 
phosphorylation of Cdc25C, which results in the consensus binding site for 14-3-3 protein.  
The binding of 14-3-3 proteins to Cdc25C results in the nuclear export and cytoplasmic 
sequestration of the phosphatase, with subsequent G2 arrest through the inhibition of CDK1 
(Stewart, et al., 2003). 
 
1.3. Apoptosis 
Cell death can occur via apoptosis, necrosis, autophagic cell death or other forms of cell death 
that cannot be easily classified (Debatin, 2004, Hsu, et al., 2004). Apoptosis or programmed 
cell death, which was originally defined in 1972, can be defined as a distinct physiological 
mode of cellular suicide that occurs under various physiological and pathological conditions 
(Debatin, 2004, Hsu, et al., 2004, Scoltock, et al., 2004). It is a tightly controlled process 
where cell death is executed through the activation of specific signalling pathways 
functioning as an important mechanism to regulate cell death signalling (Huang, et al., 2004, 
Pulido, et al., 2003). Apoptosis plays a pivotal role in embryogenesis, development, immune 
response, morphogenesis, pathophysiology and normal tissue homeostasis thus any disruption 
in this process can have severe consequences (Pulido, et al., 2003, Scoltock, et al., 2004). The 
discovery of apoptosis has stimulated contemporary concepts in the development of cancer 
and other diseases (Hsu, et al., 2004). There are positive and negative regulatory pathways of 
apoptosis and a balance between these pathways determines cell fate (Pulido, et al., 2003).  
 
The morphological and biochemical features of apoptosis are distinct (Debatin, et al., 2004, 
Huang, et al., 2004) and include depolarisation of the plasma membrane, phosphotidylserine 
translocation, membrane blebbing, cell shrinking, alterations in intracellular ion 
concentrations, mitochondrial membrane depolarisation and disruption in mitochondrial 
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membrane integrity, nuclear condensation, chromatin aggregation, degradation of DNA and 
apoptotic body formation prior to cell lysis (Figure 1-2) (Debatin, et al., 2004, Decaudin, et 
al., 2002, Hsu, et al., 2004, Pulido, et al., 2003, Scoltock, et al., 2004). Neighbouring cells 
and macrophages then rapidly digest cellular fragments or apoptotic bodies without inducing 
inflammation or damage (Pulido, et al., 2003).  
 
 
Figure 1-2: Morphological Features of Apoptosis 
(Reference: URL: http://www-micro.msb.le.ac.uk/3035/kalmakoff/baculo/pics/Apoptosis.gif) 
 
Apoptosis occurs in many organelles including the mitochondria, endoplasmic reticulum, 
Golgi apparatus and lysosomes (Pulido, et al., 2003). However, most research has focused on 
the role of mitochondria in apoptosis, which is considered to be the regulatory centre of the 
apoptotic process and plays an important role in cellular homeostasis (Pulido, et al., 2003, 
Strohmeier, et al., 2002).  
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The biochemical and molecular factors regulating apoptosis are complex and not completely 
defined. However, some regulatory mechanisms that have been identified include death 
receptors, cysteinyl aspartate-specific proteases (caspases), mitochondria, Bcl-2 family of 
proteins and tumour suppressor genes (Pulido, et al., 2003). 
 
1.3.1. Pathways of Apoptosis 
Diverse internal and external stimuli including damage of DNA or other critical molecules or 
subcellular structures propagate the cellular stress response that initiates apoptosis through 
complex signal transduction pathways that eventually lead to a central cascade of effectors 
that mediate the final stages of cell death (Debatin, et al., 2004, Scoltock, et al., 2004). 
Distinct pathways are activated depending on both the cell type and the initiating factor 
(Pulido, et al., 2003). Two primary modes of apoptosis have been identified: (i) the extrinsic 
pathway or receptor pathway, which is mediated via Fas or TNF receptors at the plasma 
membrane and (ii) the intrinsic pathway or mitochondrial pathway, which is mediated by the 
disruption of cellular homeostasis and is initiated intracellularly at the mitochondria (Debatin, 
2004, Huang, et al., 2004, Pulido, et al., 2003). However, even though these two pathways are 
divergent with respect to induction, they tend to converge at later stages and may be 
interconnected at different levels (Debatin, 2004, Pulido, et al., 2003). 
 
1.3.1.1. Caspases 
Caspases are aspartate-specific cysteine proteases that function as cytoplasmic proenzymes 
that play an important role in the initiation and effector phases of apoptosis (Debatin, 2004, 
Pulido, et al., 2003). These proteins are synthesised as inactive zymogens that are activated by 
proteolytic cleavage, that is cleavage takes place between the large subunit and the small 
subunit of caspases (Debatin, 2004). Once activated, they target important cellular proteins 
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that are important in both the extrinsic and intrinsic pathway of apoptosis (Pulido, et al., 
2003).  
 
Depending on their substrate specificity, two types of caspases have been identified. These 
include the initiator caspases that function in the initiation and amplification of the death 
signal and thus functions as a direct link to death-inducing signalling complexes (DISCs) and 
the effector caspases that function in the degradation of vital cellular components that may be 
cytoplasmic or nuclear marking the morphological features of cell death (Debatin, 2004, 
Pulido, et al., 2003). Examples of initiator caspases include caspase-8, caspase-9 and caspase-
10 and examples of effector caspases include caspase-2, caspase-3, caspase-4, caspase-6 and 
caspase-7 (Pulido, et al., 2003). 
 
Furthermore caspases are capable of activating other caspases, thus resulting in the activation 
of the caspase cascade. For example, caspase-8 activates caspase-3, caspase-4, caspase-7 and 
caspase-9 while caspase-9 activates caspase-3 and caspase-7 (Pulido, et al., 2003). Caspase-3 
is the most potent effector caspase having many substrates that results in the amplification of 
the c-Jun amino-terminal kinase (JNK) pathway by cleaving MAPK/extracellular-signal 
related kinase (ERK) kinase (MEK) kinase (MEKK)1 (Pulido, et al., 2003). 
 
The activation of the caspase cascade resulting in apoptosis is regulated by a variety of 
proteins that act as cofactors such as apoptosis activating factor (Apaf)-1 and inhibitors such 
as Fas-associated death domain (FADD)-like interleukin-1 converting enzyme inhibitory 
protein (FLIP) and inhibitors of apoptosis protein (IAP) (Pulido, et al., 2003). Inappropriate 
caspase activity can have a potentially detrimental effect on cell survival, thus the activation 
of caspases has to be tightly controlled (Debatin, 2004).  
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1.3.1.2. Extrinsic or Death Receptor Pathway of Apoptosis 
The extrinsic pathway of apoptosis is activated when external signals or ligands interact with 
a death receptor on the plasma membrane resulting in the initiation of a cascade of events that 
leads to apoptosis  (Figure 1-3) (Pulido, et al., 2003). The death receptor family includes TNF 
receptors (TNFR) such as cell determinant (CD)95 (apoptosis-mediating surface antigen Fas 
(APO)-1/Fas), Fas, TNF-related apoptosis inducing ligand (TRAIL) receptor death receptors 
and decoy receptors (Debatin, 2004, Huang, et al., 2004) and consists of an extracellular 
cysteine-rich ligand binding domain and an intracellular death domain (Pulido, et al., 2003). 
Once a ligand binds to the death receptor, this receptor interacts with death adaptor proteins 
such as FADD, receptor-integrating protein (RIP), dishevelled anadaxin domain (DAX) and 
TNFR-I-associated death domain (TRADD) which in turn activates caspases and signalling 
pathways such as MAPK and NF-B (Pulido, et al., 2003). Thereafter, the death domain 
adaptor proteins remain attached to the activated death receptors and with other signalling 
molecules form the DISC, which recruits and activates initiator caspases such as caspase-8 
and caspase-10 via their death effector domain, which then activate other downstream initiator 
caspases such as caspase-4 and caspase-9 and effector caspases such as caspase-3, caspase-6, 
caspase-7, which degrade a variety if cellular components resulting in apoptosis (Debatin, 
2004, Pulido, et al., 2003, Scoltock, et al., 2004).  
 
Caspase-8 may also result in the cleavage of Bcl-2-interacting domain death agonist (Bid), a 
Bcl-2 Homologue (BH)3 domain containing protein of the Bcl-2 family (Figure 1-3). This 
truncated form of Bid translocates to the mitochondrial membrane where it complexes with 
Bax and lipids resulting in the release of cytochrome c and downstream activation of caspase-
9 and thus apoptosis. Thus, Bid results in the initiation of the mitochondrial amplification 
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loop (Debatin, 2004, Hsu, et al., 2004, Scoltock, et al., 2004). The activation of caspase-6 
may feed back into the extrinsic pathway by cleaving caspase-8 (Debatin, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3: Extrinsic or Death Receptor Pathway of Apoptosis 
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1.3.1.2.1. The Influence of Mitogen-Activated Protein Kinase Pathways in Extrinsic 
Apoptosis Pathway 
The mitogen-activated protein kinase (MAPK) superfamily is made up of three 
serine/threonine kinase cascades including: (i) the extracellular-signal-related kinases (ERKs) 
pathway, which respond to growth factors or other external mitogenic signals and functions in 
the induction of cell proliferation, cell differentiation, cell survival and the inhibition of death 
signals (Torii, et al., 2004), (ii) the p38 MAPK pathway and  (iii) the JNK pathway, both of 
which are stress-activated kinases that function in the induction of inflammation or in some 
cases apoptosis (Olson, et al., 2004). Hence, the activation of the p38 MAPK pathway has 
pro-apoptotic effects while the activation of the ERK pathway has anti-apoptotic effects and 
cell survival, thus functioning as opposing faces of each other (Pulido, et al., 2003, Sutter, et 
al., 2004). 
 
Activated death receptors also activate other signalling pathways that play a significant role in 
apoptosis. For example, the activation of TNFR results in the initiation of the JNK/MAP 
kinase pathway leading to the phosphorylation of pro-apoptotic and anti-apoptotic proteins 
and the regulation of gene expression and the activation of caspase-3 results in the activation 
of the JNK pathway through the cleavage of MEKK (Pulido, et al., 2003). The JNK pathway 
is also thought to play a role in the inhibition of Bcl-2 and in the phosphorylation of an 
essential transcription factor c-jun (Pulido, et al., 2003). 
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1.3.1.2.1.1. The Extracellular-Signal-Related Kinase Pathway 
In quiescent cells, ERK is located in the cytoplasm in association with MAPK kinases 
(MAPKKs), MEK1 and MEK2, dual specificity kinases that phosphorylates ERK (Figure 1-
4). Extracellular stimuli such as growth factors that bind to a receptor on the plasma 
membrane stimulates the activation of the Ras family of oncoproteins and protein kinase 
(PK)C, which stimulates the activation of riboflavin-aldehyde forming enzyme (Raf)1, which 
in turn stimulates the phosphorylation MEK1/2 and the downstream phosphorylation of ERK, 
which results in the dissociation of ERK from MEK1/2 (Fang, et al., 2005, Sutter, et al., 
2004, Torii, et al., 2004). PKC stimulates the binding of guanosine triphosphate (GTP) to 
members of the Ras family leading to Raf1 activation while members of the Ras family 
guanosine triphosphatases (GTPases) switch from the inactive guanosine diphosphate (GDP)-
bound form to the active GTP-bound form, which interacts with and activates Raf1 (Fang, et 
al., 2005). Several subtypes of the ERK family of protein exist including ERK-1, ERK-2, 
ERK-3, ERK-5 and ERK-6 (Fang, et al., 2005). The released ERK activates cytoplasmic 
targets such as membrane proteins or is translocated to the nucleus via three mechanisms: (i) 
passive diffusion of a monomer, (ii) active transport of a dimer that is mediated by GTPase 
Ras-related protein (Ran) and the importin- family and (iii) Ran/importin- family 
independent transport that is mediated by direct interaction of ERK with the nuclear complex 
(Fang, et al., 2005). When in the nucleus ERK phosphorylates and activates a variety of 
nuclear targets including transcription factors such as c-Fos and Elk-1 that function in the 
induction of cell proliferation, differentiation, cell survival and in the inhibition of apoptosis 
as well as protecting cell against apoptosis (Fang, et al., 2005, Torii, et al., 2004). 
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Figure 1-4: The Extracellular Signal-Related Pathway  
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The ERK signalling pathway is inhibited by Sprouty through various proteins and Sprouty-
related protein with Enabled (Ena)/ vasodilator-stimulated phosphoprotein (VASP) homology 
(EVH)-1 domain (Spred) at the level of Raf by binding to Ras and Raf (Figure 1-4) (Torii, et 
al., 2004). Sef is another protein that is a negative feed back inhibitor of the ERK signalling 
pathway. It is thought to act downstream or at MEK and inhibits phosphorylation of ERK or 
specifically blocks ERK nuclear translocation without inhibiting its activity in the cytoplasm  
(Figure 1-4) (Torii, et al., 2004). 
 
1.3.1.2.1.2. The p38 Mitogen-Activated Protein Kinase Pathway 
The p38 MAPK pathway, which was first described in 1994, regulates a variety of cellular 
responses in response to stress, inflammation and other signals (Olson, et al., 2004). There are 
four different isoforms of p38 MAPK, namely p38 MAPK-, p38 MAPK-, p38 MAPK- 
and p38 MAPK-
. The p38 MAPK- and p38 MAPK- are expressed in most tissues while 
the p38 MAPK- and the p38 MAPK-
 have a limited tissue expression (Olson, et al., 2004). 
 
Stimuli including environmental stresses such as heat shock, inflammatory cytokines, TNF- 
and interleukin-1 are delivered to p38 MAPK pathway via small GTPases of the rennin 
angiotensin system homology (Rho) family that includes Rac, Rho and Cdc42 (Figure 1-5). 
The Rho family induces the phosphorylation of MAPKK-3 and MAPKK-6. Apoptotic stimuli 
activate apoptosis signal-regulating kinase (ASK)-1, which directly activates MAPKK-3 and 
MAPKK-6. MAPKK-3 and MAPKK-6 then phosphorylates and activates the 
unphosphorylated and inactive p38 MAPK. This active p38 MAPK then phosphorylates and 
activates activating transcription factor (ATF)-2, CCAAT/Enhancer binding protein (C/EBP) 
homologous protein (CHOP)-1, myocyte enhancer factor (MEF)-2 and other transcription 
factors, cell cycle regulators p53 and p73 and immediate targets such as MNK-1, mitogen and 
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stress-activated kinase (MSK)-1/2, Elk-1, MAPK-activated protein (MAPKAP)-2, MAPKAP 
kinase (MAPKAPK)-3 and heterogeneous nuclear ribonuclear protein (hnRNP). These 
phosphorylated proteins than result in the activation of various cellular processes, including 
cell-cycle arrest, apoptosis, cytokine production, regulation of RNA splicing and cell 
differentiation. In addition, it indirectly induces the cyclic adenosine monophosphate 
responsive element binding protein (CREB) cycle via the activation of MSK-1 (Olson, et al., 
2004). 
 
The active p38 MAPK is inactivated by phosphatases such as protein phosphatase 1, protein 
phosphatase 2A or MAPK phosphatase. These phosphatases are activated by the phospho-p38 
MAPK, which suggest that there is a tight regulation of active p38 MAPK (Olson, et al., 
2004). 
 
1.3.1.3. Intrinsic or Mitochondrial Pathway of Apoptosis 
1.3.1.3.1. The Mitochondrial Permeability Transition Pore 
The mitochondrial permeability transition pore (MPTP), which is also known as the mega 
channel or multiple conductance channel, is a large multiprotein complex formed at the 
contact site between the inner and the outer mitochondrial membranes (Casellas, et al., 2002, 
Hans, et al., 2005, Jordà, et al., 2005). Although the exact structure of the MPTP is not 
known, it is thought to be composed of six proteins including: (i) the hexokinase located in 
the cytosol that converts glucose to glucose-6-phosphate, which is the initial phosphorylated 
intermediate in the glycolytic pathway and is an important precursor of many cellular building 
blocks, (ii) the voltage-dependent anion channel (VDAC), which is also known as the 
mitochondrial porin located in the outer membrane functions as the main pathway in 
metabolite diffusion across the outer mitochondrial membrane, (iii) creatine kinase located in 
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the intermembrane space facilitates the production and export of phosphocreatine into the 
cytosol after which it enters into the creatine/phosphocreatine circuit and thus provides an 
efficient buffering and transport system connecting energy production sites (mitochondria and 
glycolysis) with energy consumption sites (adenosine triphosphatases (ATPases)), (iv) the 
adenine nucleotide carrier (ANC), which is also known as the adenine nucleotide transporter 
(Veenman, et al., 2004) located in the inner membrane functions as an antiporter for the 
exchange of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) as part of 
oxidative phosphorylation, (v) cyclophilin D located in the mitochondrial matrix where it 
interacts with the ANC and (vi) the peripheral benzodiazepine receptor (PBR) (Figure 1-6) 
(Decaudin, et al., 2002, Casellas, et al., 2002).  
 
MPTP also functions as the critical area for the metabolic coordination between the cytosol, 
the mitochondrial intermembrane space and the mitochondrial matrix as it helps regulate 
matrix calcium ion concentration, hydrogen ion concentration (pH), transmembrane 
electrochemical gradient that drives ATP synthesis, and mitochondrial volume by acting as a 
calcium-gated channel, voltage-gated channel, pH-gated channel and a redox-gated channel
 
with several levels of conductance and little ion selectivity (Casellas, et al., 2002). 
 
Furthermore, the MPTP functions in the process of cell damage and death, that is, in the 
initiation and regulation of apoptosis in various cells including hepatocytes, fibroblasts, and 
thymocytes and is also thought to function in several oncogenic processes (Decaudin, et al., 
2002, Jordà, et al., 2005). Therefore, it is considered the central executioner of cell fate 
(Casellas, et al., 2002) and is believed to be the key regulator of stress-associated signals 
(Maaser, et al., 2005). Exposure to factors such as growth factor removal, exposure to 
cytokines like TNF- and high calcium concentrations coupled with low adenine nucleotide 
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concentrations, high phosphate concentrations, oxidative stress and the Bcl-2 family of 
proteins results in the opening of the MPTP, which leads to either necrosis if ATP production 
is severely impaired or to apoptosis when ATP production remains normal (Hans, et al., 
2005). Pharmacological inhibition of this pore prevents cell death (Decaudin, et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5: The p38 Mitogen-Activated Protein Kinase Pathway  
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Figure 1-6: Schematic Structure of the Mitochondrial Permeability Transition Pore 
(Reference: Casellas, et al., 2002) 
 
1.3.1.3.2. The Mitochondrial Permeability Transition Pore and the Intrinsic Pathway of 
Apoptosis 
The intrinsic pathway of apoptosis occurs through three general mechanisms including: (i) the 
caspase-dependent pathway, which involves the activation of caspases that coordinate 
downstream events often associated with apoptosis, (ii) the caspase-independent pathway and 
(iii) loss of mitochondrial functions that are essential for cell survival (Green, et al., 2004). 
These events all occur as a result of mitochondrial membrane permeabilisation (Green, et al., 
2004). 
 
1.3.1.3.2.1. Caspase-Dependent Pathway of Apoptosis 
The intrinsic pathway is initiated within the cell, most often through the disruption of cellular 
homeostasis resulting in the opening of the MPTP that is extensive and prolonged after which 
the mitochondrial membrane permeability suddenly increases and results in the loss of 
mitochondrial transmembrane potential (m) before, during or after mitochondrial 
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membrane permeabilisation, which in turn results in the uncoupling of the mitochondria and 
causes swelling, thus putatively serving as the initial event leading to apoptosis (Casellas, et 
al., 2002, Green, et al., 2004, Pulido, et al., 2003, Hans, et al., 2005, Maaser, et al., 2005, 
Strohmeier, et al., 2002). This instability of the mitochondrial membrane results in the release 
of intermembrane apoptogenic proteins, that is proteins located between the inner and the 
outer mitochondrial membrane such as apoptosis inducing factor (AIF), cytochrome c, 
procaspase-2 or procaspase-9, second mitochondrial activator of caspases (Smac)/direct IAP 
binding protein with low isoelectric point (pI) (Diablo), Omi/high temperature requirement 
protein (Htr) A2 and endonuclease G into the cytosol (Figure 1-7A) (Debatin, 2004, Green, et 
al., 2004). Smac/Diablo and Omi/HtrA2 induce caspase activation by neutralising the 
inhibitory effects of IAPs and cytochrome c forms a complex with Apaf-1 and procapase-9 
via its caspase recruitment domain (CARD) domain, which is known as the apoptosome 
resulting in the activation of a proteolytic cascade that cleaves procaspase-9 to active caspase-
9, which in turn leads to the activation of caspase-3 from procaspase-3 (Debatin, 2004, Hans, 
et al., 2005, Huang, et al., 2004, Pulido, et al., 2003).  
 
Caspase-3, which is the executioner of the caspase cascade, then activates a variety of 
enzymes that are critical for inducing the structural changes of the nucleus, cytoskeleton and 
plasma membrane that is characteristic of apoptosis and the repair proteins (Huang, et al., 
2004, Hsu, et al., 2004, Casellas, et al., 2002). These include proteins such as Poly (ADP-
Ribose) Polymerase (PARP), apoptotic chromatin condensation inducer in the nucleus 
(Acinus), fodrin, gelsolin, actin, plectrin, cytokeratin, inhibitor of caspase-activated 
deoxyribonuclease (ICAD), X-linked IAP (XIAP), signal transducer and activator of 
transcription (STAT)-1, topoisomerase-1, vimentin, lamin, Rb (Debatin, 2004, Hsu, et al., 
2004). ICAD is the inhibitor of endonuclease caspase-activated deoxyribonuclease (DNase) 
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(CAD) that functions in the cleavage of DNA into characteristic oligomeric fragments while 
Acinus functions in DNA condensation  (Debatin, 2004). Proteolysis of cytoskeletal proteins 
such as gelsoloin, actin, plectrin, and cytokeratin results in loss of overall cell shape and lamin 
results in nuclear shrinking and budding (Debatin, 2004). It should be noted that PARP and 
lamin might also be activated by caspase-7 and caspase-6 (Hsu, et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-7: Intrinsic or Mitochondrial Pathway of Apoptosis  
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1.3.1.3.2.2. Caspase-Independent Pathway of Apoptosis 
Mitochondrial-induced apoptosis may also involve a caspase-independent pathway (Huang, et 
al., 2004). In this case, an apoptotic stimulus results in an increase in mitochondrial 
membrane permeability and thus decrease in m, which allows for the release of AIF in the 
presence of cyclophilin A and endonuclease G, which activates a DNase that causes DNA 
cleavage and thus ultimately leads to apoptosis (Figure 1-6B) (Green, et al., 2002, Pulido, et 
al., 2003). 
 
The excessive generation of reactive oxygen species (ROS) in apoptosis as a result of stimuli 
such as UV radiation is an important factor in apoptosis because the mitochondria are the 
source and target of excessive ROS production (Pulido, et al., 2003, Scoltock, et al., 2004). 
Excessive ROS production results in an increase in mitochondrial membrane permeability and 
damage of the respiratory chain that results in further increased ROS production. Disruption 
in the mitochondrial membrane results in the release of cytochrome c from the mitochondria, 
which initiates events leading to apoptosis (Pulido, et al., 2003). Further, it is thought that 
ROS production plays a role in TNFR and Fas receptor-mediated apoptosis although the 
mechanism by which this occurs is not known (Pulido, et al., 2003). 
 
Tumour suppressor genes are able to induce apoptosis. For example, p53, which functions in 
the regulation of gene expression, is activated in response to DNA damage and UV radiation 
(Pulido, et al., 2003, Scoltock, et al., 2004). p53 may induce apoptosis by suppression of Bcl-
2 and the transactivation of several genes that contribute to apoptosis such as Bax and Fas. 
Also, p53 may function in a caspase-independent manner by activating Bax, which in turn 
results in the release of cytochrome c, which then activates caspase-9. Furthermore, p53 up 
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regulates the expression of genes involved in ROS production and metabolism (Pulido, et al., 
2003). 
 
1.3.1.3.3. Regulatory Mechanisms Involved in Intrinsic Pathway of Apoptosis 
The exact mechanisms regulating the opening of the MPTP and the release of apoptogenic 
factors are not completely understood but it may vary in different cell lineages and types of 
stress (Maaser, et al., 2005). 
 
1.3.1.3.3.1. The Bcl-2 Family of Proteins 
A family of proto-oncogenes known as the Bcl-2 family regulates mitochondrial membrane 
permeability as it localises to the mitochondrial membrane and thus induces or suppresses 
apoptosis (Casellas, et al., 2002, Debatin, 2004, Pulido, et al., 2003, Maaser, et al., 2005). 
The Bcl-2 family of proto-oncogenes can be divided into three types: the anti-apoptotic 
members such as Bcl-2, Bcl-XL and Mcl-I, the pro-apoptotic members such as Bax, Bak and 
Bcl-2-antagonist of cell death protein (Bad) and the BH3 domain-only molecules that link the 
extrinsic pathway to the intrinsic pathway such as Bid, Bcl-2-interacting mediator of cell 
death (Bim), a microtubule-associated protein, Puma and nicotinamide adenine dinucleotide 
hydrogenase (NADH) oxidase (Noxa), which are p53-induced proteins (Debatin, 2004, 
Huang, et al., 2004, Pulido, et al., 2003). Thus, a balance between the anti-apoptotic members 
and the pro-apoptotic members determines cell fate (Pulido, et al., 2003). 
 
When activated by BH3 domain-only proteins, Bax and its family members with 
multidomains, which resides in the cytosol translocates and is inserted into the outer 
mitochondrial membrane where it interacts with ANC and oligomerises to form a pore-like 
structure that results in the release of cytochrome c. Bax and its family members also induce 
an increase in mitochondrial membrane permeability and m that promotes the release of 
 32 
cytochrome c, which in turn results in apoptosis (Figure 1-8) (Casellas, et al., 2002, Debatin, 
2004, Pulido, et al., 2003).  
 
Bcl-2 and its related proteins when activated however, inhibits the ability of Bax to increase 
m and thus prevents the release of cytochrome c and thus inhibits apoptosis induction 
(Decaudin, et al., 2002, Casellas, et al., 2002, Pulido, et al., 2003). Bcl-2 and Bcl-XL exert 
this anti-apoptotic function in part by sequestering of BH3 domain-only proteins in stable 
mitochondrial complexes, which prevents the activation and translocation of Bax or Bak to 
the mitochondria (Debatin, 2004). Bcl-2 and Bcl-XL inhibit apoptosis by preventing 
cytochrome c release through a direct effect on the MPTP by inhibiting its opening or through 
VDAC (Casellas, et al., 2002, Debatin, 2004). The Bcl-2 proteins are located in the outer 
mitochondrial membrane in close proximity to the MPTP, and acts to stabilise the integrity of 
the mitochondrial membrane (Figure 1-8) (Casellas, et al., 2002). 
 
1.4. The Peripheral Benzodiazepine Receptor 
1.4.1. Introduction 
The peripheral benzodiazepine receptor (PBR) was initially described as a binding site for 
benzodiazepines such as diazepam outside the nervous system but was later found to be 
expressed in most mammalian tissues including the central nervous system (CNS) (Hans, et 
al., 2005, Strohmeier, et al., 2002, Sutter, et al., 2004, Veenman, et al., 2004). It was so 
named because Braestrup and Squires first described it in 1977 as a high affinity-binding site 
for diazepam in the rat kidney as well as other peripheral tissues (Bribes, et al., 2004, 
Casellas, et al., 2002, Lacapère, et al., 2003). Alternative names proposed for the PBR include 
mitochondrial benzodiazepine receptor, mitochondrial DBI receptor, omega (	)3 receptor and 
p-sites (Casellas, et al., 2002, Miettinen, et al., 1995). The PBR has been implicated in 
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numerous biological processes; however, to the date the precise function of the PBR remains 
an enigma (Bribes, et al., 2004. Casellas, et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8: Regulatory Mechanisms of the Bcl-2 Family of Proteins in the Control of 
Apoptosis 
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complex (Casellas, et al., 2002, Kletsas, et al., 2004, Miettinen, et al., 1995), in their 
anatomical distribution, pharmacological and biological functions, its structure and its relative 
affinities for specific ligands (Kassiou, et al., 2004, Sutter, et al., 2004). Diazepam binds with 
high affinity to both classes of receptors (Casellas, et al., 2002). PBR and CBR can be 
distinguished from one another by their affinities for different signals where Ro5-4864 and 
PK11195, which exhibits no anxiolytic activity, binds with nanomolar affinity to PBR but 
with micromolar affinity to CBR while clonazepam, fumazenil and iomazenil binds with high 
affinity to the CBR but with extremely low affinity that is less than micromolar affinity to 
PBR (Casellas, et al., 2002, Kassiou, et al., 2004, Sutter, et al., 2003). 
 
1.4.2. Molecular Identity of the Peripheral Benzodiazepine Receptor 
The human PBR gene is located on the long arm of chromosome 22 in the region q13.3 and 
consists of 10 kb to 13 kb (Riond, et al., 1991, Woods, et al., 1996). The PBR gene consists of 
four exons disrupted by three introns, with the first exon and half of the fourth exon being 
untranslated to form the PBR protein (Figure 1-9). This gene consists of one transcription 
initiation site (Gavish, et al., 1999, Woods, et al., 1996). A study has reported that an 
alternatively spliced variant of the PBR mRNA is found in human tissue where a 211 bp 
internal deletion is observed, that is the exon 2 sequences has been spliced out resulting in an 
altered reading frame that is unable to translate to form a second type of PBR protein (Gavish, 
et al., 1999, Woods, et al., 1996). However, it should be noted that this alternative form is 
expressed at ten times the level to the PBR mRNA but the function of this alternative form is 
not known (Woods, et al., 1996). 
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Figure 1-9: Molecular Identity of the Peripheral Benzodiazepine Receptor 
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that are associated with the outer mitochondrial membrane or span the membrane lipid bilayer 
and an extramitochondrial carboxyl-terminal tail (Figure 1-9) (Casellas, et al., 2002, Joseph-
Liauzun, et al., 1998, Lacapère, et al., 2003, Riond, et al., 1991, Vin, et al., 2004). In its 
native form PBR exists at various higher molecular mass complexes ranging from 30 kDa to 
200 kDa, which occurs as a result of the 18 kDa protein forming polymers both in vitro and in 
vivo in response to reactive oxygen species (Corsi, et al., 2005, Corsi, et al., 2004). In 
addition, these polymeric complexes exhibit a higher binding affinity for PBR ligands (Corsi, 
et al., 2004).  
 
1.4.3. Proteins Associated with the Peripheral Benzodiazepine Receptor 
PBR forms a trimeric protein complex with the 32 kDa voltage-dependent anion channel 
(VDAC) and 30 kDa adenine nucleotide carrier (ANC) in the outer mitochondrial membrane 
(Casellas, et al., 2002, Kassiou, et al., 2004, Weisinger, et al., 2004), which together 
associates with creatine kinase and the Bcl-2 family of proteins (Veenman, et al., 2004) and 
with other proteins results in the formation of the MPTP (Bribes, et al., 2004, Maaser, et al., 
2005, Sutter, et al., 2003). Thus, the PBR has been implicated in the regulation of the MPTP 
(Vin, et al., 2005). Although, the exact way in which these proteins are arranged is not 
known, a study in mouse Leydig tumour cells (MA-10) mitochondria focused on the 
topographical analysis of the receptor distribution on the mitochondrial membrane has 
indicated that the trimeric receptor complex is formed by clusters of four to six PBR subunits 
associated with one VDAC molecule that forms the core of the complex that is located on the 
outer mitochondrial membrane and inner membrane contact site resulting in the formation of 
“single pores” (Figure 1-9) (Kassiou, et al., 2004, Lacapère, et al., 2003, Veenman, et al., 
2004). The role of ANC is not clear while VDAC functions in increasing the ability of PBR to 
bind to benzodiazepines (Lacapère, et al., 2003). Furthermore, studies have shown that the 
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ratio of PBR to VDAC and ANC is tissue-specific and condition-specific (Veenman, et al., 
2004). The trimeric protein complex is also thought to associate with other proteins resulting 
in the formation of a 200 kDa complex (Kassiou, et al., 2004). Thus, the molecular structure 
of the trimeric protein complex is dependent on the interaction of the different binding 
domains with other proteins (Kassiou, et al., 2004). 
 
Cytosolic proteins have been reported to be associated with the PBR. These are the 10 kDa 
protein that was co-immunoprecipitated with PBR localised in the mitochondrial fractions 
that has not been further identified and the PBR-associated protein-1 (PRAX-1), a 240 kDa 
protein that is located in the cytoplasm and on association with the carboxyl-terminus of the 
PBR exhibits several motifs implicated in protein-protein interactions such as the linking and 
dimerisation of the 10 kDa protein to PBR (Casellas, et al., 2002, Kassiou, et al., 2004). 
PRAX-1 interacts with PBR in a 1:2 PRAX-1:PBR stoichiometry (Casellas, et al., 2002) and 
is expressed in the brain and thymus but is absent from steroidogenic tissues and liver 
(Lacapère, et al., 2003). The role of PRAX-1 is undefined, although it is thought to be 
involved in the recruitment of additional targets to the vicinity of the PBR so as to modulate 
the function of PBR (Casellas, et al., 2002). Another cytosolic protein that associates with 
PBR is the PBR-associated protein (PAPs). In particular PAP7 shows high affinity for PBR 
and has a tissue distribution close to that of PBR (Lacapère, et al., 2003). Both PRAX-1 and 
PAP7 are proteins that contain glutamic acid stretches (Lacapère, et al., 2003). 
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Other mitochondrial membrane proteins that have been identified to associate with the PBR 
proteins include a 170 kDa to 210 kDa protein that was eluted with PBR photolabeled with 
PK14105, a nitrophenyl derivative of an isoquinoline carboxamide which is an analogue of 
PK11195 (Bribes, et al., 2004) when detergent solubilised, a 30 kDa to 35 kDa protein 
identified in liver and manganese-dependent dismutase (MnSOD) (Lacapère, et al., 2003). 
 
1.4.4. Evolutionary Conservation of the Peripheral Benzodiazepine Receptor 
The cDNA that encodes the PBR protein has been cloned from various species of mammals 
including rodents, cows and humans and shows a 71% identity and 80% sequence homology 
between species (Casellas, et al., 2002, Lacapère, et al., 2003, Woods, et al., 1996). 
Furthermore, highly similar proteins have been identified in plants, yeast and bacteria, which 
suggests that it is a highly conserved protein and plays a fundamental role in the cell (Gavish, 
et al., 1999, Lacapère, et al., 2003). Riond, et al. reported that the first methionine in the open 
reading frame in the cDNA encoding the rat PBR is highly similar to the amino-terminal 
sequence of the Chinese hamster ovary (Riond, et al., 1991). Studies have shown that the 
PBR promoter in both rat and humans does not contain a TATAA box but does contain 
multiple stimulatory protein (Sp) 1 boxes, which suggests further that PBR has a 
“housekeeping gene” function (Gavish, et al., 1999).  
 
PBR has also been identified in vegetable such as potato (Solanum tuberosum). It was found 
that an increase of PBR occurred in the nuclei of the cells during germination. In particular 
meristematic cells, which have a great proliferation ratio showed a high density of PBR in the 
perinuclear/nuclear region when compared to the parenchymal tissue where PBR expression 
was barely detectable (Corsi, et al., 2005, Corsi, et al., 2004). 
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The tryptophan-rich sensory protein (TspO), a 17 kDa protein that is very similar to the PBR, 
is located as a homodimer on the outer membrane in Rhodobacter sphaeroides 2.4.1. and is 
thought to consist of five membrane-spanning domains (Woods, et al., 1996, Yeliseev, et al., 
2000). TspO functions in the negative regulation of transcriptional expression of highly 
specific photosynthesis genes belonging to the PspR-repressor regulon in response to oxygen 
or light and in the transport or efflux of tetrapyrrole intermediates of the 
heme/bacteriochlorophyll biosynthetic pathway (Yeliseev, et al., 2000). In one study where 
the rat PBR was expressed in Rhodobacter sphaeroides TSPO1 cells; the rat PBR was 
functionally substituted for its bacterial homologue and negatively affected the transcription 
of specifically targeted photosynthesis genes in the presence of oxygen (Casellas, et al., 2002, 
Yeliseev, et al., 2000). Also, it was found that the rat PBR was located on the outer membrane 
of Rhodobacter sphaeroides as TspO and that it still binds benzodiazepines with the same 
affinity as when expressed on the outer mitochondrial membrane (Yeliseev, et al., 2000).  
 
PBR exhibits a 32% sequence homology with the CrtK protein of Rhodobacter capsulatus, a 
photosynthetic bacterium, which suggests that these proteins are homologues that descended 
from a common ancestor (Casellas, et al., 2002). It is interesting to note that Rhodobacter 
capsulatus is a member of the subdivision of purple bacteria that are the likely sources of the 
endosymbiont that gave rise to the mitochondrion (Casellas, et al., 2002). TspO, which is an 
analogue of CrtK in Rhodobacter sphaeroides, suggests that CrtK and its cognate signal 
transduction pathway may be a progenitor of mammalian PBR (Casellas, et al., 2002). 
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Thus, the above-mentioned results and others suggest a close evolutionary and functional 
relationship between the bacterial and mammalian receptors. This suggests that this receptor 
plays a similar biological role in their respective cell types (Yeliseev, et al., 2000).  
 
1.4.5. Expression and Subcellular Localisation of the Peripheral Benzodiazepine Receptor 
Subcellularly, PBR is expressed mainly in the outer mitochondrial membrane in close 
association with the mitochondrial enzymes cytochrome oxidase, succinate dehydrogenase 
and monoamine oxidase and is concentrated near the inner mitochondrial membrane and outer 
mitochondrial membrane contact sites (Hans, et al., 2005, Kletsas, et al., 2004, Lacapère, et 
al., 2003). However, it may be located on the inner mitochondrial membrane as is seen in rat 
lung mitochondria (Gavish, et al., 1999). It is also expressed on the plasma membranes of 
some cells such as erythrocytes, which are devoid of mitochondria, non-mitochondrial 
fractions in hepatocytes, in the nucleus and perinuclear area, in the Golgi apparatus, 
lysosomes, peroxisomes and is associated with the cell membrane of the liver, specifically the 
non-parenchymal/biliary epithelial cells (Woods, et al., 1996), heart, adrenal glands and testes 
(Bribes, et al., 2004, Casellas, et al., 2002, Gavish, et al., 1999, Kassiou, et al., 2004, Maaser, 
et al., 2002, Sutter, et al., 2004).  
 
PBR is expressed with varying degrees of density in the majority of tissues tested especially 
steroid-producing tissues (Corsi, et al., 2005, Kletsas, et al., 2004, Weisinger, et al., 2004). 
High expression of PBR have been seen in glandular and secretory tissues such as the pineal 
gland, adrenal glands, ependyma, pituitary gland and gonads, testis, ovary and uterus 
intermediate expression of PBR have been seen in renal and myocardial tissue and lung and 
low expression of PBR have been seen in liver, brain in areas such as the olfactory bulb and 
the cerebellum, with highest expression seen in the cerebellum, and spinal cord (Bribes, et al., 
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2004, Casellas, et al., 2002 Galiègue, et al., 2004, Kassiou, et al., 2004, Miettinen, et al., 
1995, Venturini, et al., 1998).  
 
Further, it has been found that the tissue distribution of the protein within a given organ was 
not homogenous. For example, in the adrenal glands, the medulla is virtually devoid of PBR 
while in the cortical density the expression of PBR is high (Bribes, et al., 2004, Casellas, et 
al., 2002). Another example is that of the kidney where it was found that there is a selective 
localisation of PBR in the distal convoluted tubule and the thick ascending limbs of the loop 
of Henle (Bribes, et al., 2004, Casellas, et al., 2002). This tissue distribution has also been 
noticed in the thymus (Bribes, et al., 2004). 
 
PBR is expressed in non-neuronal tissue or the ependyma, epithelial cells of choroid plexus 
olfactory epithelium and predominantly in glial cells and in some neuronal cell types such as 
neuroblastoma cells, cultured cortical neurons of the CNS and particularly the brain and in 
peripheral nervous system (PNS) (Ferzaz, et al., 2002, Jordà, et al., 2005, Kassiou, et al., 
2004, Miettinen, et al., 1995, Veenman, et al., 2004), all human peripheral blood leukocyte 
subsets, particularly in monocytes and polymorphonuclear cells such as neutrophils shows 
high expression, lymphocytes shows intermediate expression and platelets and erythrocytes 
show low expression (Casellas, et al., 2002, Woods, et al., 1996) and in the skin of healthy 
donors PBR is up regulated in the superficial differentiated layers of the epidermis (Bribes, et 
al., 2004). Low expression of PBR is seen in the normal gut mucosa (Maaser, et al., 2002). 
Also, the expression of PBR is seen at high levels in bronchopulmonary structures such as the 
submucosal glands, epithelium, ductal smooth muscles and type II alveolar cells (Bribes, et 
al., 2003). 
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1.4.6. Ligands of the Peripheral Benzodiazepine Receptor 
Two types of ligands bind to PBR with high affinity. These are the endogenous ligands and 
synthetic ligands. 
 
1.4.6.1. Endogenous Ligands 
Endogenous ligands that bind to the PBR with high affinity include the diazepam binding 
inhibitor (DBI), its derived fragments, porphyrins such as protoporphyrin IX, a dicarboxylic 
porphyrin, mesoporphyrin IX, deuteroporphyrin IX and hemin that binds to PBR with 
nanomolar affinity and cholesterol (Bribes, et al., 2004, Casellas, et al., 2002, Hans, et al., 
2005, Venturini, et al., 1998).  These endogenous ligands are capable of competitively 
inhibiting PBR binding (Venturini, et al., 1998). 
 
DBI is an 11 kDa polypeptide consisting of 86 amino acids that binds to PBR with nanomolar 
affinity and is capable of displacing benzodiazepine binding (Casellas, et al., 2002, 
Strohmeier, et al., 2002, Venturini, et al., 1998). It is highly expressed in steroidogenic cells, 
preferentially localised in the periphery of mitochondria and has the ability to bind to long 
chain acyl-coenzyme A (CoA)-esters (Lacapère, et al., 2003, Miettinen, et al., 1995). DBI is 
thought to function in the regulation of multiple biological processes such as stimulation of 
cell growth, stimulation of steroidogenesis where it functions in directly loading cholesterol to 
the inner mitochondrial membrane side chain cleavage cytochrome P-450 (P-450scc) (Gavish, 
et al., 1999) and inhibition of glucose-induced insulin secretion from the pancreas with 
expression been restricted to special cell types in a given organ such as seen in the brain 
where high concentrations have been detected in circumventricular organs and cerebellum but 
not in the normal cerebral cortex with particular expression seen in ependymal cells, glial 
cells and  neurons (Miettinen, et al., 1995). This protein is identical to the acyl-CoA binding 
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protein (ACBP) that has a broad range of distribution throughout tissues and species from 
animal to the plant kingdom and thus has been suggested to function as a housekeeping gene 
(Lacapère, et al., 2003).  
 
Porphyrins modulate enzymatic activity of several enzymes such as tryptophan pyrrolase, 
guanylate cyclase and gluthathione-S-transferase and several mitochondrial proteins (Gavish, 
et al., 1999). Cholesterol, which binds to PBR to the carboxyl-terminal part of PBR 
(Lacapère, et al., 2003, Yeliseev, et al., 2000) with high affinity (Corsi, et al., 2005) 
encompasses the lipid bilayer and maintains membrane fluidity (Akech, et al., 2005). 
 
1.4.6.2. Synthetic Ligands 
Synthetic drug ligands that bind to PBR are diverse in chemical nature (Kletsas, et al., 2004) 
that can be divided into three main families: (i) the benzodiazepines such as the 4’ chloro 
derivative of diazepam Ro5-4864 [7-choloro-1,3-dihydro-1-methyl-5(4’-cholorphenyl)2H-
1,4-benzodiazepine] (Figure 1-10A), (ii) isoquinoline carboxamides such as PK11195 [1-(2-
chlorphenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide] (Figure 1-10B) and 
(iii) indoacetamide derivatives such as FGIN-1-27 [N, N-di-n-hexyl-2-(4-fluotophenyl)indole-
3-acetamide] (Figure 1-10 C) (Hans, et al., 2005, Veenman, et al., 2004). Studies determining 
the role of the PBR have been inferred from the biological effects of these ligands (Hans, et 
al., 2005). 
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(A) (B) 
(D) 
(C) 
Benzodiazepines Isoquinoline Carboxamides Indoacetamide Derivatives     
                      
 
 
 
Figure 1-10: Chemical Structures of Synthetic Ligands that bind to the Peripheral 
Benzodiazepine Receptor 
(Reference: Casellas, et al., 2002, http://www.chemexper.com/chemicals/supplier/cas/142720-24-9.html, Ferzaz, 
et al., 2002) 
 
Ro5-4864 binds to PBR with nanomolar affinity in rodents but with a two-fold lower affinity 
in human and the interaction of Ro5-4864 with PBR is highly species dependent (Bribes, et 
al., 2004, Carmel, et al., 1999, Casellas, et al., 2002). This variation in binding affinity may 
be due to amino acid differences that occur in the region near the carboxyl-terminal end of the 
PBR (Lacapère, et al., 2003). PK11195 is the most widely used PBR ligand that binds to PBR 
with high (nanomolar) affinity from all species (Bribes, et al., 2004, Casellas, et al., 2002). 
PK11195 was classified as an antagonist while Ro5-4864 was classified as an agonist based 
on the entropy and enthalpy driven nature of ligand-receptor interactions (Casellas, et al., 
2002). This distinctive property displayed by both classes of ligands suggest that their binding 
domains either overlap or are allosterically coupled (Casellas, et al., 2002). PK11195 interacts 
Ro5-4864 PK11195 FGIN-I-27 
SSR180575 
(A) (B) (C) 
(D) 
 45 
directly with the PBR protein while Ro5-4864 and other benzodiazepines binds to a site that 
is made up of the PBR protein and VDAC (Gavish, et al., 1999, Kassiou, et al., 2004). 
However, it should be noted that under some physiological conditions both ligands induce 
similar effects (Casellas, et al., 2002).  Further, mutation studies have shown that conserved 
amino acid such as glutamic acid (Glu)29, arginine (Arg)32 and lysine (Lys)39 as well as non-
conserved amino acids Leu31 and Arg24 located in the first putative cytoplasmic loop are 
involved in the binding of benzodiazepines but not that of binding isoquinoline carboxamides 
(Yeliseev, et al., 2000). However, the first cytoplasmic loop is involved in binding PK11195 
(Lacapère, et al., 2003). 
 
FGIN-1-27 displays high affinity to PBR (Maaser, et al., 2005). SSR180575 is a novel 
pyridazinoindole derivative that binds to PBR irreversibly with nanomolar affinity (Figure 1-
10D) (Bribes, et al., 2004, Vin, et al., 2004).  
 
The order of potency with which different ligands bind to PBR is as follows from the most 
potent to the least potent: PK11195 > Ro5-4864 > SSR180575 > diazepam > clonazepam 
(Vin, et al., 2004). 
 
1.4.7. Functions of the Peripheral Benzodiazepine Receptor 
The exact function of PBR remains controversial although it is thought to function in several 
physiological and pathological processes including the regulation of steroidogenesis and 
cholesterol transport, regulation of cellular proliferation (growth) and differentiation, 
immunomodulation (immune and phagocytic host defence response) by inducing moncoyte 
chemotaxis, inflammation, oxygen consumption, porphyrin transport and heme biosynthesis, 
anion transport, responses to stress and regulation of apoptosis (Casellas, et al., 2002, Hans, et 
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al., 2005, Kassiou, et al., 2004, Maaser, et al., 2005, Riond, et al., 1991, Veenman, et al., 
2004). These different functions have been suggested to be tissue-specific (Weisinger, et al., 
2004). Furthermore, the PBR is involved in regulatory processes and metabolic functions 
pertaining to the tissue in which they are present such as calcium homeostasis and modulation 
of the VDAC and thus functions in the regulation of the opening of the MPTP (Kassiou, et al., 
2004, Leducq, et al., 2003, Miettinen, et al., 1995, Veenman, et al., 2004).  
 
PBR is also thought to function in the respiratory system. It is thought to be involved in 
bronchomotor tonus modulation and epithelial functions such as ionic transport modulation, 
ciliary and/or anti-inflammatory function via Clara cells (Bribes, et al., 2003). Further, PBR is 
thought to play a role in the cardiac system, in the pathogenesis of hypertension and in renal 
and salt-water balance (Katz, et al., 1989). 
 
However, the best characterised function of PBR is in steroidogenesis where PBR is a 
functional component of the steroidogenic machinery functioning in the transport of 
cholesterol from the outer mitochondrial membrane to the inner mitochondrial membrane that 
forms the rate-limiting step (Casellas, et al., 2002, Ferzaz, et al., 2002, Joseph-Liauzun, et al., 
1998, Venturini, et al., 1998) and functions in the conversion of cholesterol to pregnenolone, 
a precursor of all steroids, P-450scc enzyme that is located on the inner mitochondrial 
membrane (Ferzaz, et al., 2002, Kassiou, et al., 2004). The induction of steroidogenesis has 
been observed in adrenal glands, the placenta and the nervous tissues such as brain and 
endocrine tissues (Brown, et al., 2000, Ferzaz, et al., 2002).  
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PBR is thought to have a function in the regulation of oxidative process (mitochondrial 
respiration, oxidative phosphorylation) via two aspects (Bribes, et al., 2004, Veenman, et al., 
2004). Firstly, it may function as an oxygen sensor by transducing an oxygen-triggered signal 
that leads to an adaptive cellular response, which is done through the regulation of 
mitochondrial swelling and the activity of the succinate-cytochrome c oxidoreductase (site II), 
which is a complex multi-subunit enzyme that functions as both a component of the electron 
transport chain and an essential enzyme of the tricarboxylic acid cycle (TCA) cycle (Ackrell, 
2002, Casellas, et al., 2002, Ferzaz, et al., 2002). Secondly, it may mediate protective effects 
on the mitochondria against ROS (radical) damage where production of ROS leads to the 
inhibition of oxidative phosphorylation and increases the permeability of the mitochondrial 
membrane through the opening of the MPTP that ultimately leads to the uncoupling of the 
oxidative phosphorylation, psi (
) collapse, mitochondrial swelling and the release of 
cytochrome c, which leads to the activation of caspases and thus cell death via necrosis and/or 
apoptosis (Casellas, et al., 2002, Leducq, et al., 2003). PBR is also thought to function 
mitochondrial electrophysiology (Joseph-Liauzun, et al., 1998). 
 
1.5. The Peripheral Benzodiazepine Receptor and Cell Proliferation 
The role that PBR plays in cell proliferation was mainly investigated using PBR-specific high 
affinity drug ligands such as PK11195 and Ro5-4864. Results from these investigations have 
suggested that it may induce or suppress cell proliferation, which probably reflects the tissue-
specificity of PBR function (Kletsas, et al., 2004). However, studies have also shown that 
PBR-specific ligands may also affect cell proliferation independent of their ability to bind to 
PBR (Kletsas, et al., 2004). 
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1.5.1. The Effect of the Peripheral Benzodiazepine Receptor in the Induction of Cell 
Proliferation 
PBR is thought to function in the induction of cell proliferation (Veenman, et al., 2004). For 
example, it was found that PBR knockout Leydig cells grew much slower than their wild-type 
counterparts and in breast cancer cell lines, it was found that the level of PBR expression 
correlated inversely with the doubling time and positively with the ability of the tumours to 
grow in vivo in severe combined immunodeficiency (SCID) mice (Galiègue, et al., 2004, 
Maaser, et al., 2005). It is also thought to increase tumour proliferation in glial tumours 
(Veenman, et al., 2004) and gene-silencing approaches have shown that PBR is required for 
epithelial breast cell proliferation (Kletsas, et al., 2004). 
 
PBR ligands in the presence of nerve growth factor caused an induction of c-fos, which 
regulates the synthesis and replenishment of phospholipids required for signal transduction 
pathways and thus subsequently regulates enzymes that are involved in the genesis of new 
membranes necessary for cell growth. Furthermore, high expression of PBR and ligand 
binding induces cell proliferation when induced by c-fos and phosphotidylcholine synthesis in 
different breast cancer epithelial cell lines (Akech, et al., 2005). 
 
Concentrations of PK11195 in the receptor binding range, that is nanomolar range, can 
stimulate DNA synthesis (mitosis) concomitant with increased cholesterol transport in the 
nuclear membrane (Akech, et al., 2005, Venturini, et al., 1998). High concentration of PBR 
ligands such as Ro5-4864 could inhibit cell proliferation by inhibiting DNA synthesis in 
different mammalian cell lines (Akech, et al., 2005, Sänger, et al., 2000). Thus, a biphasic 
effect on cell proliferation occurs depending on the concentration of the PBR ligands (Sänger, 
et al., 2000). Nanomolar concentrations of PBR ligands stimulate proliferation in aggressive 
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breast cancer cells while it inhibits cell proliferation in mildly aggressive breast cancer cells, 
which is inversely correlated with nuclear cholesterol uptake (Brown, et al., 2000). 
 
PBR has been suggested to stimulate cell proliferation in glioma and breast cancer cell 
proliferation where the receptor has been linked to the growing aggressive potential of the 
tumour cells in vitro and in vivo (Corsi, et al., 2005).  
 
1.5.2. The Effect of the Peripheral Benzodiazepine Receptor in the Suppression of Cell 
Proliferation 
PBR ligands such as FGIN-1-27 and PK11195 have been shown to inhibit cell proliferation 
and thus reverse the growth-promoting properties of PBR in various tumours such as that of 
the skin, colon, oesophagus, breast and brain (Maaser, et al., 2005, Maaser, et al., 2004, 
Sutter, et al., 2004, Veenman, et al., 2004). The mechanisms by which this occurs is still been 
investigated but it has been shown that the anti-proliferative effects of PBR ligands are due to 
both induction of apoptosis and cell cycle arrest (Maaser, et al., 2005, Sutter, et al., 2004, 
Sutter, et al., 2003, Veenman, et al., 2004).  
 
In gastrointestinal cancers and oesophageal cancer cells as well as haematopoietic and 
epithelial cells PBR ligands induce cell cycle arrest at the G1/S checkpoint only, in breast 
cancer cells PBR ligands induce cell cycle arrest at both the G1/S and G2/M checkpoint while 
in lung and melanoma cells PBR ligands induce cell cycle arrest at the G2/M checkpoint only 
(Maaser, et al., 2005, Sutter, et al., 2004, Sutter, et al., 2003, Veenman, et al., 2004). 
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The mechanisms by which PBR induces cell cycle arrest is not known, however, recently the 
signalling molecules that are involved in PBR ligand-induced G1 arrest have been identified 
(Maaser, et al., 2005, Maaser, et al., 2004). These signalling molecules are mitochondrial 
alterations, cyclin D1 and p21CIP1/p27Kip1 and the activation of the p38 MAPK pathway, 
which results in the overexpression of the growth arrest and DNA damage-inducible (gadd) 
genes, specifically gadd153 and gadd45 (Maaser, et al., 2004, Sutter, et al., 2004, Sutter, et 
al., 2003).  
 
Sutter et al. also found that PBR ligands induced a MEK-dependent activation of ERK1/2 in 
oesophageal cancer cells and when PBR ligands were combined with MEK1/2 kinase 
inhibitors, they induced apoptosis and cell cycle arrest. This suggests that the induction of 
ERK1/2 compromises the anti-neoplastic effects of PBR ligands and thus serves a protective 
role (Sutter, et al., 2004). Treatment with both PBR ligands and 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMG-CoAR) inhibitors also showed the synergistic inhibition of cell 
proliferation in hepatocellular carcinoma cells by inducing apoptosis and cell cycle arrest 
(Sutter, et al., 2005). 
 
1.6. The Peripheral Benzodiazepine Receptor and Apoptosis 
It is thought that the PBR has a role in the induction and suppression of apoptosis 
(Strohmeier, et al., 2002). 
 
 
 
 
 
 51 
1.6.1. The Effect of the Peripheral Benzodiazepine Receptor in the Induction of Apoptosis 
The direct apoptotic effects of PBR ligands were observed in colorectal, oesophageal and 
hepatocellular cancer cells (Maaser, et al., 2005). The molecular mechanism(s) of PBR 
ligands-induced cell death is not well understood, however, most studies haves suggested that 
it functions in apoptosis induction (Hans, et al., 2005). PBR ligands have been shown to 
induce apoptosis by the: (i) activation of caspase-3 and caspase-9, (ii) the cytosolic release of 
cytochrome c, (iii) and increase in ROS production, (iv) activation of the p38 MAPK pathway 
and (v) the opening of the MPTP (Hans, et al., 2005, Maaser, et al., 2004). Also, to date very 
little is known about other transcriptional responses than the ones mentioned in this section 
when cancer cells are treated with PBR-specific ligands (Sutter, et al., 2003). 
 
The role of PBR in the opening of the MPTP is thought to be the most important since the 
PBR is thought to be a component of the MPTP (Hans, et al., 2005).  It is thought that PBR 
ligands can activate the opening of the MPTP without further addition of calcium and thus 
functions in the regulation of the MPTP in producing apoptosis because of PBR’s close 
association with the proteins of the MPTP (Casellas, et al., 2002, Maaser, et al., 2005). 
Furthermore, it is thought that Ro5-4864 and PK11195, that have been classified as a 
pharmacological agonist and antagonist respectively, maintain their identity in regulating the 
MPTP (Casellas, et al., 2002). It has been shown that induction of apoptosis by FGIN-1-27 is 
dependent on the opening of the MPTP and the decrease of m while PK11195 induced 
apoptosis without any alteration in m in colorectal and oesophageal cancer cells (Maaser, et 
al., 2005, Sutter, et al., 2003). Thus, PK11195 is thought to function in the facilitation of the 
dissipation of the m, which results in the release of apoptogenic factors (Decaudin, et al., 
2002). To date, very little evidence is available that suggests that PBR ligands directly 
triggers the opening of the MPTP and it is thought that the loss of m seen is due to a 
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downstream event occurring in many apoptotic processes where mitochondria acts as 
executioners (Hans, et al., 2005). 
 
Bcl-2 is an anti-apoptotic protein that is overexpressed in many cancers (Sutter, et al., 2005). 
PBR ligands have been shown to overcome Bcl-2 mediated chemoresistance in lung cancer 
(Sutter, et al., 2004). PK11195 eradicates the inhibition of Bcl-2 via a direct effect on 
mitochondria (Decaudin, et al., 2002). Thus, it has been successfully applied for combination 
therapy with several cytotoxic drugs in vitro and in vivo (Sutter, et al., 2004). Furthermore, 
PBR ligands induced apoptosis in conjunction with the down regulation of Bcl-2 expression 
and dephosphorylation of PKB and Bad in hepatic stellate cells (Sutter, et al., 2003). 
 
PBR ligands such as PK11195 when it interacts with the MPTP has been shown to have an 
indirect pro-apoptotic effect as seen when the susceptibility of cells to the induction of 
apoptosis was enhanced by a variety of different stimuli such as DNA damage, ligation of the 
glucocorticoid receptor and ceramide, a proapoptotic second messenger, and the reverse 
suppression of apoptosis by Bcl-2 (Decaudin, et al., 2002, Casellas, et al., 2002, Jordà, et al., 
2005, Strohmeier, et al., 2002). Thus, it has been suggested that the collapse of the m could 
modulate apoptotic process as any alterations in the mitochondrial structure plays a crucial 
role in the release of apoptotic factors from the mitochondria (Jordà, et al., 2005). 
 
Studies have been reported showing the indirect anti-neoplastic effect of PBR-specific ligands 
where the PBR ligands increased apoptosis induced by other cytostatic drugs (Maaser, et al., 
2005). In hepatocellular carcinoma PK11195 and FGIN-1-27 enhanced the chemosensitivity 
of tumour cells to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1 (Maaser, 
et al., 2005). In thymocytes, PBR ligands such as PK11195 enhanced apoptosis as a result of 
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cells becoming more sensitive to actinomycin D, cycloheximide and the protein kinase 
inhibitor H7, which suggest a requirement for protein synthesis and phosphorylation 
(Strohmeier, et al., 2002, Sutter, et al., 2003). Furthermore, similar sensitising effects were 
observed by the use of tamoxifen, lonidamine, anti-CD95, etoposide, gemtuzumab 
ozogamicin, dexamethasone, daunomycin and -irradiation in different tumours cell lines 
(Decaudin, et al., 2002, Maaser, et al., 2005). 
 
The induction of apoptosis by PK11195 is only observed at concentrations of a thousand fold 
higher than what is required for its binding to PBR (Decaudin, et al., 2002). Micromolar 
concentrations of a series of pyrrolo-1, 5-benzoxazepines as well as PK11195 and Ro5-4864 
resulted in the induction of apoptosis in leukaemic cells (HL60) (Strohmeier, et al., 2002). 
Nanomolar concentrations of PK11195 enhanced the apoptotic effect of TNF- while it 
inhibited the anti-apoptotic effect of Ro5-4864 (Strohmeier, et al., 2002). 
 
1.6.2. The Effect of the Peripheral Benzodiazepine Receptor in the Suppression of 
Apoptosis 
However, other studies have reported contrasting effects where the action of PBR ligands on 
cellular survival has reported pro-survival effects (Hans, et al., 2005). For example, 
transfection and subsequent overexpression of PBR protected cells against UV-induced 
apoptosis and hydrogen peroxide-induced apoptosis exhibited a delayed m drop (Ferzaz, et 
al., 2002, Maaser, et al., 2005, Strohmeier, et al., 2002).  
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Ro5-4864 and PK11195 failed to induce apoptosis in cell lines of haematopoietic and 
epithelial origin (Strohmeier, et al., 2002). Furthermore, nanomolar concentrations 
(concentration in the binding range) of Ro5-4864 resulted in anti-apoptotic activities in 
human pleural effusion histiocytic lymphoblastoid (U937) cells as well as in PBR-transfected 
leukaemic Jurkat cells where it protected the cells from undergoing TNF- apoptosis 
(Casellas, et al., 2002, Leducq, et al., 2003, Strohmeier, et al., 2002). This suggests the 
pharmacological modulation of the PBR may influence cell survival (Ferzaz, et al., 2002). 
 
1.7. The Peripheral Benzodiazepine Receptor and Cancer 
An increase expression of PBR has been seen in a wide variety of malignant cells and tissues 
(Casellas, et al., 2002, Hans, et al., 2005, Veenman, et al., 2004). Increase in PBR densities 
has been observed in ovarian carcinoma, breast cancers, hepatic carcinoma and colonic 
carcinomas (colorectal cancers), colon adenocarcinoma, oesophageal cancers, endometrial 
carcinomas, astrocytomas and gliomas when compared to their untransformed counterpart 
(Casellas, et al., 2002, Sutter, et al., 2004, Sutter, et al., 2003). It is thought to function as the 
hallmark of cancerogenesis in some tissues such as gliomas (Hans, et al., 2005). 
 
Many studies have been devoted to the effects of PBR ligands on cell survival and especially 
on their toxicity towards tumour cell lines (Hans, et al., 2005). From these studies it may be 
deduced that PBR may be involved in growth control because it is overexpressed in a variety 
of tumour models and specific PBR ligands inhibit cell proliferation (Maaser, et al., 2004, 
Sutter, et al., 2005). It may also be involved in cell proliferation of carcinogenic tissue that is 
controlled by the cell’s apoptotic and mitogenic properties (Veenman, et al., 2004). For 
example, in human breast cancer cell lines the expression of PBR and the mitochondrial 
density correlates with the high mitotic activity of the cells (Corsi, et al., 2005) while in C6 
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glioma cells PBR ligands such as benzodiazepines affect proliferation rate in a dose-
dependent manner, which suggests the role of PBRs in the mitotic process (Corsi, et al., 
2004). 
 
Further, it has been found that PBR expression correlates with tumour malignancy grade and 
patient survival. The nature by which this up regulation occurs is not known (Hardwick, et al., 
2002). A study conducted showed that normal breast tissue and mildly aggressive breast 
cancer cells express very low levels of PBR mRNA levels, ligand binding sites and protein 
that are located in the mitochondria while highly aggressive human breast cancer cells, 
rapidly proliferating breast cancer cells and metastatic human breast tumours have high PBR 
mRNA levels, PBR ligand binding sites and protein located mainly in the nucleus (Akech, et 
al., 2005, Bribes, et al., 2004, Brown, et al., 2000, Casellas, et al., 2002, Hardwick, et al., 
2002, Sänger, et al., 2000). Also, in brain tumours such as human astrocytomas, the 
expression of PBR correlates positively with tumour malignancy and proliferation rate and 
inversely with patient survival (Corsi, et al., 2005, Galiègue, et al., 2004, Guo, et al., 2001). 
 
An increased binding of ligands has been seen in different brain tumours. For example, 
studies in rat C6 glioma PBR densities increased by up to 30-fold when compared to its 
surrounding neocortex while in human post-mortem tissue, high levels of PBR ligand binding 
was observed in intact glioma cells and not in necrotic areas of the tumour and the 
surrounding normal tissue (Veenman, et al., 2004). Further studies have suggested that the 
binding of PK11195 to human gliomas may be used to differentiate between high-grade and 
low-grade gliomas (Veenman, et al., 2004). In rat C6 glioma cells and human T98G glioma 
cells, PK11195 and Ro5-4864 induced morphological changes of the tumour cells and 
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treatment with nanomolar concentrations of PK11195 resulted in an increase in growth rate 
and thymidine incorporation by up to 20 to 30% (Veenman, et al., 2004).  
 
Nuclear and perinuclear localisation of PBR has been found in glioblastoma biopsies, highly 
aggressive breast cancer cell lines and metastatic human breast tumour biopsies (Casellas, et 
al., 2002, Galiègue, et al., 2004, Hardwick, et al., 2002). This nuclear localisation seen in 
breast cancers and gliomas suggests a role of PBR in the development and progression of the 
disease, as it would regulate cell proliferation by facilitating cholesterol transport into the 
nucleus (Galiègue, et al., 2004). Thus, it has been hypothesised that the presence of PBR may 
be a determinant factor for the aggressive phenotype of the tumour and the expression of PBR 
may be monitored in tumour samples for diagnostic and/or prognostic purposes in the clinic 
(Galiègue, et al., 2004). 
 
A study demonstrated the prognostic relevance of PBR in colorectal cancer. In this study 
conducted by Maaser, et al., it was shown that the over-expression of PBR protein resulted in 
the reduction of the mean patient survival rate by 35% with stage III colorectal cancer tissue 
(Galiègue, et al., 2004, Maaser, et al., 2002, Veenman, et al., 2004). 
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1.8. Rationale 
One of the major problems of chemotherapy is the resultant of drug resistance, which results 
in treatment failure that leads to progressive disease (Sutter, et al., 2005, Sutter, et al., 2004). 
Drug resistance may be induced by potential mechanisms that include the activation of the 
Ras/Raf/MEK/ERK signal transduction cascade, overexpression of the anti-apoptotic protein 
Bcl-2, overexpression of epidermal growth factor receptor (EGFR) and the increase in 
cholesterol in cancer cells (Sutter, et al., 2005, Sutter, et al., 2004). Furthermore, failure of 
cell death induction leads to the induction of cancer cells to antitumour therapies, thus 
overcoming this apoptotic resistance and the consequent induction of cytotoxic effects is a 
challenge in the improvement of chemotherapy (Decaudin, et al., 2002). 
 
Data thus far obtained on the expression level and tissue distribution of PBR have been done 
in other species and very few studies have been performed in humans (Bribes, et al., 2004). 
The increase of PBR expression in various cancers suggests the role of PBR in the growth 
control of various cancers (Maaser, et al., 2005). PBR is also thought to be involved in the 
regulation of MPTP activity in response to signals triggering apoptosis, however the precise 
mode of action is not known (Casellas, et al., 2002). Thus, it appears to be a pharmacological 
target for apoptosis modulation (Decaudin, et al., 2002). The level of PBR expression has 
been suggested to serve as a clinically relevant prognosis factor, which has led many 
researchers to believe that it may serve as a promising drug target in the field of cancer by the 
use of specific exogenous PBR ligands (Hans, et al., 2005, Maaser, et al., 2005, Sutter, et al., 
2004) or as receptor-mediated drug carriers to selectively target anticancer drugs (Guo, et al., 
2001). Furthermore, the increase expression of PBR in cancers has suggested that PBR 
ligands alone or in combination with other agents may be good candidates as 
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chemotherapeutic or at the very least as chemosensitising agents (Hans, et al., 2005, Sutter, et 
al., 2005). 
 
1.9. Objectives 
The general objective of this study was to determine the expression pattern and tissue 
distribution of the PBR mRNA in different human cancer tissues. Specific objectives were: (i) 
to localise the expression of the PBR mRNA in various normal and in various human cancer 
tissues via in situ hybridisation, (ii) to determine whether the expression levels of PBR 
mRNA varies between the different types of normal tissues, between the different types of 
cancerous tissues and between the normal and the diseased state via in situ hybridisation and 
quantitative reverse transcriptase (RT) real-time-polymerase chain reaction (PCR) and (iii) to 
isolate the PBR protein. Thus, the question here was to determine whether PBR mRNA is 
expressed in all cancer tissues, whether the expression levels differ in the different cancer 
tissues and whether the expression levels are increased or decreased between the normal and 
diseased state of a specific tissue.   
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2. MATERIALS AND METHODS 
 
2.1. Materials 
Ethics clearance (Protocol Number: M050223) and higher degrees approval was obtained 
from the University of the Witwatersrand Research Committee and the Faculty of Science 
Postgraduate Committee respectively. 
 
2.1.1. Cell Lines 
The following cell lines were used: Graham 293 cell line, which is a normal human 
embryonic kidney cell line, MRC5 cell line, which is a normal human embryonic fibroblast-
like lung cell line, A549 cell line, which is a human epithelial cell lung carcinoma cell line, 
HeLa cell line, which is a human epithelial cell cervical carcinoma cell line and HepG2 cell 
line, which is a human liver hepatocellular carcinoma cell line. All these cell lines were 
purchased from Highveld Biological (Pty) Ltd (Johannesburg, South Africa). 
 
2.1.2. Human Tissue Array 
Tissue arrays of multiple organs containing normal and diseased tumour tissues that was 
formalin-fixed were purchased from Cybrdi Inc. (Frederick, Maryland, USA), catalogue 
number: CC00-11-002. Each of the tissue arrays contained 48 dots in the array panel, which 
represented a disease or normal tissue spot from a specimen that was selected and 
pathologically confirmed. The array dot diameter was 1.5 mm and the section thickness was 5 
µm. The total number of cases on this tissue array was obtained from 46 individual patients 
(normal and diseased combined) (Appendix 1 Tables 1-3). 
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2.2. Methodology (For composition of solutions refer to Appendix 2) 
2.2.1. Preparation of Competent Cells  
Normally Escherichia coli cells do not possess the ability to take up DNA from the 
environment. However, if their cell walls are altered, these bacterial cells become more likely 
to incorporate foreign DNA and thus these cells are said to be “competent”. These cells can be 
made competent by chemical or physical treatment. Chemical treatment includes the calcium 
chloride method while physical treatment includes electroporation whereby the bacterial cell 
is shocked with 2500 V. In addition, bacterial cells that are undergoing rapid growth, that is 
bacterial cells in the log phase can become competent more easily than bacterial cells that are 
in the other stages of growth. 
 
The chemical treatment method was used in order to make MC1061 Escherichia coli cells 
(Fermentas Life Sciences, Hanover, MD, USA) and BL-2 Escherichia coli (donated from the 
University of the Western Cape, Department of Biotechnology) competent. The MC1061 
strain was used for cloning while the BL-2 strain was used in the expression of the PBR 
protein. 
 
1. The night before making competent cells the desired bacterial strain was plated on 10 mM 
Magnesium Chloride (MgCl2) Luria-Bertani (LB) agar (LA) plates.  
2.  A single colony of the desired strain was added to 20 ml Tryptone Yeast Extract MgCl2 
(TYM) Broth in a 500 ml conical flask and grown at 37 ˚C overnight, shaking constantly 
at 300 rpm. 
3. 1 ml of cells in the TYM Broth were added to 100 ml fresh TYM Broth in a 2 l conical 
flask. The cells were grown for a further 2-3 hours or until optical density at 550 nm 
equals 0.2 at 37 ˚C, shaking constantly at 300 rpm. 
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4. Thereafter, 400 ml of fresh TYM broth was added to the 2 l conical flask and cells 
allowed to grow for a further 2-3 hours or until optical density at 550 nm lies between 0.4 
and 0.6 at 37 ˚C, shaking constantly at 300 rpm. 
5. Bacterial cells were rapidly cooled in ice water, shaking constantly after which they were 
centrifuged in two 125 ml propylene tubes at 3000 rpm for 10 minutes at 4 ˚C using the 
JA-10 rotor and J2-21 Beckman centrifuge (Beckman Coulter, Inc., Fullerton, CA, USA). 
6. The supernatant was discarded and the pellet resuspended in 125 ml Tfb1. This solution 
was allowed to incubate for 30 minutes on ice after which the bacterial cells were 
centrifuged at 3000 rpm for 10 minutes at 4 ˚C using the JA-10 rotor and J2-21 Beckman 
centrifuge.  
7. The bacterial cells were gently resuspended in 80 ml Tfb2 after which 300 µl were 
aliquoted into 0.5 ml eppendorf tubes and frozen in liquid nitrogen or dry ice. These 
aliquoted cells were then stored at -70 ˚C for further use. 
 
2.2.2. Expression of the Peripheral Benzodiazepine Receptor mRNA in Various Human 
Cancer Tissues 
2.2.2.1. Molecular Cloning 
2.2.2.1.1. RNA Extraction  
RNA extraction is the technique by which total ribonucleic acid (RNA) can be extracted from 
tissues or cell line samples. Total RNA can be extracted using the TRIzolTM LS Reagent 
method, which can be divided into four stages namely, the disruption stage, the 
homogenisation stage, the phase separation stage and the RNA precipitation stage. During the 
disruption stage a complete disruption of the cell wall and plasma membrane of the cell and 
organelles found in the cell occurs allowing for the release of all the RNA contained in the 
sample. At homogenisation the viscosity of the cell lysates produced during disruption is 
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reduced and the shearing of high molecular weight genomic DNA and other high molecular 
weight cellular components occurs using the TRIzolTM LS Reagent. RNA is separated from 
the rest of the lysate using chloroform while RNA is isolated by RNA precipitation using 
isopropyl propanol. 
 
Total RNA was extracted and purified from the Graham 293 cell line, which was cultured in a 
25 cm3 tissue culture plate with 10 % Foetal Bovine Serum (FBS)-Dulbecco’s Modified Eagle 
Media (DMEM) (Invitrogen Corporation, Life Technologie, Carlsbad, CA, USA) until cells 
became confluent. These cells were grown in monolayer and washed with phosphate buffered 
saline (PBS) prior to RNA extraction. 
 
1. The confluent cells were homogenised by the addition of 2 ml of TRIzolTM LS reagent 
(Invitrogen Corporation, Life Technologie, Carlsbad, CA, USA) per 25 cm3 of culture 
plate and vigorously shaken for 2 hours. 
2. Cells were passed through a pipette several times to ensure that the cells were completely 
homogenised after which the homogenate was transferred to a 2 ml eppendorf tube.  
3. 1 ml of chloroform (Merck Chemicals (Pty) Ltd, Saarchem, Wadeville, Gauteng, South 
Africa) was added to the homogenate and vigorously vortexed for 15 seconds. 
4. The mixture was then incubated at room temperature for 10 minutes after which it was 
centrifuged at 15000 rpm at 4 ˚C for 1 hour in order to allow for phase separation. 
5. The top aqueous layer was transferred to a fresh 2 ml eppendorf tube, to which 1 ml 
isopropyl alcohol (Merck Chemicals (Pty) Ltd, Saarchem, Wadeville, Gauteng, South 
Africa) was added, mixed thoroughly by inverting the tube and left to incubate at room 
temperature for 1 hour after which it was incubated overnight at 4˚C. 
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6. The following day the sample was centrifuged at 3000 rpm for 30 minutes at 4 ˚C after 
which the supernatant was discarded.  
7. The RNA pellet was then washed with 70 % (v/v) ethanol by centrifuging the mixture at 
3000 rpm for 5 minutes at 4 ˚C. 
8. The pellet was resuspended in 100 µl of 0.1 % (v/v) diethyl pyrocarbonate (DEPC)-treated 
water (H2O), which was then stored at –70 ˚C for further use. 
9. The quality of the RNA extracted was determined by formaldehyde agarose gel 
electrophoresis (Section 2.2.5.1.). 
 
2.2.2.1.2. Reverse Transcription/Complementary DNA Synthesis  
Reverse transcription is the technique that involves the synthesis of complementary 
deoxyribonucleic acid (cDNA) through a two-step process. This involves isolation of 
messenger RNA (mRNA) from total RNA using oligo-deoxythymidines (dT) primers, which 
are specific for mRNA, after which it is reverse transcribed into single-stranded cDNA using 
the enzyme reverse transcriptase. All mRNA have poly-adenosines (poly-A) tail at its 3’ end, 
thus enabling oligo-dT primers to bind to them. 
 
Reverse transcription was performed using a First Strand cDNA Synthesis Kit for RT-PCR 
(AMV) purchased from Roche Diagnostics GmbH (Manneheim, Germany). 1-2 ng of total 
RNA sample was used as the template for reverse transcription via AMV reverse 
transcriptase. mRNA was isolated from total RNA using the oligo-p(dT)15 primers. The 
reverse transcription reaction was carried out in a total volume of 20 µl that was composed of 
the reagents seen in Appendix 3 Table 1. A negative control was used, which was to perform 
reverse transcription in the absence of total RNA. The reaction was carried out under the 
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following conditions seen in Appendix 3 Table 2 after which samples were cooled by placing 
it on ice for 10 minutes. Thereafter, the cDNA was stored at 4 ˚C for further use. 
 
2.2.2.1.3. Polymerase Chain Reaction  
Polymerase chain reaction (PCR) is the technique that results in the selective amplification of 
the region of interest in the deoxyribonucleic acid (DNA) molecule through three cyclic steps. 
These three steps are denaturation, annealing and extension. The gene of interest is amplified 
using primers that are complementary to the sequence of interest. Denaturation is the step at 
which double-stranded DNA is denatured. Annealing is the step at which the forward and 
reverse primers anneal to the template DNA. Extension is the step at which DNA polymerase 
usually Taq polymerase in the presence of MgCl2, dNTPs and PCR buffer synthesises new 
DNA. This repetitive cycle is carried out for a number of cycles to amplify the region of 
interest resulting in the exponential multiplication of the region of interest. 
 
The PBR gene transcript was amplified from cDNA by using primers specific for the PBR 
gene. These primers were 5’-TTCACAGAGAAGGCTGTGGTTC-3’ and 5’-
GCCATACGCAGTAGTTGAGTGT-3’, which represent the forward and reverse primers 
respectively. This results in the amplification of a region of the PBR gene constituting 247 bp 
located between the mRNA positions 283 and 532 (Appendix 4 Figure 1). 
 
PCR was carried out in a total volume of 25 l using the reagents as indicated in Appendix 3 
Table 3. A negative control was used, which was to perform PCR in the absence of template 
DNA. The PCR reaction was performed in a GeneAmp® PCR System 9700 thermocycler 
(Applied Biosystems, Foster City, CA, USA) under the conditions indicated in Appendix 3 
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Table 4. Results were analysed by agarose gel electrophoresis (Section 2.2.5.2.) and the 
product stored at 4 ºC for further use. 
 
2.2.2.1.4. Cloning  
Cloning is the technique by which the DNA segment of interest is inserted into an 
autonomously replicating DNA molecule (cloning vector) so that the DNA segment of 
interest is replicated with the vector. Cloning involves two steps: ligation and transformation. 
 
2.2.2.1.4.1. Ligation 
Ligation is the technique by which recombinant DNA molecules are constructed by joining 
together the vector molecule and the DNA segment of interest using DNA ligase usually T4 
DNA ligase. 
 
The PCR product was ligated into pGEM-T Easy vector (Appendix 5 Figure 1). pGEM-T 
Easy vectors are convenient vectors by which PCR products can be cloned. The vectors are 
prepared by cutting pGEM-T Easy vectors with EcoRV restriction enzyme and adding 3’ 
terminal thymidines (T) to both ends. These 3’ T overhangs at the insertion site improves the 
efficiency of ligation of a PCR product into plasmids by preventing recircularisation of the 
vector and providing a compatible overhang for certain thermostable polymerases that often 
add a single adenosine (A), in a template-independent fashion, to the 3’ ends of the amplified 
fragments. Thus, the vector has T tails that can be ligated to the A overhangs of Taq 
polymerase PCR reaction products. 
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The ligation reactions were carried out using the LigaFastTM Rapid Ligation System (Promega 
Corporation, Madison WI, USA). Ligation reactions were carried out in a total volume of 10 
l consisting of the reagents indicated in Appendix 3 Table 5. Two controls were used, a 
negative control performed in the absence of pGEM-T Easy vector and PCR product and the 
other performed in the absence of PCR product, that is only containing the pGEM-T Easy 
vector. These reactions were then incubated at room temperature for 1 hour after which 
transformation was performed. 
 
2.2.2.1.4.2. Transformation 
Transformation is the technique that ultimately allows for the selection and propagation of 
plasmid DNA via competent bacterial cells taking up the plasmid DNA. Positive selection for 
bacterial cells containing the plasmid DNA is accomplished by growth on medium containing 
an appropriate antibiotic since the plasmid DNA is engineered to contain the corresponding 
antibiotic resistant gene. 
 
Two controls used in this protocol include the ligation mixtures from the above protocol, that 
is, a negative control performed in the absence of pGEM-T Easy vector and PCR product and 
the other performed in the absence of PCR product, that is only containing only the pGEM-T 
Easy vector. 
 
1. Transformation was performed by the addition of 100 µl of MC1061 Escherichia coli 
competent cells (refer to Section 2.2.2.) to each 10 µl ligation mixture. 
2. All three reactions were incubated on ice for 30 minutes followed by incubation at 37 ˚C 
for 5 minutes after which the reactions were immediately placed on ice for 2 minutes. 
3. Thereafter, 900 µl LB broth was added and incubated at 37 ˚C for 1 hour. 
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4. 100 µl of each reaction was plated on warmed 269 mM ampicillin-containing agar plates 
as well as on agar plates containing no ampicillin and incubated at 37˚C overnight. 
5. An image of the plates was captured using a scanner. 
 
2.2.2.1.5. Colony Polymerase Chain Reaction 
Colony PCR is a technique by which the success of cloning can be measured by screening for 
positive colonies, that is, colonies that are positive in the sense that they have acquired the 
right recombinant DNA molecule. PCR amplifies the insert found in the recombinant DNA 
molecule. 
 
Gene specific primers for the PBR gene were used to amplify the insert in the recombinant 
DNA molecule. The template DNA was the colony dissolved in 10 µl of sterile distilled water 
(sdH2O). The negative control used, was to perform the PCR reaction in the absence of 
template DNA. The PCR reactions were performed using the protocols stated in Section 
2.2.2.1.3. and the results were analysed using agarose gel electrophoresis (Section 2.2.5.2). 
 
2.2.2.1.6. Miniprep Analysis/Plasmid DNA Extraction 
Miniprep analysis, which is also known as the alkaline lysis or the plasmid DNA extraction 
method is the technique by which plasmid DNA is extracted from bacterial cells such as 
Escherichia coli. The yield of plasmid will vary depending on a number of factors including 
copy number, cell density of bacterial culture, type of culture medium and the bacterial strain 
used.  
 
 
 
 68 
Production of alkaline lysates involves four basic steps: resuspension, lysis, neutralization and 
clearing of lysates. Resuspension involves the resuspending of harvested bacterial cells in Tris 
(hydroxymethyl) aminomethane (Tris) - hydrochloric acid (HCl) - ethylenediamine tetra 
acetic acid (EDTA) buffer containing ribonuclease (RNase) A. RNase A ensures that liberated 
cellular RNA is digested during lysis. Lysis results in the disruption of the integrity of the 
bacterial cell wall and membrane and in the denaturation of cellular proteins, which in turn 
results in the isolation of plasmid DNA. This is achieved with the ionic detergent sodium 
dodecyl sulphate (SDS). Sodium hydroxide (NaOH) denatures the chromosomal DNA, 
plasmid DNA and proteins. Neutralization of the lysate is achieved by the addition of sodium 
potassium acetate. This high salt concentration causes potassium dodecyl sulphate (KDS) to 
precipitate the denatured proteins and chromosomal DNA. Cellular debris is co-precipitated in 
the unstable salt-detergent complexes. Plasmid DNA being circular and closed renatures 
quickly and remains in solution while chromosomal DNA also begins to renature but because 
it is much larger, the renaturation step is interrupted. Clearing of lysates involves the removal 
of precipitated debris by either centrifugation or filtration. 
 
The Promega WizardPlus® SV Miniprep Purification System (Promega Corporation, 
Madison, WI, USA) was used to purify plasmid DNA. 
1. The rest of the colony mix prepared for colony PCR was mixed with 5 ml LB broth 
containing 5 µl 269 mM ampicillin. 
2. The mixture was left to grow overnight (12-16 hours) at 37 ˚C with vigorous shaking.  
3. The overnight bacterial culture was centrifuged at 10000 rpm for 5 minutes at room 
temperature after which the supernatant was discarded. 
4. The pellet was resuspended in 250 µl Cell Resuspension Solution after which 250 µl Cell 
Lysis Solution was added and incubated at room temperature for 5 minutes. 
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5. 10 µl Alkaline Protease Solution was added and incubated at room temperature for 5 
minutes. 
6. 350 µl of Neutralization Solution was added and centrifuged at top speed for 10 minutes 
at room temperature. 
7. The cleared lysate was decanted into a spin column that had been inserted into a collection 
tube, which was then centrifuged at top speed for 1 minute at room temperature. 
8. The flow through was discarded followed by the addition of 250 µl Wash Solution, which 
was then centrifuged at top speed for 1 minute at room temperature. 
9. The column was transferred to a 1.5 ml eppendorf tube, to which 100 µl of nuclease free 
H2O was added followed by centrifugation at top speed for 1 minute resulting in the 
elution of the plasmid DNA, which was stored at –20 ˚C for further use. 
10.  To determine if plasmid DNA was isolated the results were analysed by agarose gel 
electrophoresis (Section 2.2.5.2.). 
 
2.2.2.1.7. Restriction Digestion  
Restriction digestion is a technique used to determine the presence of the insert by 
ascertaining the size of the insert. The recombinant DNA molecule is usually digested with 
restriction endonucleases. Restriction endonucleases are bacterial enzymes that bind and 
cleave DNA at specific target sequences. Type II restriction endonucleases are nucleases that 
cleave DNA at very specific recognition sequences consisting of a short palindromic 
sequence, cleaving within this site to generate specific termini. These termini are either 
cohesive which can have either 5’ or 3’ overhangs of generally between 2 to 4 bases or blunt 
which have no overhangs and their termini are flush. 
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EcoRI, which recognises the recognition sequence GAATTC1 at the T7 promoter region and 
the SP6 promoter region of the pGEM-T Easy vector (Appendix 5 Figure 1), cuts on either 
side of the insert resulting in its release.  PstI, which recognises the recognition sequence 
CTGCAG at the SP6 promoter region of the pGEM-T Easy vector (Appendix 5 Figure 1), 
results in the linearisation of the recombinant DNA molecule. 
 
Restriction digestions were performed using restriction enzymes purchased from Roche 
Diagnostics GmbH (Manneheim, Germany). The restriction digestion reactions were carried 
out in a total volume of 30 µl composed of the reagents indicated in Appendix 3 Table 6. As 
indicated in Appendix 3 Table 6 either 1 µl of EcoRI was added to the reaction or 1 µl of PstI 
was added to the reaction.  
 
1. The reactions were incubated at 37 ˚C for 1 hour in a waterbath. 
2. Thereafter, the reactions were incubated at 65 ˚C for 5 minutes, which terminated the 
reactions. 
3. Results were analysed using agarose gel electrophoresis (Section 2.2.5.2.). Controls used 
on the gel were the undigested clone and the colony PCR product, that is, the PBR 
fragment to determine if the insert was released. 
 
2.2.2.1.8. Sequencing 
The purified clone was sent to Inqaba Biotechnical Industries (Pty) Ltd (Pretoria, Gauteng, 
South Africa), to determine the sequence of the PBR fragment. Results were analysed using 
CHROMAS, version 1.62 (Technelysium (Pty) Ltd, Helensville, Queensland, Australia) and 
BLAST from the National Centre for Biomedical Information (NCBI) at URL: 
                                                 
1
  indicates where restriction endonucleases cuts the DNA  
 71 
http://www.ncbi.nlm.nih.gov to compare the sequence obtained to a reference sequence 
(Accession Number: BT006949). 
 
2.2.2.1.9. Linearisation of Recombinant DNA Molecules  
Restriction digestion was done to linearise the recombinant DNA molecule in preparation for 
in vitro transcription. PstI and ApaI were used to linearise the recombinant DNA molecule. 
ApaI recognises the recognition sequence GGGCCC2 and cleaves the pGEM-T Easy vector 
at the T7 promoter region (Appendix 5 Figure 1). Thus, the linearised fragment digested by 
PstI is used for the generation of the anti-sense strand while the linearised fragment digested 
by ApaI is used for the generation of the sense strand. 
 
The protocol was followed as mentioned in Section 2.2.2.1.7. However, it should be noted 
that the ApaI restriction digestion reaction was incubated at 30 ˚C and the reaction was 
performed in Restriction Buffer A. This enzyme was purchased from Roche Diagnostics 
(Manneheim, Germany). In the case of PstI, 3 µl of the enzyme and 16 µl of sdH2O were 
required and an incubation period of 3 hours was required in order to perform the reaction. 
This discrepancy occurs as in this case PstI was purchased from Fermentas Life Sciences, 
(Hanover, MD, USA) and thus the restriction buffer used was Restriction Buffer O+. Results 
were analysed agarose gel electrophoresis (Section 2.2.5.2). The control used on the gel was 
undigested plasmid DNA. 
 
 
 
 
                                                 
2
  indicates where restriction endonuclease cuts the DNA 
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2.2.2.1.10. Purification of Linearised Recombinant DNA Molecules  
DNA fragments can be extracted and purified from any agarose gel in Tris-Acetate/EDTA 
(TAE) or Tris-Borate/EDTA (TBE) buffers without phenol extraction and ethanol 
precipitation. This procedure is based on the ability of DNA to bind to silica membranes in 
the presence of chaotropic salts. DNA of 100 bp to 10 kb can be isolated using 
microcentrifugation to force the dissolved gel slice through the membrane while 
simultaneously binding the DNA on the surface of the silica. After, electrophoresis, which 
separates the DNA fragments, the band(s) of interest is excised and dissolved in the presence 
of guanidine thiocyanate. The washing steps follow this, which removes small contaminating 
molecules. 
 
The linearised DNA fragments were purified using the Promega Wizard® SV Gel and PCR 
Clean-Up System (Promega Corporation, Madison, WI, USA). 
 
1. The DNA band of interest was visualized on the agarose gel using an UV light 
transilluminator (UMP, California, USA) and cut out from the gel using a sterile blade. 
2. The gel was dissolved in 10 µl Membrane Binding Solution per 10 mg of the gel slice by 
incubating this solution at 65 ˚C. 
3. The dissolved gel mixture was then transferred to a Minicolumn assembly and incubated 
at room temperature for 1 minute followed by centrifugation at 10000 rpm for 1 minute at 
room temperature. 
4. The flow through was discarded and 700 µl Membrane Wash Solution added followed by 
centrifugation at 10000 rpm for 1 minute at room temperature. 
5. The flow through was discarded and 500 µl Membrane Wash Solution added followed by 
centrifugation at 10000 rpm for 5 minutes at room temperature. 
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6. The Minicolumn was then transferred to a 1.5 ml eppendorf tube to which 30 µl of DEPC-
treated H2O was added followed by centrifugation at 10000 rpm for 1 minute at room 
temperature resulting in the elution of the purified linearised DNA, which was stored at –
20 ˚C for further use. 
7. The results were analysed by quantification using a Milton Roy Spectronic Genesys 5 
spectrophotometer (Biomed Device Engineering, San Francisco, CA, USA) where 
absorbance was measured at 260 nm and 280 nm. In order to quantify the DNA solution, 5 
µl of the linearised DNA solution was dissolved in 0.995 µl DEPC-treated H2O and the 
control used was DEPC-treated H2O alone. 
8. Results were further analysed by agarose gel electrophoresis (Section 2.2.5.2). 
 
2.2.2.2. Sense and Anti-Sense Probe Synthesis 
2.2.2.2.1. In Vitro Transcription of Digoxigenin Labelled Sense and Anti-Sense Transcripts  
In vitro transcription is the technique by which small amounts of RNA can be synthesized 
from a DNA template under the suitable control of a promoter for RNA polymerase such as 
SP6, T3 and T7 RNA polymerase. Thereafter, each RNA copy is labelled with digoxigenin 
(DIG)-deoxyuridine triphosphate (dUTP) at every 20-25th nucleotide position. DIG is a 
steroid that is isolated from the digitalis plant, thus allowing for the detection of the sequence 
of interest during in situ hybridisation when bound to anti-DIG conjugates. 
 
DIG-labelled anti-sense and sense complementary RNA (cRNA) transcripts were generated 
using 2 ng/ml linearised purified pGEM-T Easy vectors containing the PBR gene that was 
digested with PstI and ApaI respectively and the DIG RNA Labelling Kit (SP6/T7) purchased 
from Roche Diagnostics GmbH (Manneheim, Germany). The anti-sense probe was generated 
in the presence of T7 RNA polymerase while the sense probe was generated in the presence 
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of SP6 RNA polymerase. To determine the specificity of labelling a control cRNA was also 
generated from control DNA PSPT 18-Neo/PvuII in the presence of SP6 RNA polymerase. 
All three reactions were carried out under the same conditions in a total volume of 20 µl 
containing the following reagents as seen in Appendix 3 Table 7. 
 
1. These reactions were incubated at 37 ˚C for 2 hours in a GeneAmp® System 2700 
thermocycler (Applied Biosystems, Foster City, CA, USA). 
2. The reactions were terminated by the addition of 2 µl of 0.2 M EDTA, pH 8.0 after which 
it was briefly vortexed and centrifuged. 
3. 2.2 µl of 4 M lithium chloride (LiCl) was added to each reaction. 
4. The reactions were precipitated by the addition of 75 µl of cold absolute ethanol (Merck 
Chemicals (Pty) Ltd, Saarchem, Wadeville, Gauteng, South Africa) followed by brief 
vortexing and centrifugation after which the reactions were incubated at –20 ˚C for 2 
hours. 
5. The precipitate was pelleted at 13000 rpm for 15 minutes at 4 ˚C after which the 
supernatant was discarded. 
6. The pellet was washed with the addition of 100 µl of cold 70 % (v/v) ethanol after which 
the pellet was precipitated by centrifugation at 13000 rpm for 15 minutes at 4 ˚C.  
7. The supernatant was discarded and the pellet dried for 2 hours in an air lamina flow. 
8. The pellet was dissolved in 25 µl of DEPC-treated H2O and left to stand at 4 ˚C for 1 hour 
after which the DIG labelled transcripts were stored at –70 ˚C in aliquots of 10 µl in tight 
capped 0.5 ml eppendorf tubes. 
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2.2.2.2.2. Estimation of Minimal Concentration of Probes  
The minimal concentration of the probe that can be detected was estimated using the 
guideline described in the DIG’s user guide (Roche Diagnostics GmbH, Manneheim, 
Germany). This was done by 10-fold serial dilutions of the DIG-labelled cRNA transcripts 
synthesised in Section 2.2.2.2.1.  and DIG-labelled control RNA having a concentration of 10 
g/100 µl provided in the DIG RNA Labelling Kit in sdH2O as tabulated in Appendix 3 Table 
8. 
 
The optimal concentrations of the sense and anti-sense probes were determined by the 
comparing the spot intensities of each of the probes to the DIG-labelled control cRNA. 
 
1. 1 µl of each dilution was spotted on a nylon membrane (Hybond, Amersham Biosciences, 
California, USA), where spots were lightly marked with a pencil after which the 
membrane was allowed to air-dry in a lamina flow for 10 minutes. 
2. The probe was fixed onto the membrane by placing it under UV light for 5 minutes. 
3. 50 ml 1X Washing Buffer was used to wash the membrane, shaking constantly for 5 
minutes after which the membrane was blocked using 50 ml 1X Blocking Solution, 
shaking constantly for 30 minutes. 
4. The membrane was incubated with 50 ml of sheep anti-DIG Alkaline Phosphatase (AP) 
Immunoglobulin (Ig) G (Roche Diagnostics GmbH, Manneheim, Germany) that was 
diluted 1:10000 with 1X Blocking Solution, shaking constantly for 30 minutes. 
5. Thereafter, the membrane was washed twice with 50 ml 1X Washing Buffer, shaking 
constantly for 15 minutes after which 50 ml 1X Detection Buffer was used to immerse the 
membrane, shaking constantly for 2 minutes. 
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6. This membrane was then incubated overnight in the dark in 50 ml nitroblue tetrazolium 
(NBT)/5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Roche Diagnostics GmbH, 
Manneheim, Germany) that was diluted 1:50 with 1X Detection Buffer with constant 
shaking. This allowed for the colour reaction to occur. 
7. The reaction was terminated by placing the membrane in 1X Tris-HCl/EDTA (TE) buffer 
for 5 minutes after which the membrane was air-dried and the minimal concentration of 
the sense and anti-sense probes determined by comparing it with DIG-labelled control 
cRNA. 
 
2.2.2.3. In Situ Hybridisation 
In situ hybridisation is the process by which specific mRNA sequences are localized and 
detected in morphologically preserved tissue sections or cell preparations by hybridising a 
complementary strand of a nucleotide probe to the sequence of interest. This technique can be 
divided into three major steps: pre-hybridisation, hybridisation and post-hybridisation. Pre-
hybridisation is the step at which tissue sections are dewaxed and treated with various 
chemicals such as acetic anhydride and HCl to reduce background staining. Hybridisation is 
the step at which the DIG-labelled RNA probes bind to the mRNA sequence of interest in the 
tissue sections. Post-hybridisation is the step at which excess probe is removed and the 
labelled mRNA sequence of interest can be colorimetrically and fluorescently detected. 
 
Two controls were used to perform this technique. The first was a negative control, which 
was prepared by the localisation of the sense probe on a tissue preparation, thus allowing for 
one to determine if localisation occurred when tissue preparations were hybridised with the 
anti-sense probe. The other control used was to compare the diseased tissue to the normal 
tissue, both of which were hybridised with the anti-sense probe. 
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2.2.2.3.1. Pre-Hybridisation   
1. The tissue sections were dewaxed in fresh xylene (Merck Chemicals (Pty) Ltd, Saarchem, 
Wadeville, Gauteng, South Africa) for 30 minutes, which consisted of 3 changes of 10 
minutes each. 
2. Thereafter, the tissue sections were rehydrated in fresh 100% ethanol for 6 minutes, which 
consisted of 2 changes of 3 minutes each. This was followed by serial hydration of the 
tissue sections for 3 minutes each in 90%-, 70%-, 50%-ethanol and DEPC-H2O. 
3. The tissue sections were fixed in 4% paraformaldehyde (PFA) for 20 minutes after which 
it was washed in fresh Tris Buffer Saline (TBS) for 3 minutes, which consisted of 3 
changes of 1 minute each. 
4. The proteins in the tissue sections were denatured in 0.1 M HCl for 10 minutes at room 
temperature followed by washing in fresh TBS for 3 minutes, which consisted of 3 
changes of 1 minute each. 
5. This was followed by the limitation of non-specific labelling with freshly prepared 0.5% 
acetic anhydride for 10 minutes after which it was washed in fresh TBS for 3 minutes, 
which consisted of 3 changes of 1 minute each. 
6. Subsequently, the cell membrane was permeabilised with 10g/l Proteinase K (Promega 
Corporation, Madison, WI, USA) dissolved in TBS for 20 minutes at 37 ˚C followed by 
washing with fresh TBS for 3 minutes, which consisted of 3 changes of 1 minute each. 
7. Proteinase K activity was terminated by placing tissue sections in TBS for 5 minutes at 4 
˚C. 
8. This was followed by the serial dehydration of the tissue slides for 1 minute each in 50%-, 
70%- and 90%-ethanol. The tissue sections were further dehydrated in 100% ethanol for 2 
minutes, which consisted of 2 changes of 1 minute each. 
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9. Thereafter, the tissue sections were dried in chloroform (Merck (Pty) Ltd, Saarchem, 
Wadeville, Gauteng, South Africa) for 10 minutes in the fume hood. 
10. The tissue sections were then stored in a dust-free environment for days at room 
temperature for further use. 
 
2.2.2.3.2. Hybridisation 
1. Probes were prepared for hybridisation. The probes were thawed on iced. 2 µl 10 µg/ml 
Herring Sperm DNA (Promega Corporation, Madison, WI, USA) was dissolved in 198 µl 
of hybridisation buffer and vortexed vigorously after which 1 µl in the case of the sense 
probe and 0.8 µl in the case of the anti-sense probe was added. 0.8 µl was used in the case 
of anti-sense probe because the concentration of the probe was very high, which results in 
increase trapping during hybridisation and thus a lower value was used to prevent this. 
These probe preparations were than boiled for 5 minutes followed by placing it 
immediately on ice for 2 minutes. 
2. 100 µl of the probe was placed on each slide that was enclosed with a GENE Frame 
(Southern Cross Biotechnology, Cape Town, South Africa). 
3. Hybridisation was allowed to take place by placing slides in a Hybaid Omnislide Flat 
Block Humidity Chamber (Thermo Electron Company, Massachusetts, USA) containing a 
solution composed of 50% (v/v) formamide and 5% (v/v) 20X NaCl sodium citrate 
solution (SSC), which prevents the evaporation of the hybridisation solution, overnight (± 
16 hours) at 55 ˚C. 
 
2.2.2.3.3. Post-Hybridisation  
The Roche Diagnostics Washing and Blocking Kit (Roche Diagnostics GmbH, Manneheim, 
Germany) were used to conduct this protocol. 
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1. The slides were removed from the humid chamber and the excess probe was removed by 
dropping it off after which GENE Frames were removed. 
2.   Slides were then washed in 2X SSC for 30 minutes at 37 ˚C in a wash module after which 
they were washed in 1X SSC, 0.5X SSC and 0.1X SSC for 20 minutes each at 55 ˚C. 
3. The slides were then washed in fresh TBS for 3 minutes, which consisted of 3 changes of 
1 minute each. 
4. Thereafter, 100 µl of 1X Blocking Solution was added to each slide and incubated at room 
temperature for 15 minutes in a humidity chamber. This allows for the blocking of non-
specific binding sites on tissue sections. 
 
The protocol hereafter varies depending on the detection method used. 
 
2.2.2.3.3.1. Colorimetric Detection 
DIG-labelled probes that have hybridised to the target sequence can be detected 
colorimetrically with AP conjugated to anti-DIG. This occurs when the tissue sections are 
incubated with a suitable substrate such as NBT/BCIP allowing for AP activity to occur, 
which results in the formation of a purple/blue precipitate, which can be viewed under a light 
microscope. 
 
1. Tissue sections were incubated with 100 µl sheep anti-DIG-AP IgG diluted 1:500 in 1X 
blocking solution per slide and incubated in a humid chamber for 1 hour at room 
temperature. 
2. The tissue slides were washed in fresh TBS for 3 minutes, which consisted of 3 changes 
of 1 minute each. 
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3. Thereafter, tissue sections were incubated with 100 µl of chromogen NBT/BCIP diluted 
1:50 in 1X Detection Buffer per slide and left to develop in a dark humid chamber 
overnight at room temperature. 
4. The reaction was terminated by incubating the slides with 100 µl of 1X TE for 5 minutes 
after which the slides were washed in running tap water for 5 minutes. 
5. Tissue sections were counterstained with 5 drops of Mayer’s Haematoxylin (Sigma 
Diagnostics, St. Louis, MO, USA) per slide for 1 minute followed by washing in running 
tap water for 10 minutes. 
6. Thereafter, tissue sections were mounted with aqueous glycerol jelly and allowed to dry at 
37 ˚C for ± 1 hour. 
7. Tissue sections were viewed and images captured using the AxioCam (MRm/MRc) 
camera and AxioVision software package (Carl Zeiss AG, Oberkochen, Germany). 
 
2.2.2.3.3.2.  Fluorescent Detection 
DIG-labelled RNA probes that have hybridised to the target sequence can be detected 
fluorescently with fluorescein isothiocyanate (FITC) conjugated to anti-DIG. FITC does not 
require the presence of a suitable substrate in order to emit a colour substrate. When FITC is 
excited at 490 nm, it results in the emission of an apple green colour, which can be viewed 
under a fluorescent microscope. 
 
1. The slides were washed in TBS-Tween for 5 minutes after which they were incubated in a 
Tri-Sodium-Blocking (TNB) solution at 37 ˚C for 30 minutes. 
2. Tissue sections were then incubated at 37 ˚C with 75 µl anti-DIG fluorescein for 30 
minutes after which the slides were washed in TBS-Tween for 15 minutes, which 
consisted of 3 changes of 5 minutes each. 
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3. The tissue sections were mounted with Molecular Probes SlowFade® Light Antifade Kit 
(Molecular Probes, Eugene, Oregon, USA) using the manufacturer’s instructions.  
3.1. Slides were mounted by placing a drop of component C that is Equilibration Buffer 
on tissue samples. These slides were then incubated at room temperature for 10 
minutes or until dry. 
3.2. Thereafter, a drop of component A that is the Mounting Media was added to which a 
coverslip was placed. 
4. Tissue sections were then viewed under the fluorescence microscope and images captured 
using the AxioCam (MRm/MRc) camera and AxioVision software package. 
 
2.2.3. Expression Levels of the Peripheral Benzodiazepine Receptor mRNA in Various 
Human Cancer Tissues 
2.2.3.1.  RNA Isolation  
RNA was isolated from MRC5, A549, HeLa and HepG cultured cells using the High Pure 
RNA Isolation kit purchased from Roche Diagnostic GmbH (Manneheim, Germany). 
 
1. Cells were resuspended in 200 µl PBS after which 400 µl of Lysis/Binding Buffer was 
added and vortexed for 15 seconds. 
2. The sample was then transferred to a High Pure filter tube inserted into a collection tube 
after which the sample was centrifuged for 15 seconds at 10000 rpm at room temperature 
and the flow through discarded.  
3. 90 µl DNase Incubation Buffer and 10 µl DNase I was added into a sterile reaction tube, 
mixed, after which the solution was transferred into the High Pure filter tube. This was 
left to incubate for 15 minutes at 15 ˚C. 
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4. 500 µl Wash Buffer I was added to the filter tube assembly and centrifuged at 10000 rpm 
for 15 seconds at room temperature. 
5. The flow through was discarded and 500 µl Wash Buffer II added to the filter tube 
assembly. This was centrifuged at 10000 rpm for 15 seconds at room temperature. 
6. The flow through was again discarded and 200 µl Wash Buffer II added to the filter tube 
assembly. This was centrifuged at 10000 rpm for 2 minutes at room temperature, which 
ensured the removal residual Wash Buffer. 
7. The collection tube containing the flow through was discarded and the High Pure filter 
tube was inserted into a 1.5 ml eppendorf tube. 100 µl Elution Buffer was added to the 
filter tube assembly and centrifuged at 10000 rpm for 1 minute at room temperature. This 
was then stored at –80 ˚C for further use. 
 
2.2.3.2. Relative Quantitative Reverse Transcriptase- Real-Time Polymerase Chain Reaction 
Quantitative reverse transcriptase-real-time PCR is the process by which mRNA can be 
quantified both in relative terms and absolute terms. It is a two-step process involving reverse 
transcription and real-time PCR. The quantification of the PCR product relies on the detection 
of a fluorescent signal proportional to the amount of product. PCR products can be measured 
in real-time by the used of double-stranded DNA-binding dye, namely SYBR Green I, which 
binds to double-stranded DNA, that is the PCR product. The amount of PCR product can be 
directly measured in real time using a fluorimeter. Quantification is based on a threshold 
cycle, that is the first PCR cycle with detectable fluorescence. By monitoring during the 
period when PCR amplification is exponential provides precise data for accurate 
quantification. 
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2.2.3.2.1. Reverse Transcription/Complementary DNA Synthesis  
Reverse transcription was performed using an ImProm-IITM Reverse Transcription System 
purchased from Promega Corporation (Madison, WI, USA). 1-2 ng of total RNA samples was 
used as a template for reverse transcriptase. mRNA was isolated from total RNA using the 
oligo-(dT)15 primers. The reverse transcription reaction was carried out in a total volume of 
20 µl that was composed of the reagents indicated in Appendix 3 Table 9. A negative control 
was used, which was to perform reverse transcription in the absence of total RNA. The 
reaction was carried out under the following conditions as seen in Appendix 3 Table 10 after 
which samples were cooled by placing on ice for 10 minutes. The concentration of the cDNA 
was spectrophotometrically determined using an Ultraspec2000 (Amersham Pharmacia 
Biotech, Picataway, NJ, USA) after which the cDNA was stored at 4 ˚C for further use. 
 
2.2.3.2.2. Real-Time Polymerase Chain Reaction  
Real-Time PCR was carried out in a total volume of 25 µl using the reagents as indicated in 
Appendix 3 Table 11. The negative control used was to perform real-time PCR in the absence 
of both the forward and reverse primers and template DNA. The relative quantitative PCR 
was performed in a Bio-Rad MJ Mini Personal Thermal Cycler (Bio-Rad Laboratories, 
Hercules, CA, USA) under the conditions indicated in Appendix 3 Table 12. Results were 
analysed by quantitation and melting curves using the Opticon 3.1 software (Bio-Rad 
Laboratories, Hercules, CA, USA) and agarose gel electrophoresis (Section 2.2.5.2.). 
 
 84 
2.2.4. Peripheral Benzodiazepine Receptor Protein Expression 
2.2.4.1. Restriction Digestion of the Peripheral Benzodiazepine Receptor Insert and pGEX-
6P-2 Expression Vector  
The insert that is the DNA fragment of interest (PBR) was digested from the pGEM-T Easy 
vector using BamHI and XhoI. These two recognition sequences had been built in with the 
PCR primers, thus allowing for the insert to contain the two recognition sequences found on 
the multiple cloning site of the protein expression vector, pGEX-6P-2 (Appendix 5 Figure 2), 
that is pGEX-6P-2 recognises the recognition sequence for BamHI GGATTC3 and XhoI 
CTCGAG3. 
 
The protocol was followed as mentioned in Section 2.2.3.1.7. However it should be noted that 
BamHI and XhoI digestion were purchased from Fermentas Life Sciences (Hanover, MD, 
USA), thus the Restriction Buffer for BamHI was Buffer BamHI and the Restriction Buffer 
for XhoI was Buffer R. The Restriction Buffer used for double digestion was Buffer Tango. 
Three controls were used. These included the undigested clone, digesting the clone with 
BamHI only and digesting the clone with XhoI only. The protocol in Section 2.2.3.1.7. varied 
as follows: the two controls that is the clone digested with BamHI only and the clone digested 
with XhoI only required 3 µl of restriction enzyme and 16 µl sdH2O, the clone digested with 
both BamHI and XhoI required 3 µl of each restriction enzyme, 2 µl Restriction Buffer and 12 
µl sdH2O and each of the reaction were incubated for 3 hours. The restriction digestion 
reactions were carried out for the clone containing the PBR gene and the pGEX-6P-2 
expression vector and the controls used for each were as mentioned above. Results were 
analysed using agarose gel electrophoresis (Section 2.5.2). 
 
                                                 
3
  indicates where restriction nucleases cuts the DNA 
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2.2.4.2. Purification of the Peripheral Benzodiazepine Receptor Insert and pGEX-6P-2 
Expression Vector 
The released insert and the pGEX-6P-2 vector digested with BamHI and XhoI were purified 
by the protocol seen in Section 2.2.3.1.10. after which results were analysed by agarose gel 
electrophoresis. 
 
2.2.4.3. Cloning 
The purified insert was ligated into the protein expression vector, pGEX-6P-2 after which the 
recombinant molecules were transformed into competent MC1061 Escherichia coli cells 
(Section 2.2.1.) as described in Section 2.2.2.1.4. Two controls were used, a negative control 
performed in the absence of pGEX-6P-2 vector and the purified insert and the other 
performed in the absence of the PCR product, that is, only containing the pGEX-6P-2 vector. 
An image was captured using a scanner. 
 
2.2.4.4. Colony Polymerase Chain Reaction 
Colony PCR was done to determine the success of cloning by amplifying the insert found in 
the recombinant DNA molecule via PCR using the protocol as described in Section 2.2.2.1.5. 
The negative control used, was to perform the PCR reaction in the absence of template DNA. 
Results were analysed by agarose gel electrophoresis (Section 2.2.5.2.). 
 
2.2.4.5. Miniprep Analysis/Plasmid DNA Extraction 
The recombinant DNA molecules, that is the insert ligated to the pGEX-6P-2 expression 
vector was extracted from the bacterial cells via miniprep analysis or plasmid DNA extraction 
as described in Section 2.2.1.6. Results were analysed by agarose gel electrophoresis (Section 
2.2.5.2.). 
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2.2.4.6. Restriction Digestion 
Restriction digestion was done to determine the presence of the insert using the protocol in 
Section 2.2.2.1.7. with the variations as described in 2.2.4.2. Four controls used include the 
undigested clone, digesting the clone with BamHI only, digesting the clone with XhoI only 
and the colony PCR product. Results were analysed by agarose gel electrophoresis (Section 
2.2.5.2.). 
 
2.2.4.7. Sequencing 
The purified clone was sent to Inqaba Biotechnical Industries (Pty) Ltd to determine the 
sequence of the PBR fragments. Results were analysed using CHROMAS, version 1.62 and 
BLAST from NCBI to compare the sequence obtained to a reference sequence (Accession 
Number: BT006949) and to determine the orientation of the PBR fragment. The sequence was 
then converted into an amino acid sequence using DNAMAN, trial version 6.0 (Lynonn 
Corporation, Vaudreuil, Quebec, Canada) in order to determine the size of the protein that 
will be synthesised when expressed. 
 
2.2.4.8. Optimisation of the Gluthathione-S-Transferase Fusion Protein using Isopropyl--D-
Thiogalactopyranoside  
Gluthathione-S-Transferase (GST) fusion protein that is GST fused with PBR was synthesised 
by inducing the cloned pGEX-6P-2 vector with isopropyl--D-thiogalactopyranoside (IPTG), 
which binds to the lac repressor, encoded by the lac Iq gene thus allowing for the transcription 
of all genes downstream of the tac promoter in the pGEX-6P-2 expression vector. 
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1. 2 µl PBR ligated into pGEX-6P-2 expression vectors were transformed into competent 
BL-2 Escherichia coli cells (refer to Section 2.2.1) as described in Section 2.2.2.1.3.  
2. A single colony was inoculated in 5 ml LB containing 5 µl of 269 mM ampicillin and 
grown overnight at 37 ˚C, shaking constantly at 110 rpm. 
3. 1 ml of this overnight culture was then added to 60 ml fresh LB containing 60 µl of 269 
mM ampicillin after which it was incubated at 37 ˚C, shaking constantly at 110 rpm for ± 
2 hours until the optical density at 550 nm was ± 0.4. 
4. Thereafter, 10 ml of culture were transferred to six different sterile tubes where they were 
induced with different concentrations of 0.5 M IPTG, namely 0.1 mM, 0.3 mM, 0.5 mM, 
0.7 mM and 0.9 mM. The control used was bacterial culture uninduced with IPTG. These 
cultures were then allowed to shake at 110 rpm at 25 ˚C overnight. 
5. The overnight induced cultures were transferred to six 50 ml isopropylene tubes and 
centrifuged at 10000 rpm for 5 minutes at 4 ˚C using the JA-20 rotor and J2-21 Beckman 
centrifuge. 
6. The supernatant was discarded and the pellet resuspended in 2 ml PBS. 
7. The resuspended culture was freeze-thawed by placing it at 37 ˚C for 15 minutes and –80 
˚C for 15 minutes. This step was repeated twice. 
8. Thereafter, the resuspended culture was centrifuged at 10000 rpm for 30 minutes at 4 ˚C 
using the JA-20 rotor and J2-21 Beckman centrifuge. 
9. The supernatant was transferred to a 1.5 ml eppendorf tube and stored at –80 ˚C for 
further use. Results were analysed using SDS-PAGE (Section 2.2.5.3.). 
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2.2.5. Electrophoresis 
2.2.5.1. Formaldehyde Agarose Gel Electrophoresis  
Formaldehyde agarose gel electrophoresis is the technique by which RNA can be separated 
according to size. This can occur because formaldehyde prevents the RNA from forming a 
secondary structure, thus it acts as a denaturing agent. The nucleic acid material is loaded 
onto the formaldehyde agarose gel, to which an electric current is applied. Due to the negative 
charge of the RNA, which results from the phosphate molecules on the RNA backbone, the 
RNA migrates towards the positive electrode. The agarose gel, which contains randomly, 
distributed pores acts a “molecular sieve”, separating the molecules according to size. The 
RNA fragments are visualised by staining the gel with ethidium bromide. Ethidium bromide 
intercalates between the bases of the RNA, which can then be visualised under UV light as 
the ethidium bromide fluoresces under these conditions. 
 
1. The formaldehyde agarose gel was prepared by dissolving 1 g of agarose-D-1-LE 
(Hispanagar, Whitehead Scientific (Pty) Ltd, Brackenfell, South Africa) in 10 ml of 10X 
3-[N-morpholino] propane sulfonic acid (MOPS) and 85 ml DEPC-treated H2O. 
2.  The solution was allowed to reach 50 ˚C after which 5.4 ml 37% formaldehyde (v/v) was 
added followed by addition of 10 mg/ml ethidium bromide (Merck KGoA, Darmstadt, 
Germany) and the gel allowed to set on a casting tray.  
3. Thereafter, 10 µl of freshly prepared formaldehyde gel loading buffer was added 
subsequent to which the mixture was heated at 65 ˚C for 5 minutes, which allowed for the 
denaturation of RNA.  
4. This mixture was then cooled on ice for 10 minutes before it was loaded onto the gel. 
5. The gel was electrophoresed with 1X MOPS at 50 V and allowed to run until the loading 
dye reached three-quarters of the gel after which it was viewed and image captured under 
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a Bio-Rad Universal Hood II UV transilluminator  (Bio-Rad Laboratories-Segrate, Milan, 
Italy) and using the QuantityOne-D-Analysis Software (Bio-Rad Laboratories, Hercules, 
CA, USA) or a UVP BioDoc-ItTM System SG (The Scientific Group). 
 
2.2.5.2. Agarose Gel Electrophoresis 
Agarose gel electrophoresis is the technique by which DNA can be separated according to its 
size. The nucleic acid material is loaded onto the agarose gel, to which an electric current is 
applied. Due to the negative charge of the DNA, which results from the phosphate molecules 
on the DNA backbone, the DNA migrates towards the positive electrode. The agarose gel, 
which contain randomly distributed pores acts as a “molecular sieve”, separating the 
molecules by size. The DNA fragments are visualised by staining the gel with ethidium 
bromide. Ethidium bromide intercalates between the bases of the DNA, which can then be 
visualised under UV light as the ethidium bromide fluoresces under these conditions.  
 
1. A 1% agarose gel was prepared by dissolving 1 g of agarose in 100 ml TBE buffer. 0.3 
µg/ml ethidium bromide was added to the solution once it reached about 50 ˚C and the gel 
allowed to set on a casting tray.  
2. DNA samples were mixed with a fifth of the sample volume bromophenol loading dye. 
3. DNA samples were run with a DNA molecular weight marker of 100 to 1050 bp known as 
DNA Molecular Weight Marker XIV (Roche Diagnostics, Manneheim, Germany) 
(Appendix 6 Figure 1A) or 80 to 1031 bp known as GeneRulerTM 100 bp DNA Ladder 
(Fermentas Life Sciences, Hanover, MD, USA) (Appendix 6 Figure 1B) or 50 to 1031 bp 
known as GeneRulerTM 50 bp DNA Ladder (Fermentas Life Sciences, Hanover, MD, 
USA) (Appendix 6 Figure 1C). 
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4. The DNA samples and the DNA molecular weight marker were loaded onto the gel and 
run at 70 V in 1X TBE buffer. The gel was allowed to run until the bromophenol blue dye 
reached three-quarters of the gel after which the gel was viewed and image captured using 
a UV transilluminator. 
 
2.2.5.3. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis  
Sodium dodecyl sulphate (SDS)- polyacrylamide gel electrophoresis (PAGE) is the technique 
by which proteins can be separated according to their size. SDS is an anionic detergent which 
means it is a detergent which denatures proteins to their primary structures by “wrapping 
around” the polypeptide backbone thus binding to proteins in a mass ration of 1.4:1 and 
conferring a negative charge to the denatured protein. Thus, all proteins in the gel will migrate 
to the positive electrode when placed in an electric field. -mercaptoethanol or dithiothreitol 
(DTT) reduces disulphide bridges in proteins, which allows for the random configuration 
necessary for separation by size. N, N, N’, N’-tetramethylenediamine (TEMED) is a free 
radical stabilizer that catalyses the decomposition of the persulphate ion in ammonium 
persulphate to give a free radical, which in turn results in the initiation of polymerisation of 
acrylamide. The polyacrylamide gel is a polymer of acrylamide monomers that are 
polymerised in a head-to-tail fashion into a long chain and bis-acrylamide, which is a cross-
linking agent that is occasionally built into the growing acrylamide chain thus inducing a 
second site for chain extension resulting in the formation of a cross-linked matrix that 
functions as a “molecular sieve” to separate proteins according to their size when placed 
under an electric field. Proteins can be visualised by staining the gel with Coomassie Brilliant 
Blue, a sulphated trimethlyamine in a methanol: H2O: glacial acetic acid mixture. This glacial 
acetic acid-methanol mixture acts as a denaturing agent by precipitating or fixing the protein 
in the gel preventing it from being washed away during staining and functions in complexing 
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the Coomassie Brilliant Blue to the protein. Thereafter, the gel is destained with Destaining 
Solution to remove excess staining solution. 
 
1. Two glass plates, one notched and one having spacers were assembled by clamping the 
two plates together. The clamped plates were placed on a sponge in order to clamp the 
bottom and held in an upright position. 
2. A 12% (v/v) separating gel was prepared as indicated in Appendix 3 Table 13 and poured 
between the plates until three-quarters filled. This gel was then allowed to stand until it 
solidified. 
3. A 7% (v/v) stacking gel was prepared as indicated in Appendix 3 Table 13 and poured 
between the plates until completely filled after which a comb was inserted between the 
two plates and allowed to solidify. 
4. After solidification, the comb was removed and the plate placed in a bucket containing 
Electrophoresis Buffer in a manner that each well was submerged with the buffer. 
5. 30 µl of protein samples were mixed with 10 µl of 2X sample dye, boiled for 4 minutes at 
95 ˚C after which it was loaded onto the gel with PageRulerTM Prestained Protein Ladder 
(Fermentas Life Sciences, Hanover, MD, USA) (Appendix 6 Figure 2).  
6. The gel was allowed to run at 150 V until the loading dye reached ±0.5 cm from the 
bottom of the gel. 
7. The gel was then removed from the glass plates by lifting the plate using a spatula and 
stained overnight with Coomassie Brilliant Blue, shaking constantly. The Coomassie 
Brilliant Blue was removed and the gel rinsed with dH2O to remove excess stain. 
8. Thereafter, the gel was destained overnight with Destain Solution shaking constantly. The 
gel was washed with dH2O after which the image was captured using a Bio-Rad Universal 
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Hood II Transilluminator (Bio-Rad Laboratories-Segrate, Milan, Italy) and using the 
QuantityOne-D-Analysis Software (Bio-Rad Laboratories, Hercules, CA, USA).  
  
 93 
APPENDIX 1: Information of Tissue Array Panel 
 
Table 1: Tissue Array Panel Display 
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Number Age Sex Organ Pathology Diagnosis Grade 
1 46 Male Liver Hepatocellular Carcinoma II 
2 78 Female Colon Adenocarcinoma III 
3 57 Female Epiploon Squamous Cell Carcinoma III 
4 66 Male Prostate Adenocarcinoma III 
5 60 Female Breast Infiltrating Duct Carcinoma No Grade 
6 57 Male Lung Adenocarcinoma III 
7 60 Female Kidney Chromophobe Carcinoma No Grade 
8 67 Male Brain Astrocytic Carcinoma II 
9 41 Male Liver Hepatocellular Carcinoma III 
10 66 Male Colon Adenocarcinoma II 
11 52 Male Epiploon Squamous Cell Carcinoma III 
12 64 Male Prostate Adenocarcinoma II 
13 49 Female Breast Infiltrating Duct Carcinoma No Grade 
14 46 Male Lung Squamous Cell Carcinoma III 
15 53 Female Kidney Clear Cell Carcinoma No Grade 
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16 49 Female Brain Lymphoma - 
17 77 Male Liver Hepatocellular Carcinoma II 
18 57 Male Colon Adenocarcinoma I 
19 60 Male Epiploon Squamous Cell Carcinoma III 
20 72 Male Prostate Adenocarcinoma III 
21 48 Female Breast Infiltrating Duct Carcinoma No Grade 
22 36 Female Lung Small Cell Carcinoma No Grade 
23 45 Male Kidney Clear Cell Carcinoma No Grade 
24 57 Male Brain Ependymoblastoma - 
25 48 Male Liver Normal Tissue - 
26 66 Male Colon Normal Tissue - 
27 65 Male Stomach Normal Tissue - 
28 67 Male Prostate Proliferative Tissue  - 
29 43 Female Breast Normal Tissue - 
30 46 Male Lung Normal Tissue - 
31 45 Male Kidney Normal Tissue - 
32 67 Male Brain Normal Tissue - 
33 37 Male Liver Normal Tissue - 
34 52 Female Colon Normal Tissue - 
35 74 Female Stomach Normal Tissue - 
36 78 Male Prostate Proliferative Tissue - 
37 42 Female Breast Normal Tissue - 
38 36 Female Lung Normal Tissue - 
39 51 Female Kidney Normal Tissue - 
40 67 Male Brain Normal Tissue - 
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41 48 Male Liver Normal Tissue - 
42 57 Male Colon Normal Tissue - 
43 64 Female Epiploon Greater Omentum  - 
44 68 Male Prostate  Proliferative Tissue - 
45 51 Female Breast Harden Adenosis Tissue - 
46 57 Male Lung Normal Tissue - 
47 49 Female Kidney Normal Tissue - 
48 59 Male Brain Normal Tissue - 
1. Case numbers 1-24 represent diseased tissues, case numbers 25-27, 29-35, 37-43 and 45-48 represent 
normal tissues and case numbers 28, 36 and 44 represents hyperplastic tissues. 
2. Grade indicates the level of malignancy of a tumour. Tumours are graded based on their mitotic index 
(growth rate), vascularity, presence of necrotic centres, invasive potential (border distinctness) and 
similarity to normal cells. Malignant tumours contain several grades of cells, however the most malignant 
cell found in the tumour determines the grade for the entire tumour even if most of the tumour is a lower 
grade. According to the World Health Organization grading system, grade I tumours are the least malignant 
and these tumours grow slowly and microscopically appear almost normal. Grade II tumours grow slightly 
faster than grade I tumours, have slightly abnormal microscopic appearance and these tumours may invade 
surrounding normal tissue. Grade III tumours are malignant containing actively reproducing normal cells 
that invade surrounding normal tissue. Grade IV tumours are the most malignant invading wide areas of 
surrounding tissue that reproduce rapidly. These tumours have an unusual microscopic appearance and are 
necrotic in the centre. In addition, Grade IV tumours have new blood vessels forming that maintain the rapid 
growth of the tumour. 
(Reference: URL: http://www.cybrdi.com/viewproduct.php?id=245 and URL: 
http://www.abta.org/pdf/ABTA%20Primer-Chapter%202.pdf) 
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Table 2: Summary of the Number of Patients with Cancer on the Tissue Array Panel 
Organ Type of Cancer Grade Number of Patients 
II 2 
Liver Hepatocellular Carcinoma 
III 1 
I 1 
II 1 Colon Adenocarcinoma 
III 1 
Stomach/Epiploon Squamous Cell Carcinoma III 3 
II 1 
Prostate Adenocarcinoma 
III 2 
Breast Infiltrating Ductal Carcinoma - 3 
Adenocarcinoma III 1 
Squamous Cell Carcinoma III 1 Lung 
Small Cell Carcinoma - 1 
Chromophobe Carcinoma - 1 
Kidney 
Clear Cell Carcinoma - 2 
Astrocytic Carcinoma II 1 
Lymphoma - 1 Brain 
Ependymoblastoma - 1 
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Table 3: Summary of the Number of Normal Patients on the Tissue Array Panel 
Organ Number of Patients 
Liver 2 
Colon 3 
Stomach 2 
Epiploon 1 
Prostate (Proliferative Tissue) 3 
Breast (Normal Tissue) 2 
Breast (Adenosis Tissue) 1 
Lung 3 
Kidney 3 
Brain 2 
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APPENDIX 2: Composition of Reagents and Solutions 
 
Solution Composition 
0.5% Acetic Anhydride (v/v) 
0.25 ml 100% Acetic Anhydride (v/v) (Merck Chemicals 
(Pty) Ltd, Saarchem, Wadeville, Gauteng, South Africa) in 
5 ml 1M Tris, pH 7.5 and 45 ml DEPC-treated H2O 
10% Ammonium Persulphate 
(w/v) 
Dissolve 0.1 g ammonium persulphate (Promega 
Corporation, Madison, WI, USA) in 1 ml dH2O. Prepare 
fresh for every use 
269 mM Ampicillin 
0.1g Ampicillin (Roche Diagnostics GmbH, Manneheim, 
Germany) in 1 ml sdH2O 
Anti-DIG-AP IgG Diluted in 
1:500 in 1X Blocking Solution 
Add 1 µl Anti-DIG-AP IgG to 500 µl 1X Blocking Solution 
Anti-DIG-AP Diluted 1:10000 
in 1X Blocking Solution 
Add 5 µl Anti-DIG-AP IgG to 50 ml 1X Blocking Solution 
10X Blocking Stock Solution 
Dissolve Blocking Reagent (Roche Diagnostics GmbH, 
Manneheim, Germany) in 10% 10X Maleic Acid Buffer 
(v/v) constantly stirring at 65 ˚C. Store at 2-8 ˚C. 
1X Blocking Solution 
Dilute 1:10 10X Blocking Solution 
Dilute 1:10 10X Maleic Acid Buffer 
Make solution up to final volume with sdH2O 
Bromophenol Blue Loading 
Dye 
30% Glycerol (v/v) (Merck Chemicals (Pty) Ltd, Saarchem, 
Wadeville, Gauteng, South Africa) 
15 mM EDTA (Merck Laboratory Supplies (Pty) Ltd, 
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Saarchem, Midrand, Gauteng, South Africa), pH 8.0 
0.05% Bromophenol Blue (w/v) (Riedel-de-Haën, Sigma 
Aldrich Laborchemikalien GmbH, Seelze) 
Buffer BamHI 
10 mM Tris-HCl, pH 8.0 
5 mM MgCl2 
100 mM Potassium Chloride (KCl) 
1 mM 2-Mercaptoethanol 
0.02% Triton X-100 
0.1 mg/ml BSA 
Buffer R 
 10 mM Tris-HCl, pH 8.5 
10 mM MgCl2 
100 mM KCl 
0.1mg/ml BSA 
Buffer Tango, pH 7.9 
33 mM Tris-Acetate 
100 mM Magnesium Acetate 
66 mM Potassium Acetate 
0.1 mg/ml BSA 
Cell Resuspension Solution 
100 µg/ml RNase A 
25 mM Tris-HCl, pH 7.5 
10 mM EDTA 
Cell Lysis Solution 
1 % SDS (w/v) 
0.2 % NaOH (w/v) 
Coomassie Brilliant Blue 
0.025%  (w/v) Coomassie Brilliant Blue R250 
(Searle Diagnostics, High Wycombe Bucks, England) 
40% (v/v) Methanol 
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(Merck Chemicals (Pty) Ltd, Saarchem, Wadeville, 
Gauteng, South Africa) 
7% (v/v) Glacial Acetic Acid 
(Merck Chemicals (Pty) Ltd, Saarchem, Wadeville, 
Gauteng, South Africa) 
0.1 % DEPC-Treated H2O 
(v/v) 
1 ml DEPC (Sigma-Aldrich Chemie GmbH, Steinheim, 
Switzerland) in 1 l dH2O.  
Shake at 37 ˚C overnight and autoclave. 
Destain Solution Ratio 13: 2: 5 – dH2O: Glacial Acetic Acid: Ethanol 
10X Detection Buffer (Roche 
Diagnostics GmbH, 
Manneheim, Germany)  
0.1 M Tris-HCl, pH 9.5 
0.1 M Sodium Chloride (NaCl) 
1X Detection Buffer 
Dilute 1:10 10X Detection Buffer  
Make solution up to final volume with sdH2O 
40% Dextran (v/v) 
Dissolved 40 g Dextran Sulphate Sodium Salt (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) in 70 ml 
DEPC-treated H2O by heating at 68 ˚C for 3-4 hours and 
making up to a final volume of 100 ml with DEPC-treated 
H2O. Store at 4 ˚C. 
DNA Molecular Weight 
Marker XIV 
10 mM Tris-HCl, pH8.0 
1 mM EDTA 
DNase Incubation Buffer 
1 M NaCl 
20 mM Tris-HCl, pH 7.0 
10 mM (Manganese Chloride) MnCl2 
dNTP Mix (First Strand 10 mM Deoxyadenine Triphosphate (dATP) 
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cDNA Synthesis Kit) 10 mM Deoxycytosine Triphosphate (dCTP) 
10 mM dT Triphosphate (dTTP) 
10 mM Deoxyguanine Triphosphate (dGTP) 
dNTP Mix (ImProm-IITM 
Reverse Transcription 
System) 
10 mM dATP 
10 mM dTTP 
10 mM dCTP 
10 mM GTP 
0.5 M EDTA, pH 8.0 
Dissolved 18.62 g EDTA in 50 ml sdH2O. Added 1.0 M 
drops of NaOH until pH reaches 8.0 and made up to 100 ml 
with DEPC-treated H2O 
Electrophoresis Buffer 
3 g Tris (Merck Chemicals (Pty) Ltd, Saarchem, Wadeville, 
Gauteng, South Africa) 
14.4 g Glycine (Riedel-de-Haën, Sigma-Aldrich 
Laborchemikalien GmbH, Seelze) 
1.0 g SDS (Roche Diagnostics GmbH, Manneheim, 
Germany) 
Dissolve in 1 l dH2O 
Elution Buffer Nuclease-Free, Sterile, Double dH2O 
90% Ethanol (v/v) 45 ml 100% Ethanol in 5ml DEPC-treated H2O 
70 % Ethanol (v/v) 35 ml 100 % Ethanol in 15 ml DEPC-treated H2O 
50% Ethanol (v/v) 25 ml 100% Ethanol in 25 ml DEPC-treated H2O 
37% Formaldehyde  (v/v) Add 3.7 ml to 6.3 ml DEPC-treated H2O 
Formaldehyde Gel Loading 
Buffer 
720 µl Formamide (Fluka Chemie GmbH, Sigma-Aldrich 
Chemie Gmbh, Steinheim, Switzerland) 
160 µl 10X MOPS Buffer 
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260 µl 37% Formaldehyde (v/v) 
(Riedel-de-Haën, Sigma-Aldrich Laborchemikalien GmbH, 
Seelze) 
100 µl sdH2O 
10 mg/ml Ethidium Bromide 
80 µl Bromophenol Blue in DEPC-treated H2O 
50% Formamide (v/v) 12.5 ml 100% Formamide in 12.5 ml DEPC-treated H2O 
GeneRulerTM 100 bp DNA 
Ladder/ GeneRulerTM 50 bp 
DNA Ladder (ready to use 
ladders) 
10 mM Tris-HCl, pH7.6 
1 mM EDTA 
0.005% Bromophenol Blue 
0.005% Xylene Cyanol FF 
10% Glycerol (v/v) 
0.1 M HCl 
Dilute 10 ml 9 M HCl (v/v)  (Merck Chemicals (Pty) Ltd, 
Saarchem, Wadeville, Gauteng, South Africa) with 990 ml 
DEPC-treated H2O 
Hybridisation Buffer 
1 ml 20X SSC 
2.5 ml 40% Dextran (v/v) 
20 µl 10% SDS 
5 ml 100% Formamide  
1.4 ml DEPC-treated H2O 
Store at –20 ˚C in 1 ml aliquots. 
0.5 M IPTG 
Dissolved 0.12 g IPTG (Fermentas Life Sciences, Hanover, 
MD, USA) in 1 ml dH2O 
IQTM SYBR® Green 
Supermix 
100 mM KCl 
40 mM Tris-HCl, pH 8.4 
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0.4 mM dATP 
0.4 mM dCTP 
0.4 mM dGTP 
0.4 mM dTTP 
Taq DNA Polymerase (50 units/ml) 
6 mM MgCl2 
SYBR Green I 
20 nM Fluorescein 
LB Broth 
1% Bacto-Tryptone (w/v) (Merck Chemicals (Pty) Ltd, 
BioLab Diagnostics (Pty) Ltd, Wadeville, Gauteng, South 
Africa) 
0.5% Bacto-Yeast Extract (w/v) (Merck Chemicals (Pty) 
Ltd, BioLab Diagnostics (Pty) Ltd, Wadeville, Gauteng, 
South Africa) 
1% NaCl (w/v) 
Bring to 1 litre with dH2O and autoclave. 
LB Agar (LA) containing 269 
mM Ampicillin 
1.4% Nutrient Agar (w/v) (Fluka Chemie Gmbh, Sigma-
Aldrich Chemie GmbH, Steinheim, Switzerland) 
Boil to dissolve and autoclave. Dissolve 50 µl 269 mM 
Ampicillin to slightly cooled LA and swirl to mix. Pour 
agar in petri dishes and store at 4 ˚C 
LB Plates containing MgCl2 
1.4% Nutrient Agar (w/v) 
10 mM MgCl2 (Merck Chemicals (Pty) Ltd, Saarchem, 
Wadeville, Gauteng, South Africa) 
Boil to dissolve and autoclave. 
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4 M LiCl 
Dissolved 8.478 g LiCl (Sigma-Aldrich GmbH & Co KG, 
Steinheim, Germany) in 50 ml sdH2O 
Lysis/-Binding Buffer, pH 6.6 
4.5M Guanidine-HCl 
50 mM Tris-HCl 
30% Triton X-100 (w/v) 
10X Maleic Acid Buffer 
(Roche Diagnostics GmbH, 
Manneheim, Germany) 
0.1 M Tris-HCl 
0.15 M NaCl 
Adjust to pH 7.5 with NaOH (solid) 
Membrane Binding Solution 
4.5 M Guanidine Isothiocyanate 
0.5 M Potassium-Acetate, pH 5.0 
Membrane Wash Solution 
10 mM Potassium Acetate, pH 5.0 
80 % Ethanol 
16.7 M EDTA, pH 8.0 
10X MOPS Buffer 
400 mM MOPS (Fluka Chemie Gmbh, Sigma-Aldrich 
Chemie GmbH, Steinheim, Switzerland) 
48 mM EDTA 
400 mM Sodium Citrate 
1X MOPS Buffer Add 100 ml 10X MOPS to 900 ml DEPC-treated H2O 
5 M NaCl 
73.05g NaCl (Merck Chemicals (Pty) Ltd, Saarchem, 
Wadeville, Gauteng, South Africa) dissolved in 250 ml 
dH2O. Autoclave. 
1.0 M NaOH 
Dissolved 36.9 g NaOH (Merck Chemicals (Pty) Ltd, 
Saarchem, Wadeville, Gauteng, South Africa) in 100 ml 
dH2O. 
NBT/BCIP Diluted 1:50 in 1X Add 40 µl NBT/BCIP to 2 ml 1X Detection Buffer 
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Detection Buffer 
Neutralization Solution, pH 
4.2 
0.75 M Potassium Acetate (Kac) 
2.12 M Glacial Acetic Acid 
4.09 M Guanidine Hydrochloride 
10X NTP Labelling Mix 
10 mM ATP 
10 mM Cytosine Triphosphate (CTP) 
10 mM Guanidine Triphosphate (GTP) 
6.5 mM Uridine Triphosphate (UTP) 
3.5 mM DIG-11-UTP 
PageRulerTM Prestained 
Protein Ladder 
0.1-0.2 mg/ml of each protein in 62.5 mM Tris-H3PO4, pH 
7.5 
1 mM EDTA 
2% SDS (w/v) 
10 mM DTT 
1 mM NaN3 
33% Glycerol (w/v) 
0.01 M PBS, pH 7.4 
Dissolved 5 PBS (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany) tablets in 1 l dH2O and autoclaved. 
2X PCR Master Mix 
50 units/ml Taq DNA Polymerase 
400 M dATP 
400 M dCTP 
400 M dGTP 
400 M dTTP 
3mM MgCl2 
4% PFA 2.5 g PFA (Merck Chemicals (Pty) Ltd, Saarchem, 
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Wadeville, Gauteng, South Africa) dissolved in 25 ml 200 
mM Phosphate Buffer by slow heating to 60 ˚C until 
solution becomes clear. 
200 mM Phosphate Buffer, 
pH7.4 
4.3 g Disodium Hydrogen-Orthophosphate (Na2HPO4) 
Anhydrous (Merck Chemicals (Pty) Ltd, Saarchem, 
Wadeville, Gauteng, South Africa) 
3.1 g Sodium Dihydrogen Phosphate (NaH2PO4) (Riedel-
de-Haën, Sigma-Aldrich Laborchemikalien GmbH, Seelze) 
Add 250 ml DEPC-treated H2O and autoclave. 
2X Rapid Ligation Buffer 
60 mM Tris-HCl, pH 7.8 
20 mM MgCl2 
20 mM DTT 
2 mM ATP 
10% Polyethylene Glycol (PEG) 
10X Reaction Buffer, pH 8.3 
(First Strand cDNA Synthesis 
Kit) 
100 mM Tris 
500 mM KCl 
5X Reaction Buffer (ImProm-
IITM Reverse Transcription 
System) 
250 mM Tris-HCl, pH 8.3 
375 mM KCl 
50 mM DTT 
10X Restriction Buffer A, pH 
7.9 
330 mM Tris-Acetate 
660 mM Potassium Acetate 
100 mM Magnesium Acetate 
5 mM DTT 
10X Restriction Buffer H 500 mM Tris-HCl, pH 7.5 
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1 M NaCl 
100 mM MgCl2 
10 mM DTT 
Restriction Buffer O+ 
50 mM Tris-HCl, pH 7.5 
10 mM MgCl2 
100 mM NaCl 
0.1 mg/ml Bovine Serum Albumin (BSA) 
2X Sample Dye 
0.09 M Tris-HCl, pH 6.8 
20% (v/v) Glycerol 
2% (w/v) SDS 
0.02% (w/v) Bromophenol Blue 
0.1 M DTT (Roche Diagnostics GmbH, Manneheim, 
Germany) 
10% SDS (w/v) Dissolve 10 g SDS in 100 ml DEPC-treated H2O 
10% SDS (w/v) 
(Electrophoresis) 
Dissolve 10 g SDS in 100 ml dH2O 
20X SSC 
Dissolve 175.3 g NaCl, 88.2 g Tri-Sodium Citrate (Merck 
Chemicals (Pty) Ltd, Saarchem, Wadeville, Gauteng, South 
Africa) in 800 ml DEPC-treated H2O. Adjust to pH 7.0 with 
1 M HCl and make up to a final volume 1 l DEPC-treated 
H2O 
5X SSC 1.625 ml 20X SSC in 18.75 ml DEPC-treated H2O 
2X SSC 40 ml 20X SSC in 360 ml dH2O 
1X SSC 20 ml 20X SSC in 380 ml dH2O 
0.5X SSC 10 ml 20X SSC in 390 ml dH2O 
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0.1X SSC 2 ml 20X SSC in 398 ml dH2O 
10X TBS 
 50 ml 1 M Tris, pH 7.5 
30 ml 5 M NaCl 
Make up to 1 l with DEPC-treated H2O 
 20X TBS-Tween 20 5 ml of Tween 20 (Merch-Schuhardt) per 1 l TBS 
10X TBE Buffer, pH 8.2 
0.89 M Tris 
0.89 M Boric Acid (Riedel-de-Haën, Sigma-Aldrich 
Laborchemikalien GmbH, Seelze) 
25 mM EDTA 
Adjust to pH 8.2 with 1 M HCl 
1X TBE Buffer, pH 8.2 Add 100 ml of 10X TBE Buffer to 900 ml dH2O 
1X TE Buffer, pH 8.0 
10 mM Tris 
1 mM EDTA 
Adjust to pH 8.0 using 9M HCl 
Tfb1 
30 mM KAc (Fluka Chemie Gmbh, Sigma-Aldrich Chemie 
GmbH, Steinheim, Switzerland) 
50 mM MnCl2 (Riedel-de-Haën, Sigma-Aldrich 
Laborchemikalien GmbH, Seelze) 
100 mM KCl (Riedel-de-Haën, Sigma-Aldrich 
Laborchemikalien GmbH, Seelze) 
10 mM Calcium Chloride (CaCl2) (Riedel-de-Haën, Sigma-
Aldrich Laborchemikalien GmbH, Seelze) 
15% (v/v) Glycerol 
Solution was sterilised by filtration 
Tfb2 10 mM MOPS, pH7.0 
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75 mM CaCl2 
10 mM KCl 
15% (v/v) Glycerol 
Solution was sterilised by filtration 
TNB 
2 ml Maleic Acid 
2.5 ml Blocking Buffer 
45 ml TBS 
0.5 M Tris-HCl, pH 6.8 
Dissolve 6.05 g Tris in 95 ml dH2O. Adjust to pH 6.8 with 
9M HCl. Make the solution up to 100 ml with dH2O. 
1 M Tris, pH 7.5 
6.1 g Tris dissolved in 50 ml dH2O 
Adjust pH to 7.5 with 1 M HCl and autoclave. 
1.5 M Tris-HCl, pH 8.8 
Dissolve 18.15 g Tris in 95 ml dH2O. Adjust to pH 8.8 with 
9 M HCl. Make the solution up to 100 ml with dH2O. 
TYM Broth 
2.0 % Bacto-Tryptone (w/v) 
0.5 % Bacto-Yeast Extract (w/v) 
0.1 M Sodium Chloride (NaCl) 
10 mM MgCl2 
pH to 7.0 with 1.0 M NaOH. Autoclave. 
1X Washing Buffer (Roche 
Diagnostics GmbH, 
Manneheim, Germany) 
0.1 M Maleic Acid Buffer 
0.15 M NaCl 
0.3% Polyethylene Sorbitan Monolaurat (Tween 20)  (v/v)  
Wash Buffer I  
5 M Guanidine Hydrochloride 
20 mM Tris-HCl, pH 6.6 
20 ml 100% Ethanol 
Wash Buffer II 20 mM NaCl 
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1 mM Tris-HCl, pH 7.5 
40 ml 100% Ethanol 
Wash Solution 
60.0 mM KAc, pH 7.5 
8.3 mM Tris-HCl, pH 7.5 
40 M EDTA, pH 8.0 
60 % Ethanol (v/v) 
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APPENDIX 3: Composition of Reactions and Procedures 
 
Table 1: Composition of Reverse Transcription Reaction 
Reagents Volume (l) 
10X Reaction Buffer 2  
25 mM MgCl2 4  
10 mM Deoxyribonucleotide Triphosphate (dNTP) Mix 2  
Oligo-p(dT)15 Primer (0.8 µg/µl) 2  
RNase Inhibitor 1  
Total RNA Sample 1  
AMV Reverse Transcriptase 1  
Nuclease-Free H2O 7  
Total Volume 20  
 
Table 2: Reverse Transcription Conditions used to Synthesise Complementary DNA 
Step Temperature (˚C) Time (min) 
Annealing of oligo-p(dT) Primer 25  10 
Reverse Transcription 42 60 
Denaturation 99 5 
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Table 3: Composition of Polymerase Chain Reaction (PCR) Reaction 
Reagents Volume (µl) 
2X PCR Master Mix (Promega Corporation, Madison, WI, USA) 12.5 
Forward Primer 1.0 
Reverse Primer 1.0 
25 mM MgCl2 Stock Solution (Promega Corporation, Madison, WI, USA)  2.0 
Nuclease Free H2O 7.5 
Template DNA (cDNA) 1.0 
Total Volume 25.0 
 
Table 4: PCR Conditions used to amplify the Region of Interest  
Step Temperature (˚C) Time (s) Cycle 
Denaturation 95 120 1 
Denaturation 95 30 
Annealing 58 30 
Extension 72 60 
30 
Extension 72 60 1 
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Table 5: Composition of Ligation Reaction 
Reagents Volume (l) 
2X Rapid Ligation Buffer 5 
10 ng/µl pGEM-T Easy Vector 1 
PCR Product 1 
T4 DNA Ligase 1 
Nuclease Free H2O 3 
Total Volume  10 
 
Table 6: Composition Restriction Digestion Reaction 
Reagents Volume (µl) 
Purified Clone 10 
10X Restriction Buffer H 1 
Restriction Enzyme: EcoRI or PstI 1 
SdH2O 18 
Total Volume 30 
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Table 7: Composition of In Vitro Transcription Reactions  
Reagent 
Control cRNA 
(µl) 
Sense Probe 
(µl) 
Anti-Sense Probe (µl) 
Control DNA PSPT 18-
Neo/PvuII 
4 - - 
ApaI Digested Linearised 
Clone 
- 6 - 
PstI Digested Linearised 
Clone 
- - 6 
10X NTP Labelling Mix 2 2 2 
10X Transcription Buffer 2 2 2 
SP6 RNA Polymerase 2 2 - 
T7 RNA Polymerase - - 2 
DEPC-Treated H2O 10 8 8 
Total Volume 20 20 20 
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Table 8: Serial Dilutions of Probes to Estimate Minimal Concentrations of Probes 
Dilution 
DIG-Labelled 
Control cRNA 
DIG-Labelled 
cRNA of Control 
PSPT 18-Neo/PvuII 
PBR Probes (Sense 
and Anti-Sense) 
Initial Concentration 10 g/100 µl 250 ng/50 µl 5 g/25 µl 
Dilution 1 
 [20 ng/µl] 
(1:5)  
1 µl + 4 µl sdH2O 
- 
(1:10) 
1 µl + 9 µl sdH2O 
Dilution 2 
[1 ng/µl] 
(1:20) 
2 µl + 38 µl sdH2O 
(1:5) 
2 µl + 8 µl sdH2O 
(1:20) 
2 µl + 38 µl sdH2O 
Dilution 3 
[100 pg/µl] 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O  
Dilution 4 
[10 pg/µl] 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O 
Dilution 5 
[1 pg/µl] 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O 
Dilution 6 
[0.1 pg/µl] 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O 
Dilution 7 
[0.01 pg/µl] 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O 
(1:10) 
5 µl + 45 µl sdH2O 
 
 
 
 
 
 116 
Table 9: Composition of Reverse Transcription Reaction 
Reagents Volume (µl) 
5X Reaction Buffer 4 
25 mM MgCl2 4 
 10 mM dNTP Mix 2 
Primer Oligo-(dT)15 (0.5 mg/ml) 2 
RNase Inhibitor (20-40 units/l) 1 
Nuclease Free H2O 5.2 
ImProm-IITM Reverse Transcriptase 0.8 
RNA (Template) 1 
Total Volume  20 
 
Table 10: Reverse Transcription Conditions used to Synthesise Complementary DNA 
Step Temperature (˚C) Time (min) 
Annealing of Oligo-dT Primer 25  10 
Reverse Transcription 42 60 
Denaturation 99 5 
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Table 11: Composition of Relative Quantitative Polymerase Chain Reaction (PCR) 
Reagents Volume (µl) 
iQTM SYBR® Green Mix (Bio-Rad Laboratories, Hercules, CA, USA) 12.5 
Forward Primer (10 pmol/µl) 1.0 
Reverse Primer (10 pmol/µl) 1.0 
25 mM MgCl2 Stock Solution (Promega Corporation, Madison, WI, USA) 2.0 
sdH2O x 
Template DNA (cDNA) (1 g/l) y 
Total Volume 25 
1. x and y are variable depending on the concentration of the template (cDNA). 
 
Table 12: Relative Quantitative PCR Conditions used to Amplify Region of Interest 
Step Temperature ( C˚) Time (s) Plate Read Cycle 
Denaturation 95 120 - 1 
Denaturation 
Annealing 
Extension 
95 
58 
72 
30 
30 
60 
- 
- 
Yes (Single) 
40 
Extension 72 600 - 1 
Melting Curve 
55-95 
(rises in 1 C˚ increments) 
10 (at each 
temperature) 
Yes 
(Continuous) 
1 
Cooling 20 Forever - 1 
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Table 13: Reagents used in Preparation of SDS-PAGE 
Reagent Separating Gel (ml) Stacking Gel (ml) 
dH2O 3.35 6.1 
1.5 M Tris-HCl, pH8.8 2.5 - 
0.5 M Tris-HCl, pH 6.8 - 2.5 
40% Acrylamide-Bis Stock 
Solution (Promega Corporation, 
Madison, WI, USA) 
4.0 1.3 
10% SDS (w/v) 0.1 0.1 
10% Ammonium Persulphate (w/v) 0.05 0.05 
TEMED (Promega Corporation, 
Madison, WI, USA) 
0.01 0.01 
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APPENDIX 4: Sequence 
 
  1   atggccccgc cctgggtgcc cgccatgggc ttcacgctgg cgcccagcct ggggtgcttc 
  61  gtgggctccc gctttgtcca cggcgagggt ctccgctggt acgccggcct gcagaagccc 
  121 tcgtggcacc cgccccactg ggtgctgggc cctgtctggg gcacgctcta ctcagccatg 
  181 gggtacggct cctacctggt ctggaaagag ctgggaggct tcacagagaa ggctgtggtt 
  241 cccctgggcc tctacactgg gcagctggcc ctgaactggg catggccccc catcttcttt 
  301 ggtgcccgac aaatgggctg ggccttggtg gatctcctgc tggtcagtgg ggcggcggca 
  361 gccactaccg tggcctggta ccaggtgagc ccgctggccg cccgcctgct ctacccctac 
  421 ctggcctggc tggccttcgc gaccacactc aactactgcg tatggcggga caaccatggc 
  481 tggcatgggg gacggcggct gccagagtag 
Figure 1: Sequence of the Peripheral Benzodiazepine Receptor (PBR) Gene 
The sequence of the PBR gene was obtained from GenBank at NCBI and has an Accession Number of 
BT006949. The bold nucleotides in the sequence represent the region at which the forward primer and reverse 
primer bind respectively to the PBR product. The blue coloured portion of sequence represents the fragment of 
the PBR gene that is amplified and is located between mRNA position 283 and 532. The PBR fragment 
amplified is 247 bp in size. 
(Reference: URL: http://www.ncbi.nlm.nih.gove/entrez/viewer.fcgi?db=nucleotide&val=30582736) 
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APPENDIX 5: Vectors 
 
 
Figure 1: Schematic Diagram of the pGEM-T Easy Vector 
The pGEM-T Easy vector is made up of 3018 bp. The T7 RNA polymerase transcription initiation site occurs at 
position 1, SP6 RNA polymerase initiation sites occurs at position 141, the T7 RNA polymerase promoter region 
occurs between 3002 and 3006, the SP6 RNA polymerase promoter region occurs between position 136 and 158, 
the multiple cloning site occurs between positions 10 and 128. In addition, the position at which restriction 
enzymes cleave the vector is indicated. (Reference: URL: 
http://www.tcd.ie/Genetics/staff/Noel.Murphy/recombinat%20dna%20ge4021/pgem.pdf) 
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Figure 2: Schematic Diagram of pGEX-6P-2 Expression Vector 
The pGEX-6P-2 expression vector is approximately 4900 bp in size and consists of a tac promoter that makes 
the expression vector chemically inducible, allows for a high level of expression and controls the expression of 
gluthathione-S-transferase, an internal lac Iq gene that encodes for the lac repressor which allows for the 
expression of genes downstream of the tac promoter when induced with isopropyl--D-thiogalactopyranoside 
(IPTG), PreScissionTM Protease recognition sites for cleaving the desired protein from the fusion product and an 
ampicillin resistant gene. (Reference: URL: http://www4.amershambiosciences,com/pdfs/970004M2-01.pdf)
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APPENDIX 6: DNA and Protein Ladders 
 
          
Figure 1: DNA Molecular Weight Ladders 
DNA molecular weight ladders allows for the accurate sizing of DNA fragments generated by PCR or restriction 
digest in agarose gels. (A) The DNA molecular weight marker XIV allows for the accurate sizing of DNA 
fragments of between 100 and 1050 bp. The DNA ladder mixture consists of 15 bands plus an additional band of 
2462 bp when placed under agarose gel electrophoresis. (Reference: URL: http://www.roche-applied-
science.com/pack-insert/1721933a.pdf). (B) GeneRulerTM 100bp DNA Ladder allows for the accurate sizing of 
DNA fragments of between 80 and 1031 bp. The DNA ladder mixture results in a ladder consisting of 11 
discrete bands when placed under agarose gel electrophoresis. (C) GeneRulerTM 50 bp DNA Ladder allows for 
the accurate sizing of DNA fragments of between 50 and 1031 bp. The DNA ladder mixture results in a ladder 
consisting of 13 discrete bands when placed under agarose gel electrophoresis. (Reference: URL: 
http://www.fermentas.com/catalog/electrophoresis/generuler.htmGenePlus) 
 
 
 
 
 
 
(A) (B) (C) 
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Figure 2: Protein Molecular Weight Ladder  
Protein molecular weight ladders allow for the accurate sizing of denatured proteins generated by induction with 
IPTG in SDS-PAGE gels. The PageRulerTM Prestained Protein Ladder (Fermentas Life Sciences, Hanover, MD, 
USA) allows for the accurate sizing of protein between approximately 10 kDa to 170 kDa (Reference: 
http://www.fermentas.com/catalog/electrophoresis/markmo0671.htm). 
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3. RESULTS 
 
3.1. Confirmation of the Histology and Histopathology of Normal Tissues and 
Histopathology of Cancer Tissues 
3.1.1. Introduction 
Tissue specimen that have been processed, sectioned and mounted on a slide can be viewed 
microscopically only after it has been stained making the cells visible (Brown, 2002). In 
histology, the most common used stain for tissue samples fixed in formalin or alcohol is the 
haematoxylin and eosin stain that is the H&E stain. This stain involves two separate dyes: (i) 
haematoxylin, which is a dark purplish dye that stains the chromatin within the nucleus 
resulting in a deep purplish-blue colour and (ii) eosin, which is an orange-pink to red dye that 
stains cytoplasmic material such as collagen in connective tissue leaving an orange-pink 
counterstain (Brown, 2002). H&E staining was used to confirm the histology of the different 
normal tissues studied as well as to determine the histopathologies of the different cancer 
tissues studied before in situ hybridisation results could be analysed. 
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3.1.2. Histology of Normal Tissue and Histopathology of Tumour Disease in Liver 
3.1.2.1. Normal Tissue 
 
Figure 3-1: H&E of Normal Liver Tissue 
(A) represents the hepatic venule (HV) that is lined by endothelial cells and is characterised by a clearly defined 
intimal layer devoid of elastic fibres and a tunica media consisting of one or two layers of smooth muscle fibres 
surrounded by anastomosing plates of hepatocytes and sinusoids. (B) represents the portal tract consisting of the 
hepatic portal vein (PV) consisting of a thin wall lined by flattened endothelial cells, a hepatic artery (A) that is 
thick-walled and consisting of one layer of smooth muscle cells and flattened endothelial cells and a bile duct 
(B) that is lined by a simple cuboidal or columnar epithelium. (C) represents anastomosing plates of hepatocytes 
between which the sinusoids are located. Hepatocytes (H) are large polyhedral cells with round nuclei with 
peripherally dispersed chromatin and prominent nucleoli. Sinusoid lining cells (S) are distinguished by their 
flattened condensed nuclei and attenuated poorly stained cytoplasm. (Reference: Coltran, et al., 1999, 
Eroschenko, 2000, Young, et al., 2000) (Magnification 400X) 
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 3.1.2.2. Hepatocellular Carcinoma 
 
Figure 3-2: H&E of Hepatocellular Carcinoma 
(A) represents a Grade II hepatocellular carcinoma that is characterised by tumour cells that have a tubular 
pattern. (B) represents a Grade III hepatocellular carcinoma that is characterised by a pleomorphic appearance 
with numerous anaplastic giant cells that may become small to resemble spindle cell sarcomas containing 
prominent nuclei and nucleoli and a scanty cytoplasm that appears basophilic. (Reference: Coltran, et al., 1999, 
Rosai, 2004) (Magnification 400X) 
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3.1.3. Histology of Normal Tissue and Histopathology of Tumour Disease in Colon 
3.1.3.1. Normal Tissue 
 
Figure 3-3: H&E of Normal Colon Tissue 
(A) shows the epithelial layer of the mucosa that consists of columnar epithelial cells (E) with a thin striated 
border, numerous goblet cells (G) and lamina propria (LP) consisting of abundant lymphatic tissue. (B) shows 
the submucosa (S) that is found directly below the mucosa containing the crypts of Lieberkhün (CL) consisting 
of loose collagenous connective tissue (CT) containing large blood vessels (BV). (C) represents a longitudinal 
section of the crypts of Lieberkhün (CL) showing goblet cells (G) as is indicated by the small and condensed 
nuclei. Below the goblet cells, the lamina propria (LP) can be seen that consists of abundant lymphatic tissue. 
(D) represents a traverse section of the crypts of Lieberkhün (CL) showing absorptive cells (A) as is indicated by 
the tall columnar cells consisting of the oval basal nuclei. (Reference: Coltran, et al., 1999, Eroschenko, 2000, 
Young, et al., 2000) (Magnification 400X) 
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3.1.3.2. Colonic Adenocarcinoma 
 
Figure 3-4: H&E of Colonic Adenocarcinoma 
(A) represents Grade I tubular adenomas characterised adenomatous glands (G) that are well formed, irregular 
and tubular and surrounded by a fibromuscular (FM) stroma. (B) represents Grade II tubular adenomas 
characterised by the presence of fewer adenomatous glands (G) and more of the tumour cells arranged as solid 
sheets. (C) represents Grade III tubular adenomas that is characterised by a predominantly solid pattern with 
virtually no adenomatous glands. (Reference: Barbatis, 1995, Coltran et al., 1999) (Magnification 400X) 
 
3.1.4. Histology of Normal Tissue and Histopathology of Tumour Disease in Epiploon and 
Stomach 
3.1.4.1. Normal Tissue 
3.1.4.1.1. Epiploon Normal Tissue 
 
Figure 3-5: H&E of Normal Epiploon Tissue 
The above figure represents epiploon that comprises loose connective tissue that consists of adipose tissue (A), 
plasma cells (P), neutrophils (N) and blood vessels (BV). (Reference: Eroschenko, 2000) (Magnification 400X) 
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3.1.4.1.2. Stomach Normal Tissue 
 
Figure 3-6: H&E of Normal Stomach Tissue 
(A) represents the submucosa that consists of relatively loose and distensible connective tissue that contains the 
larger blood vessels (BV) as well as the nerves supplying the mucosa. (B) represents the transverse section of the 
crypts of Lieberkhün, which show the presence of the parietal cells (P) that are characterised by a rounded shape 
with an intensely eosinophilic cytoplasm and centrally located nucleus. Neck mucous cells (N) are found lining 
the glands. (C) represents the longitudinal section of the gastric glands, which shows the surface and neck 
mucous cells (N) that have a tall columnar shape and the underlying lamina propria (LP) that appears loose, 
scanty and vascular consisting of collagen and reticular fibres and fibroblasts characterised by oval nuclei. 
(Reference: Eroschenko, 2000, Young, et al., 2000) (Magnification 400X) 
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3.1.4.2. Squamous Cell Carcinoma of the Stomach 
 
Figure 3-7: H&E of Stomach Squamous Cell Carcinoma 
The above figure represents Grade III stomach squamous cell carcinoma. (A) represents tumour cells that are 
characterised by a keratin pearl formation arranged in a mosaic pattern of ectopic squamous cell nests. (B) 
represents the invasion of tumour cells into the epiploon as is characterised by the presence of tumour cells 
within the adipose tissue.  (Reference: Schmidt, et al., 2001, Yildrim, et al., 2005) (Magnification 400X) 
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3.1.5. Histology of Normal Tissue and Histopathology of Tumour Disease in Prostate 
3.1.5.1. Hyperplastic Tissue 
 
Figure 3-8: H&E of Hyperplastic Prostate Tissue 
(A) Glandular proliferation takes the form of aggregations of small to large to cystically dilated glands (G) that 
are lined by an inner columnar (C) and an outer cuboidal to flattened endothelium (E). The epithelium is 
characteristically thrown up into numerous papillary buds and infoldings. In addition, hyperplastic tissue is 
characterised by foci of infarction that appear as nests and foci of squamous metaplasia that surrounds the foci of 
infarction. Corpora amylacea (CA) is a lamellated glycoprotein mass secreted by the prostate glands that 
becomes progressively calcified to form prostatic concretions with increasing age. (B) indicates hyperplastic 
tissue characterised by fibrous and muscular proliferation of the fibromuscular stroma.  The foci of squamous 
metaplasia (F) occur in the margins of the foci of infarction as nests of metaplastic but orderly squamous cells 
(Reference: Coltran, et al., 1999) (Magnification 400X) 
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3.1.4.2. Adenocarcinoma of the Peripheral Ducts and Acini 
 
Figure 3-9: H&E of Adenocarcinoma of the Peripheral Ducts and Acini in the Prostate 
(A) represents a Grade II prostate adenocarcinoma, which is characterised by smaller and more closely packed 
glands, of irregular outline and smooth inner surface with little intervening stroma between the glands. The gland 
consists of a single uniform layer of cuboidal to low columnar epithelium. (B) represents Grade III prostate 
adenocarcinoma, which is characterised by cells that tend to grow in sheets. (Reference: Coltran, et al., 1999) 
(Magnification 400X) 
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3.1.6. Histology of Normal Tissue and Histopathology of Tumour Disease in Breast 
3.1.6.1. Normal Tissue 
 
Figure 3-10: H&E of Inactive Mammary Gland Normal Tissue 
(A) shows terminal ducts (T) and alveoli (A) consisting of two layers of epithelial cells: an outer layer of 
discontinuous myoepithelial cells and a luminal layer of cuboidal epithelial cells. (B) shows the dense 
fibroconnective tissue known as the interlobular stroma (IE) that consists of collagen fibres admixed with 
adipose tissue and the less dense intralobular stroma (IA) that surrounds the ducts within each lobule and 
consists of collagen and more vascular tissue. (Reference: Coltran, et al., 1999, Eroschenko, 2000, Young, et al., 
2000) (Magnification 400X) 
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3.1.6.2. Invasive Carcinoma (No Special Type) 
 
Figure 3-11: H&E of Invasive Carcinoma (No Specific Type) 
(A) represents tumour cells growing in solid cell nests consisting of fibrotic stroma between the nests and the 
presence of apocrine metaplasia. (B) shows the presence of a mononuclear inflammatory infiltrate, namely 
lymphocytes between the tumour and the stroma. (Reference: Coltran, et al., 1999, Rosai, 2004) (Magnification 
400X) 
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3.1.7. Histology of Normal Tissue and Histopathology of Tumour Diseases in Lung 
3.1.7.1. Normal Tissue 
 
Figure 3-12: H&E of Lung Normal Tissue 
(A) represents a terminal bronchiole (T) characterised by a prominent mucosal fold that consists of ciliated 
columnar epithelium and Clara cells characterised by tall, columnar non-ciliated cells. A smooth muscle layer 
(M) arranged as discrete bundles of various orientations surrounds the mucosal layer. (B) represents the 
parenchyma consisting of the pulmonary artery (PA), lymph vessel (L) and connective tissue consisting mainly 
of collagen fibres. (C) represents alveoli (A) lined by flattened epithelial cells that is surrounded by a rich 
network of pulmonary capillaries (C) that are supplied by pulmonary vessels (V). (Reference: Coltran, et al., 
1999, Eroschenko, 2000) (Magnification 400X) 
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3.1.7.2. Bronchogenic Carcinomas 
3.1.7.2.1. Adenocarcinoma 
 
Figure 3-13: H&E of Lung Adenocarcinoma 
The above figure represents the growth pattern of Grade III lung adenocarcinoma that is characterised by a solid 
pattern and occasional mucin-producing glands and cells. (Reference: Coltran, et al., 1999) (Magnification 
400X) 
 
3.1.7.2.2. Squamous Cell Carcinoma 
 
Figure 3-14: H&E of Lung Squamous Cell Carcinoma 
The above diagram represents Grade III lung squamous cell carcinoma that is characterised by the presence of 
squamous metaplasia adjacent to the tumour mass. In addition, it shows the merging of the squamous tumour 
cells with the large cell pattern. (Reference: Coltran, et al., 1999) (Magnification 400X) 
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3.1.7.2.3. Classic Small Cell Carcinoma 
 
Figure 3-15: H&E of Lung Classic Small Cell Carcinoma 
The above diagram represents lung classic small cell carcinoma characterised by the growth of tumour cells in 
clusters. Tumour cells contain small round to oval nuclei that appear to resemble lymphocytes. In addition, the 
cytoplasm of tumour cells appears scanty. Tumour cells appear spindle-shaped or polygonal. (Reference: 
Coltran, et al., 1999, Rosai, 2004) (Magnification 400X) 
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3.1.8. Histology of Normal Tissue and Histopathology of Tumour Diseases in Kidney 
3.1.8.1.Normal Tissue 
 
Figure 3-16: H&E of Normal Kidney Tissue 
(A) represents the renal corpuscle that consists of the glomerulus (G) and Bowman’ s capsule. Bowman’ s capsule 
can be divided into three layers from the outside in: the parietal layer (PL), Bowman’ s space (BS) and the 
visceral layer (VS). The parietal layer, which forms the Bowman’ s capsule proper consists of a single layer of 
flattened cells resting on the basement membrane derived from the distended blind-end of the renal tubule. 
Bowman’ s space is located between the parietal and visceral layers and is continuous with the lumen of the renal 
tubule. The visceral layer is located closest to the glomerulus and consists of a layer of epithelial cells known as 
the podocytes that lies on the basement membrane that is also common to the glomerulus and is continuous with 
the parietal layer around the visceral stalk. Glomerulus can be defined as a glandular network of anastomosing 
capillaries lined by endothelial cells. (B) represents the different histophysiological zones of the renal tubule. 
The proximal convoluted tubule (PCT) is lined by a simple cuboidal epithelium with a prominent brush border 
of tall microvilli. Both the thin ascending and descending limbs (T) have a simple squamous epithelium and a 
regular round shape. The thick ascending limbs (A) are lined by low cuboidal epithelium and appear round in 
cross section. Both the ascending and descending limbs have the absence of a brush border. The distal 
convoluted tubule (DCT) consists of a simple cuboidal epithelium that is characterised by the absence of a brush 
border and larger more clearly defined lumen than that of the PCT. The collecting tubule (CT) is lined by a 
simple cuboidal epithelium, however, it appears wider and less regular in shape to the ascending limbs. The 
collecting duct (CD) is characterised by a large diameter and pale stained simple columnar epithelial lining. 
(Reference: Coltran, et al., 1999, Eroschenko, 2000, Young, et al., 2000 (Magnification 400X) 
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3.1.8.2. Renal Cell Carcinomas 
3.1.8.2.1. Chromophobe Renal Carcinoma 
 
Figure 3-17: H&E of Chromophobe Renal Carcinoma 
Chromophobe renal carcinomas are characterised by large polygonal tumour cells arranged in solid sheets. 
Tumour cells consist of pale eosinophilic stained reticular cytoplasm. (Reference: Coltran, et al., 1999, 
Zambrano, et al., 1999) (Magnification 400X) 
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3.1.8.2.2. Clear Cell Carcinoma 
 
Figure 3-18: H&E of Clear Cell Carcinoma 
(A) represents diffuse clear cell carcinoma growing in a trabecular of cord-like pattern. Tumour cells are small 
cells that have a rounded or polygonal shape containing an indistinct cell margin, a pale staining granular or 
clear, that is a vacuolated cytoplasm and normochromatic nuclei with inconspicuous nucleoli. (B) represents the 
stroma of the tumour containing a delicate branching vasculature (V) and has a fibromuscular appearance. 
(Reference: Coltran, et al., 1999, Rosai, 2004) (Magnification 400X) 
 
 
 
 
 
 
 
 
 
 
 
 
(A) (B) 
V 
 141 
3.1.9. Histopathology of Normal Tissue and Tumour Diseases in Brain 
3.1.9.1. Normal Tissue 
 
Figure 3-19: H&E of Normal Brain Tissue 
(A) represents white matter, which shows the presence of neurones characterised by their basophilic granular 
cytoplasm and glia especially astrocytes (A) that are characterised by round to oval nuclei with evenly dispersed 
polar chromatin. (B) represents grey matter that is characterised by the presence of neurones (N) such as pseudo-
unipolar neurones that are recognised by their basophilic granular cytoplasm and glia especially 
oligodendrocytes (O) that are characterised by a denser, more homogenous chromatin in rounder, smaller and 
lymphocyte-like nuclei. Oligodendrocytic cytoplasmic processes wrap around the axons of neurones. Other 
neurones found include pyramidal cells (P), which are characterised by pyramid-shaped cell bodies, with their 
apex being directed toward the cortical surface. (C) represents oligodendrocytes arranged in a linear array. All 
three diagrams show cells lying in a fibrillary network of neural processes. (Reference: Coltran, et al., 1999, 
Eroschenko, 2000, Young, et al., 2000) (Magnification 400X) 
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3.1.9.2. Brain Cancer 
3.1.9.2.1. Diffuse Fibrillary Astrocytoma 
 
Figure 3-20: H&E of Diffuse Fibrillary Astrocytoma 
The above diagram represents a Grade II diffuse fibrillary astrocytoma that is characterised by a low to moderate 
increase in glial cell nuclei that appear oval in shape and an intervening felt work of fine astrocytic cell processes 
that give the background a fibrillary appearance. (Reference: Coltran, et al., 1999, Rosai, 2004) (Magnification 
400X) 
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3.1.9.2.2. Ependymoma 
 
Figure 3-21: H&E of Ependymoma 
(A) represents ependymoma that is composed of tumour cells with regular, round to oval nuclei with abundant 
granular cytoplasm. Between the nuclei there is a variably dense fibrillary network (F). (B) represents 
perivascular pseudorosettes (P) formations where tumour cells and the dense meshwork of fibrillary cytoplasmic 
processes (F) condense in a collar-like fashion around blood vessels. (Reference: Coltran, et al., 1999, Rosai, 
2004) (Magnification 400X) 
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3.1.9.2.3. Peripheral Central Nervous System Lymphoma 
 
Figure 3-22: H&E of Primary Central Nervous System Lymphoma 
The above figure represents primary central nervous system lymphoma characterised by the presence of a large 
cell cytology consisting of mononuclear cells of an undetermined type, which may be a type of lymphocyte that 
is characterised by round to oval nuclei with prominent nucleoli and a lack of cytoplasmic processes of cellular 
cohesions. (Reference: Fine, et al., 2003, Rosai, 2004) (Magnification 400X) 
 
3.1.10. Summary 
The histology and histopathology section confirmed the histologies of the different normal 
tissues and histopathologies of the different cancer tissues to be studied via in situ 
hybridisation. This section also further provided an understanding of the main cell types and 
tissues found in each normal organ, structural changes that occurs between normal and its 
cancerous counterparts for the various organs as well as structural changes that occur as 
cancerous tissues become more progressive that is poorly differentiated. This understanding 
proved valuable when localisation studies were done.  
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3.2. Expression of the Peripheral Benzodiazepine Receptor mRNA in Various Human 
Cancer Tissues 
3.2.1. Introduction 
In order to ascertain if PBR mRNA is expressed in normal and cancerous tissues from various 
organs of the body and whether it is expressed at similar levels between the normal and 
cancerous states, colorimetric and fluorescent in situ hybridisation was performed. In situ 
hybridisation is a qualitative or semi-quantitative technique by which specific mRNA of 
interest in the cytoplasm or DNA of interest in the nucleus can be localised in 
morphologically preserved tissue sections or cell preparations through the hybridisation of a 
complimentary strand of a nucleotide probe to the sequence of interest. The sensitivity of this 
technique is such that the threshold levels of detection are in the region of 10 to 20 copies of 
mRNA or DNA per cell. This technique provides considerable information regarding the 
structure and function of cell within pathological means (Lanlani, et al., 1997). Thus, in order 
to perform this technique, labelled RNA probes specific for PBR had to be synthesised that 
binds to the complementary mRNA in tissue sections after which results were seen under light 
and fluorescent microscopy.  
 
3.2.2. Molecular Cloning 
3.2.2.1. RNA Extraction 
Total RNA was extracted using the TRIzolTM RNA extraction method and results analysed by 
formaldehyde agarose gel electrophoresis (Figure 3-23). This resulted in the formation of a 
smear, however two distinct bands could be distinguished. These bands were indicative of 
ribosomal RNA (rRNA), specifically the 18S and 28S rRNA, which have a relative molecular 
weight of 1.9 kb and 5.0 kb. Smearing seen in the lane indicates that some RNA underwent 
degradation. 
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Figure 3-23: Isolation of Total RNA 
 
3.2.2.2. Polymerase Chain Reaction 
The 247 bp region of interest of the PBR gene was amplified by PCR using PBR specific 
primers. The results were analysed by agarose gel electrophoresis where the PCR product was 
run on a 1% agarose gel (Figure 3-24). It was found that the PBR gene was amplified as is 
indicative of the bold band (Lane 3) as it lied between the 200 bp and 300 bp reference bands 
(Lane 1). A negative control run with the amplification of the PBR gene was to perform PCR 
in the absence of any template DNA by replacing it with nuclease free H2O, which resulted in 
no band formation  (Lane 2). 
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Figure 3-24: Amplification of the Peripheral Benzodiazepine Receptor Gene Region of 
Interest 
 
3.2.2.3. Cloning 
The PCR product was ligated into pGEM-T Easy vector, which contains a multiple cloning 
site, 3’ -T overhangs allowing for the correct ligation of the PCR product and an ampicillin 
resistant domain, using the LigaFastTM Rapid Ligation System (Promega Corporation, 
Madison WI, USA) after which it was transformed into competent MC1061 Escherichia coli 
cells and grown on ampicillin-containing nutrient-rich agar plates. Thus, only those bacteria 
containing the ampicillin resistant gene will grow. To determine if the MC1061 Escherichia 
coli cells were competent, a background control used was to plate the cloning reactions on 
nutrient-rich agar plates not containing ampicillin. A negative background control used was to 
allow bacteria to grow in the absence of the vector and the insert. This control served the 
purpose of determining if the bacterial cells contained the ampicillin resistant gene. A positive 
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control used was to grow bacteria in the presence of just the pGEM-T Easy vector only. This 
control serves the purpose to determine if bacterial cells are competent. It was found that 
growth occurred on ampicillin-negative plates as well as on ampicillin-positive plates where 
bacterial cells contained the pGEM-T Easy vector plus the insert or the pGEM-T Easy vector 
only while no growth occurred in bacterial cells that did not contain the pGEM-T Easy vector 
or insert (Figure 3-25). 
 
 
                            
Figure 3-25: Cloning of the Peripheral Benzodiazepine Receptor Insert into pGEM-T 
Easy Vector 
 
3.2.2.4. Colony Polymerase Chain Reaction 
Colony PCR was done to confirm that the bacterial cells that grew on the ampicillin plates 
contained the vector plus the insert. Taking colonies at random that grew on the nutrient-rich 
agar plates and amplifying the region of interest by PCR using PBR specific primers 
accomplished this. The results were analysed by agarose gel electrophoresis where the PCR 
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product was run on a 1% agarose gel (Figure 3-26). It was found that the insert was amplified 
as is indicative of the bold band (Lanes 3-10) as it lied between the 200 bp and 300 bp 
reference bands (Lane 1). A negative control run with the amplification of the recombinant 
DNA molecules was to perform PCR in the absence of any recombinant DNA by replacing it 
with nuclease free H2O, which resulted in no band formation  (Lane 2). 
 
                   
Figure 3-26: Amplification of the Peripheral Benzodiazepine Receptor Insert via Colony 
PCR 
 
3.2.2.5. Miniprep Analysis/Plasmid DNA Extraction 
The pGEM-T Easy vector containing the insert was isolated from the bacterial cells and 
purified by plasmid DNA extraction using the WizardPlus® SV Miniprep Purification System 
(Promega Corporation, Madison, WI, USA). To determine if the clones were isolated, the 
results were analysed by agarose gel electrophoresis where the clones were run on a 1% 
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agarose gel (Figure 3-27). The gel showed the formation of three bands greater than 1031 bp 
reference band (Lane 1), which indicates that pGEM-T Easy vector containing the insert was 
isolated (Lanes 2, 4-7). The three bands that can be seen are indicative of the different states 
in which plasmid DNA occurs, namely it may range from supercoiled to completely relaxed. 
The most tightly supercoiled plasmid DNA will travel furthest in the gel while the most 
relaxed plasmid DNA will travel the least on the gel. Lane 3 shows no bands, which indicates 
that the plasmid DNA was lost during the plasmid DNA extraction procedure which could 
have occurred at a number of steps such as during lysis and washing or another reason could 
be that the plasmid DNA was too dilute to be seen as a band on the gel. 
 
                    
Figure 3-27: Isolation of Plasmid DNA 
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3.2.2.6. Restriction Digestion 
The purified plasmid DNA was digested with EcoRI to determine the presence of the insert in 
the plasmid DNA and PstI to determine if the plasmid DNA could be linearised to be later 
used in the synthesis of the anti-sense probe. The results were analysed by agarose gel 
electrophoresis where the digestions were run on a 1% agarose gel (Figure 3-28). Two 
controls used in this experiment included the undigested clone (Lane 2), which resulted in the 
formation of two bands greater than the 1031 bp reference band (Lane 1) that represented the 
different states of the plasmid DNA, and the colony PCR product (Lane 3) represented by the 
band located between the 200 bp and 300 bp reference bands (Lane 1). When the recombinant 
plasmid DNA was digested with PstI, it resulted in the formation of one band (Lane 4) greater 
than the 1031 bp reference band (Lane 1), which indicates that the recombinant plasmid DNA 
is linearised by PstI. It was found that when the recombinant plasmid DNA was digested with 
EcoRI, it resulted in the formation of two bands (Lane 5), one band greater than the 1031 bp 
reference band (Lane 1) and the other lying between the 500 bp and 600 bp reference band 
(Lane 1). However, the hypothesised result was that the smaller fragment size should have 
been 247 bp, the size of the PCR product. 
 
Therefore, in order to determine if the recombinant plasmid DNA contains the PBR insert, the 
recombinant plasmid DNA underwent PCR using PBR-specific primers. Results were 
analysed using agarose gel electrophoresis where the PCR products were run on a 1% agarose 
gel (Figure 3-7). This resulted in the formation of a band (Lane 3) that lay between the 200 bp 
and 300 bp reference bands (Lane 1). A negative control used was to replace the recombinant 
plasmid DNA with nuclease free H2O, which resulted in no band formation (Lane 2). Thus, 
PCR confirmed the presence of the insert in the recombinant plasmid DNA, which was then 
sent for sequencing. 
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Figure 3-28: Restriction of Plasmid DNA containing Insert 
 
                            
Figure 3-29: Amplification of Peripheral Benzodiazepine Receptor Insert via 
Polymerase Chain Reaction 
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3.2.2.7. Sequencing 
The purified recombinant clone containing the region of interest of the PBR gene was sent to 
Inqaba Biotechnical Industries (Pty) Ltd (Pretoria, Gauteng, South Africa) for sequencing to 
determine if the insert isolated was actually the PBR gene. The results were analysed using 
CHROMAS, version 1.62 (Technelysium (Pty) Ltd, Helensville, Queensland, Australia) and 
by comparing the clone PBR sequence to that of the Homo sapiens benzodiazepine receptor 
(peripheral) mRNA reference sequence (Accession Number: BT006949) obtained from the 
Nucleotide database at NCBI. This was done using BLAST at NCBI where two sequences 
can be compared to each other (Figure 3-30). It was found that the PBR insert was 512 bp in 
size, which is the size of the entire reference PBR sequence, which means that the entire PBR 
gene was cloned into the pGEM-T Easy vector, which probably occurred as a result of 
mispriming and spontaneous mutations. The sequence was 98% accurate to the reference 
sequence and lies in a 5’  to 3’  orientation. 
 
3.2.2.8. Linearisation of Clones 
The pGEM-T Easy vectors containing the PBR inserts were digested with ApaI and PstI 
independently in order to synthesise linearised clones, which were later used in the synthesis 
of sense and anti-sense probes respectively. Results were analysed by agarose gel 
electrophoresis where purified products were run on a 1% agarose gel (Figure 3-31). It was 
found that one band (Lanes 3 and 4) greater than the 1031 bp reference band (Lane 1) 
occurred for both the independent digestion of clones with ApaI and PstI. The control used in 
this experiment was undigested clone that was run concurrently on the gel, which resulted in 
the formation of two bands that represents the different states in which plasmid DNA occurs. 
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Score = 900 bits (468), Expect = 0.0 
Identities = 504/512 (98%), Gaps = 4/512 (0%) 
Strand = Plus / Plus 
 
 
   
         
                                                            
Query: 1   atggccccgccctgggtgcccgccatgggcttcacgctggcgcccagcctggggtgcttc 60 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 64  atggccccgccctgggtgcccgccatgggcttcacgctggcgcccagcctggggtgcttc 123 
 
                                                                        
Query: 61  gtgggctcccgctttgtccacggcgagggtctccgctggtacgccggcctgcagaagccc 120 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 124 gtgggctcccgctttgtccacggcgagggtctccgctggtacgccggcctgcagaagccc 183 
 
                                                                        
Query: 121 tcgtggcacccgccccactgggtgctgggccctgtctggggcacgctctactcagccatg 180 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 184 tcgtggcacccgccccactgggtgctgggccctgtctggggcacgctctactcagccatg 243 
 
                                                                        
Query: 181 gggtacggctcctacctggtctggaaagagctgggaggcttcacagagaaggctgtggtt 240 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 244 gggtacggctcctacctggtctggaaagagctgggaggcttcacagagaaggctgtggtt 303 
 
                                                                        
Query: 241 cccctgggcctctacactgggcagctggccctgaactgggcatggccccccatcttcttt 300 
           ||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
Sbjct: 304 cccctgggcctctacactgggcagctggccctgaactgggcatggtcccccatcttcttt 363 
 
                                                                        
Query: 301 ggtgcccgacaaatgggctgggc-cttggtggatctcctgctggtcagtggggcggcggc 359 
           ||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||| 
Sbjct: 364 ggtgcccgacaaatgggctgggctcttggtggatctcctgctggtcagtggggcggcggc 423 
 
                                                                        
Query: 360 agc-cactaccgtggcctggtaccaggtgagcccgctggccgcccg-cctgctctacccc 417 
           ||| |||||||||||||||||||||||||||||||||||||||||| ||||||||||||| 
Sbjct: 424 agctcactaccgtggcctggtaccaggtgagcccgctggccgcccgtcctgctctacccc 483 
 
                                                                        
Query: 418 tacctggcctggctggccttcgcgaccacactcaactactgcgtatggcgggacaaccat 477 
           ||||||| |||||||||||||||||||||| |||| |||||||||||||||||||||||| 
Sbjct: 484 tacctggtctggctggccttcgcgaccacaatcaattactgcgtatggcgggacaaccat 543 
 
                                            
Query: 478 ggctggcatggg-ggacggcggctgccagagt 508 
           |||||||||||| ||||||||||||||||||| 
Sbjct: 544 ggctggcatgggtggacggcggctgccagagt 575 
 
 
 
 
Figure 3-30: Sequence Alignment of the Peripheral Benzodiazepine Receptor Gene 
(A) shows a graphic alignment of the two sequences. (B) shows a detailed alignment of the cloned PBR gene to 
the reference PBR gene.  
 
 
(A) 
(B) 
Key: 
Query: Reference Sequence (BT006949)                           – PBR specific primers  binding region 
Subject: Purified Recombinant PBR Sequence                  – Original size of the PBR region of interest 
Reference Sequence 
Queried Sequence 
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Figure 3-31: Linearisation of Recombinant Plasmid DNA 
 
3.2.2.9. Purification of Linearised Clones 
The linearised clones digested with PstI and ApaI were purified using the Promega Wizard® 
SV Gel and PCR Clean-Up System (Promega Corporation, Madison, WI, USA) in order to 
remove any excess salts and other contaminants. Results were analysed by agarose gel 
electrophoresis where purified products were run on a 1% agarose gel (Figure 3-32). It was 
found that both clones digested with PstI and ApaI were recovered as is indicative of the 
formation of a band (Lanes 2 and 3) at a level greater than 1031 bp reference band (Lane 1). 
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Figure 3-32: Purification of Linearised Clones 
 
Thereafter, the linearised clones were quantified to determine the concentration and purity of 
each clone digested with ApaI and PstI. Determining the concentration of each probe was 
required to determine what volume of each clone would be required to make a final 
concentration of 2 g/l required for the in vitro transcription of sense and anti-sense probes. 
This was done spectrophotometrically by measuring the absorbance at 260 nm and 280 nm for 
each clone, which was blanked against DEPC-treated H2O (Table 3-1). 260 nm is the 
wavelength at which nuclei absorbs light maximally while 280 nm is the wavelength at which 
protein absorbs light maximally. The purity of the sample can thus be determined by the ratio 
A260:A280, which was found to be 1.1 in the case of the ApaI digested clone and 1.0 in the case 
of the PstI digested clone. However, a pure DNA solution should result in a value greater than 
or equal to 1.8. The reason that the values are lower than 1.8 for the probes may be because 
the sample solutions used to measure the absorbance may have been too dilute. 
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 1        2          3      
Key: 
Lane 1: GeneRulerTM 100bp DNA 
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Lane 2: Purified Linearised Clone 
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Table 3-1: Absorbance, Purity and Concentration of Sense and Anti-Sense Probes 
Measured at 260 nm and 280 nm 
Sample A260 A280 A260:A280 Concentration (g/ml) 1 
ApaI Digested Clone 0.070 0.065 1.1 350 
PstI Digested Clone 0.082 0.083 1.0 410 
1. Concentration of each probe was determined using the formula: c = A260 x [A260dsDNA] x DF 
 
Concentration of each clone was determined using the formula: c = A260 x [A260dsDNA] x 
DF, where c is the concentration of the sample, [A260dsDNA] is the concentration of double-
stranded (ds) DNA where absorbance at 260 nm is 1.0, which is 50 µg/ml and DF is the 
dilution factor, which was 100. The concentrations of the clones were found to be 350 µg/ml 
for the ApaI digested clone and 410 µg/ml for the PstI digested clone. The volume required to 
prepare a solution of concentration 2 µg/l was determined using ratios and was found to be 
5.7 l for the ApaI digested clone and 4.9 l for the PstI digested clone (For calculation refer 
to Appendix 7 Calculations of Concentrations Linearised Clones, Volume Required to 
Synthesise Probes and Purity of Linearised Clones). 
 
3.2.3. Sense and Anti-Sense Probe Synthesis 
Clones linearised with PstI and ApaI were used to synthesise the anti-sense and sense probes 
respectively. This was done via in vitro transcription where small amounts of RNA is 
synthesised from a DNA template under the suitable control of a promoter for RNA 
polymerase after which each RNA copy was labelled with DIG-dUTP at every 20-25th 
nucleotide position. These labelled RNA probes were later used for in situ hybridisation. The 
sense probe was generated using SP6 RNA polymerase, which generates a 3’  to 5’  RNA 
copy, which prevents the sense probe from binding to the mRNA during in situ hybridisation 
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while the T7 RNA polymerase was used to generate the anti-sense probe resulting in the 
generation of a 5’  to 3’  RNA copy, which is able to bind to the 3’  end of the complementary 
mRNA strand during in situ hybridisation. 
 
3.2.3.1. Estimation of Minimal Concentration of Probes 
Serial dilutions of sense and anti-sense probes that were labelled with DIG during in vitro 
transcription, was blotted onto a nylon membrane from which the minimal concentration of 
the sense and anti-sense probes were determined (Figure 3-33). Comparing the intensity of the 
least dilute blot of both probes that appears on the membrane and comparing it to the same 
intensity blot of the DIG-labelled control RNA determined the minimal concentration of each 
probe. For the sense probe, the minimal concentration of the probe was determined to be 0.01 
pg/l and for the anti-sense probe the minimal concentration of the probe was determined to 
be 0.1 pg/l. 
 
 
                         
Figure 3-33: Blot showing Minimal Concentration of DIG-Labelled Sense and Anti-
Sense Probes 
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3.2.4. In Situ Hybridisation 
Colorimetric and fluorescent detection of the DIG-labelled anti-sense RNA probes were used 
to determine the localisation of the PBR mRNA in tissue preparations. DIG-labelled anti-
sense RNA probes hydrogen bonds to the complementary mRNA. DIG-labelled anti-sense 
RNA probes were colorimetrically detected by the binding of anti-DIG conjugated to AP to 
the DIG-labelled anti-sense RNA probes, which in the presence of a substrate such as 
NBT/BCIP allows for enzymatic activity to occur, which results in the formation of a 
purple/blue precipitate (Figure 3-34A). DIG-labelled anti-sense RNA probes were 
fluorescently detected by the binding of anti-DIG conjugated to FITC to DIG-labelled anti-
sense RNA probes. FITC does not require the presence of a substrate and emits an apple 
green colour when excited at 490 nm (Figure 3-34B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-34: Schematic Diagram of In Situ Hybridisation 
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In all cases, tissue preparations labelled with DIG-labelled sense probes showed no 
localization and served as the negative control. In order to determine a pattern of expression, 
in situ hybridisation on the tissue array was done in triplicate (3 tissue array slides were used 
for the colorimetric detection and 3 tissue array slides were used for the fluorescent detection) 
as some cancers had only 1 dot on the tissue array.   
 
Increase or decrease in expression of PBR mRNA was determined by looking at the intensity 
of the staining. It should be noted that for each of the cancers, increase and decrease in 
expression of PBR mRNA was determined relatively as there was no software available by 
which the images could be analysed to determine quantitation in absolute terms.  
 
3.2.4.1. Expression of the Peripheral Benzodiazepine Receptor mRNA in Liver Normal and 
Tumour Tissues 
Expression of PBR mRNA in liver can be determined by comparing the normal and cancerous 
tissues to the negative control (Figure 3-35). It was found that PBR mRNA is expressed in 
both normal tissue and hepatocellular carcinoma. All cases showed that PBR mRNA 
expression varies from the normal to the diseased state, with PBR mRNA expression levels 
increasing in Grade II and Grade III hepatocellular carcinoma when compared to its normal 
counterpart. Also, PBR mRNA expression levels varies for the different grades of the tumour 
showing that PBR mRNA expression levels decreases from Grade II to Grade III 
hepatocellular carcinoma. 
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Figure 3-35: Expression of the Peripheral Benzodiazepine Receptor mRNA in Liver 
(Magnification 400X) 
 
The subcellular localisation of the PBR mRNA is determined by comparing a tissue sample to 
the negative control. In normal liver tissue PBR mRNA is expressed in the cytoplasm of 
hepatocytes and in the nuclei and cytoplasm of Kupffer cells and endothelial cells of the 
sinusoids (Figure 3-36).  
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Figure 3-36: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Normal Liver Tissue (Magnification 1000X) 
 
Grade II hepatocellular carcinoma express PBR mRNA in the cytoplasm of tumour cells 
having either a trabecular or pseudoglandular pattern while Grade III hepatocellular 
carcinoma express PBR mRNA in the nuclei and cytoplasm of tumour cells that resemble 
anaplastic giant cells to spindle-shaped cells (Figure 3-37). 
 
3.2.4.2. Expression of the Peripheral Benzodiazepine Receptor mRNA in Colon Normal and 
Tumour Tissues 
Expression of PBR mRNA in colon can be determined by comparing normal and cancerous 
tissues to the negative control, which is the localisation of the sense strand to mRNA in tissue 
resulting in no localisation (Figure 3-38). It was found that PBR mRNA is expressed in both 
normal tissue and colonic adenocarcinoma. All cases showed that PBR mRNA expression 
varies from the normal to the diseased state, with PBR mRNA expression levels increasing in 
Grade I colonic adenocarcinoma when compared to its normal counterpart while decreasing in 
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Grade II and Grade III colonic adenocarcinoma when compared to its normal counterpart. 
Also all cases showed that PBR mRNA expression levels varies for the different grades of the 
tumour showing that PBR mRNA expression levels decreases from Grade I to Grade II and 
Grade III colonic adenocarcinoma respectively. However, it should be noted that in all cases 
Grade II colonic adenocarcinoma showed a lower expression level of PBR mRNA than Grade 
III colonic adenocarcinoma. 
 
 
 
Figure 3-37: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Hepatocellular Carcinoma (Magnification 1000X) 
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Figure 3-38: Expression of the Peripheral Benzodiazepine Receptor mRNA in Colon 
(Magnification 400X) 
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The subcellular localisation of the PBR mRNA is determined by comparing a tissue sample to 
the negative control. In normal colon tissue PBR mRNA is expressed in the cytoplasm of 
goblet cells and absorptive cells of the Crypts of Lieberkhün and in the cytoplasm of plasma 
cells and in the nuclei and cytoplasm of lymphocytes located in the lamina propria (Figure 3-
39).  
 
 
 
 
 
Figure 3-39: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Normal Colon Tissue (Magnification 1000X) 
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Grade I colonic adenocarcinoma express PBR mRNA in the cytoplasm of tumour cells that 
are mucin-secreting and arranged in adenomatous tubular glands and fibromuscular stroma, 
Grade II colonic adenocarcinomas express PBR mRNA in the cytoplasm of tumour cells 
arranged as adenomatous glands and tumour cells arranged as solid sheets while Grade III 
colonic adenocarcinoma express PBR mRNA in the cytoplasm of tumour cells that are 
predominantly arranged as a solid pattern (Figure 3-40). 
 
3.2.4.3.Expression of the Peripheral Benzodiazepine Receptor mRNA in Epiploon Normal and 
Tumour Tissues 
Expression of PBR mRNA in the epiploon and stomach can be determined by comparing 
normal and cancerous tissues to the negative control (Figure 3-41). It was found that PBR is 
expressed in both normal epiploon and stomach and in Grade III stomach squamous cell 
carcinoma. PBR mRNA expression varies from the normal to the diseased state, with PBR 
mRNA expression levels increasing in squamous cell carcinoma compared to its normal 
counterpart. In addition, PBR mRNA may be expressed at a higher level in epiploon than in 
the stomach of normal tissue as determined by the intensity of the staining because 50% of 
cases studied showed a high expression level while 50% of the cases studied showed an 
intermediate expression level. 
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Figure 3-40: Subcellular Localisation of Peripheral Benzodiazepine Receptor mRNA in 
Colonic Adenocarcinoma (Magnification 1000X) 
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Figure 3-41: Expression of the Peripheral Benzodiazepine Receptor mRNA in Normal 
Epiploon and Stomach (Magnification 400X) 
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The subcellular localisation of the PBR mRNA is determined by comparing a tissue sample to 
the negative control. In normal epiploon tissue PBR mRNA is expressed in the cytoplasm of 
adipose cells, collagen fibres and fibroblasts located between the collagen fibres in the stroma 
(Figure 3-42).  
 
 
 
Figure 3-42: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Normal Epiploon Tissue (Magnification 1000X) 
 
In stomach normal tissue PBR mRNA is expressed in the cytoplasm of parietal cells, chief 
cells, surface mucous cells and neck mucous cells of the gastric glands and in the cytoplasm 
of collagen fibres, plasma cells and macrophages and nuclei and cytoplasm of lymphocytes 
located in the lamina propria (Figure 3-43).  
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Figure 3-43: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Normal Stomach Tissue (Magnification 1000X) 
 
In Grade III stomach squamous cell carcinoma PBR mRNA is expressed in the cytoplasm of 
tumour cells and collagen fibres in the surrounding stroma (Figure 3-44). 
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Figure 3-44: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Stomach Squamous Cell Carcinoma (Magnification 1000X) 
 
3.2.4.4. Expression of the Peripheral Benzodiazepine Receptor mRNA in Prostate Normal and 
Tumour Tissues 
Expression of PBR mRNA in prostate can be determined by comparing normal and cancerous 
tissues to the negative control (Figure 3-45). It was found that PBR mRNA is expressed in 
both hyperplastic tissue and adenocarcinoma of the peripheral duct and acini. PBR mRNA 
expression varies from the normal to the diseased state, with all cases showing PBR mRNA 
expression levels increasing in Grade II and Grade III adenocarcinoma of the peripheral duct 
and acini when compared to its normal counterpart. Also, PBR mRNA expression levels vary 
for the different grades of the tumour showing that PBR mRNA expression levels increases 
from Grade II to Grade III adenocarcinoma of the peripheral duct and acini. 
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Figure 3-45: Expression of the Peripheral Benzodiazepine Receptor mRNA in Prostate 
(Magnification 400X) 
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The subcellular localisation of the PBR mRNA is determined by comparing a tissue sample to 
the negative control. In hyperplastic prostate tissue PBR mRNA is expressed in the cytoplasm 
of the inner columnar epithelium and in the cytoplasm and nuclei of the outer cuboidal to 
flattened endothelial cells that line the glands and in the cytoplasm of the collagen and elastic 
fibres and in the nuclei of fibroblasts of the fibromuscular stroma (Figure 3-46).  
 
 
 
 
Figure 3-46: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Hyperplastic Prostate Tissue (Magnification 1000X) 
 
Grade II adenocarcinoma of the peripheral duct and acini expresses PBR mRNA in the 
cytoplasm of cuboidal to low columnar epithelial cells lining glands and in the collagen fibres 
located in the stroma and in the nuclei and cytoplasm of lymphocytes and endothelial cells 
lining blood vessels located in the surrounding stroma while Grade III adenocarcinoma of the 
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peripheral duct and acini expresses PBR mRNA in the cytoplasm of tumour cells that grow in 
nests or sheets (Figure 3-47). 
 
 
 
Figure 3-47: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Prostate Adenocarcinoma of the Peripheral Duct and Acini (Magnification 
1000X) 
 
3.2.4.5. Expression of the Peripheral Benzodiazepine Receptor mRNA in Breast Normal and 
Tumour Tissues 
Expression of PBR mRNA in breast can be determined by comparing normal and cancerous 
tissues to the negative control (Figure 3-48). It was found that PBR mRNA is expressed in 
both normal and Grade III invasive carcinoma (NST). PBR mRNA expression varies from the 
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normal to the diseased state, with PBR mRNA expression levels increasing in invasive 
carcinoma (NST) when compared to its normal counterpart. 
 
 
 
 
Figure 3-48: Expression of the Peripheral Benzodiazepine Receptor mRNA in Breast 
(Magnification 400X) 
 
The subcellular localisation of the PBR mRNA is determined by comparing a tissue sample to 
the negative control. In normal breast tissue PBR mRNA is expressed in the cytoplasm of the 
luminal layer of cuboidal epithelial cells and the outer layer of discontinuous epithelial cells 
of the terminal ducts and alveoli, in cytoplasm of collagen fibres of the fibroconnective tissue, 
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in nuclei and cytoplasm of lymphocytes and in the nuclei of endothelial cells of the vascular 
tissue located in the intralobular stroma (Figure 4-49). 
 
 
 
 
Figure 3-49: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Normal Breast Tissue (Magnification 1000X) 
 
Grade III invasive carcinoma (NST) expresses PBR mRNA in the cytoplasm of tumour cells 
arranged as nests and collagen fibres of the fibrotic stroma and in the nuclei and cytoplasm of 
lymphocytes located between the tumour and stroma, indicating the presence of a 
mononuclear infiltrate (Figure 3-50). 
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Figure 3-50: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Breast Invasive Carcinoma (No Specific Type) (Magnification 1000X) 
 
3.2.4.6. Expression of the Peripheral Benzodiazepine Receptor mRNA in Lung Normal and 
Tumour Tissues 
Expression of PBR mRNA in lung can be determined by comparing normal and cancerous 
tissues to the negative control (Figure 3-51). It was found that PBR mRNA is expressed in 
both normal and cancerous tissues (Grade III adenocarcinoma, Grade III squamous cell 
carcinoma and small cell carcinoma). PBR mRNA expression varies from the normal to the 
diseased state, with PBR mRNA expression levels increasing in all cases Grade III squamous 
cell carcinoma, decreasing in all cases of Grade III adenocarcinoma and 50% cases of small 
cell carcinoma and showing no expression in 50% cases of small cell carcinoma. Also, the 
expression of PBR mRNA varies between the different types of cancers, with Grade III 
squamous cell carcinoma showing the most intense staining while small cell carcinoma 
showing the least intense staining. 
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Figure 3-51: Expression of the Peripheral Benzodiazepine Receptor mRNA in Lung 
(Magnification 400X) 
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The subcellular localisation of the PBR mRNA is determined by comparing a tissue sample to 
the negative control. In normal lung tissue PBR mRNA is expressed in the cytoplasm of 
macrophages, plasma cells and fibroblasts in the surrounding stroma, in the cuboidal cells that 
line the respiratory bronchiole and in the smooth muscle fibres surrounding the pulmonary 
artery, and in the nuclei and cytoplasm of the endothelial cells of the pulmonary artery and 
lymphocytes in the surrounding stroma (Figure 3-53). 
 
Grade III lung adenocarcinoma expresses PBR mRNA in the cytoplasm and nuclei of tumour 
cells and in the fibres located in the surrounding solid-like stroma (Figure 3-52). 
 
 
 
Figure 3-52: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Lung Adenocarcinoma (Magnification 1000X) 
 
Grade III squamous cell carcinoma expresses PBR mRNA in the cytoplasm and nuclei of 
tumour cells that is characterised with the merging of tumour cells with the large cell pattern 
(Figure 3-54). 
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Figure 3-53: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Normal Lung Tissue (Magnification 1000X) 
 
Lung small cell carcinoma expresses PBR mRNA in the cytoplasm of tumour cells that 
resemble lymphocytes and have a scanty cytoplasm and in the nuclei of lymphocytes and 
endothelial cells lining capillaries in the stroma (Figure 3-55). 
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Figure 3-54: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Lung Squamous Cell Carcinoma (Magnification 1000X) 
 
 
 
Figure 3-55: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Lung Small Cell Carcinoma (Magnification 1000X) 
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3.2.4.7. Expression of the Peripheral Benzodiazepine Receptor mRNA in Kidney Normal and 
Tumour Tissues 
Expression of PBR mRNA in kidney can be determined by comparing normal and cancerous 
tissues to the negative control (Figure 3-56). It was found that PBR mRNA is expressed in 
both normal and cancerous tissues (chromophobe renal cell carcinoma and clear cell renal 
carcinoma). PBR mRNA expression varies from the normal to the diseased state, with PBR 
mRNA expression levels increasing in all cases of chromophobe renal cell carcinoma and 
clear cell renal carcinoma. Also, the expression of PBR mRNA varies between the different 
types of cancers, with chromophobe renal cell carcinoma showing a higher expression of PBR 
mRNA than clear cell renal carcinoma seen by the intensity of staining. 
 
The subcellular localisation of the PBR mRNA is determined by comparing a tissue sample to 
the negative control. In normal kidney tissue PBR mRNA is expressed in the cytoplasm of the 
flattened cells located in the parietal layer of the Bowman’ s capsule, in the cytoplasm of 
endothelial cells that lines the anastomosing network of capillaries of in the glomerulus, in the 
cytoplasm of the simple cuboidal epithelium with a prominent brush border of tall microvilli 
that lines the proximal convoluted tubule (PCT), in the cytoplasm of the simple squamous 
epithelium and erythrocytes within the vasa recta characterised by an irregular shape, in the 
cytoplasm of the simple squamous epithelium that lines the thin ascending and descending 
limbs characterised by a regular round shape, in the cytoplasm of the low cuboidal epithelium 
of the thick ascending limb that appear round in cross section, in the cytoplasm of the simple 
cuboidal epithelium of the distal convoluted tubule (DCT) characterised by the absence of a 
brush border and a larger more clearly defined lumen than the PCT, in the cytoplasm of the 
simple cuboidal epithelium of the collecting tubule that appears wider and less regular in 
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shape to the ascending limb and in the cytoplasm of the simple columnar epithelium that lines 
the collecting duct (Figure 3-57). 
 
 
 
Figure 3-56: Expression of the Peripheral Benzodiazepine Receptor mRNA in Kidney 
(Magnification 400X) 
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Figure 3-57: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Normal Kidney Tissue (Magnification 1000X) 
  
Grade III chromophobe renal cell carcinoma shows expression of PBR mRNA in the nuclei 
and cytoplasm of tumour cells that are usually arranged as a solid pattern with concentrations 
of the largest cells around the blood vessels (Figure 3-58). 
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Figure 3-58: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Chromophobe Renal Cell Carcinoma (Magnification 1000X) 
 
Renal clear cell carcinoma expresses PBR mRNA in the nuclei and cytoplasm of tumour cells 
and in the cytoplasm of the delicate branching vasculature that appears fibromuscular (Figure 
3-59). 
 
 
 
Figure 3-59: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Renal Clear Cell Carcinoma (Magnification 1000X) 
Colorimetric Detection Fluorescent Detection 
Negative Control 
Tumour Tissue 
(A) 
(C) 
(B) 
(D) 
(A) (B) 
Negative Control Tumour Tissue 
Colorimetric 
Detection 
 186 
3.2.4.8. Expression of the Peripheral Benzodiazepine Receptor mRNA in Brain Normal and 
Tumour Tissues 
Expression of PBR mRNA in brain can be determined by comparing normal and cancerous 
tissues to the negative control (Figure 3-60). It was found that PBR mRNA is expressed in 
both normal and cancerous tissues (Grade II diffuse fibrillary astrocytoma, primary central 
nervous system lymphoma (PCNSL) and ependymoma). PBR mRNA expression varies from 
the normal to the diseased state, with PBR mRNA expression levels increasing in all cases of 
Grade II diffuse fibrillary astrocytoma, PCNSL and ependymoma. Also, the expression of 
PBR mRNA varies between the different types of cancers; with Grade II diffuse fibrillary 
astrocytoma showing the highest level of expression and PCNSL showing the lowest level of 
expression. Furthermore, PBR mRNA expression levels vary between the different types of 
normal tissue, with grey matter showing a higher PBR mRNA expression than white matter. 
 
The subcellular localisation of the PBR mRNA is determined by comparing a tissue sample to 
the negative control. In normal brain tissue PBR mRNA is expressed in the cytoplasm of 
neurones such as pyramidal cells, fusiform cells, in glia such as oligodendrocytes and in the 
astrocytes and in the cytoplasm of the fibrillary network of white matter and in the cytoplasm 
of glia such as oligodendrocytes, neurones such as stellate cells and astrocytes and in the 
cytoplasm of the fibrillary network of grey matter (Figure 3-61). 
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Figure 3-60: Expression of the Peripheral Benzodiazepine Receptor mRNA in Brain  
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Figure 3-61: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Normal Brain Tissue (Magnification 1000X) 
 
 
Grade II diffuse fibrillary astrocytoma expresses PBR mRNA in the cytoplasm of tumour 
cells that appear as glial cells having an oval shape appearance, neurones such as stellate cells 
and oligodendrocytes and in the astrocytes, that is, in the astrocytic processes that appears as a 
fibrillary background, in the nuclei of microglia and in the nuclei and cytoplasm of fusiform 
cells (Figure 3-62). 
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Figure 3-62: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Diffuse Fibrillary Astrocytoma (Magnification 1000X) 
 
PCNSL expresses PBR mRNA in the cytoplasm of tumour cells that appear lymphocyte-like 
and neurones such as oligodendrocytes and in the nuclei and cytoplasm of astrocytes, 
microglia and fusiform cells (Figure 3-63). 
 
Ependymomas expresses PBR mRNA in the nuclei and cytoplasm of tumour cells 
characterised by round to oval nuclei and an abundant granular cytoplasm and the fibrillary 
processes and in the nuclei of lymphocytes (Figure 3-64). 
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Figure 3-63: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Primary Central Nervous System Lymphoma (Magnification 1000X) 
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Figure 3-64: Subcellular Localisation of the Peripheral Benzodiazepine Receptor mRNA 
in Ependymoma (Magnification 1000X) 
  
3.2.5. Summary 
The PBR mRNA was expressed in all normal and cancerous human tissues studied. The 
expression of PBR was clearly seen in specific cells within a given organ in both the normal 
and the diseased state (Appendix 8 Table 1 and Table 2). From the results obtained it is clear 
that the PBR mRNA is expressed mainly in the cytoplasm, however, nuclear localisation of 
PBR mRNA were observed. 
 
The level of expression within a given organ varies in the normal and cancerous state 
(Appendix 8 Table 3 and Table 4). In order to determine if the level of expression of PBR 
mRNA increased or decreased in the cancerous state, cancerous tissues were compared to its 
normal counterpart (Appendix 8 Table 5).  
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Furthermore, the level of PBR mRNA expression varies with tumour malignancy grade 
(Appendix 8 Table 5). In hepatocellular carcinoma expression of PBR mRNA decreased as 
tumour invasion increased while in prostate adenocarcinoma of the peripheral duct and acini 
PBR mRNA level increased as tumour invasion increased. In colon adenocarcinoma 
expression of PBR mRNA decreased from Grade I to Grade II and Grade III colonic 
adenocarcinoma. However, Grade III colonic adenocarcinoma had a higher PBR mRNA 
expression level than Grade II colonic adenocarcinoma. 
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3.3. Expression Levels of Peripheral Benzodiazepine Receptor mRNA in Various 
Human Cancer Tissues 
3.3.1. Introduction 
Real-time PCR is a sensitive technique, providing ease and convenience to quantitate 
differences in mRNA expression, even when the amount of RNA available is low. The real-
time PCR machine uses both the logarithmic and linear graphs to examine data. Both graphs 
may be used because a linear relationship exists between the amount of PCR product and the 
cycle number when seen on a logarithmic scale as the amount of PCR product increases 
exponentially. Thus, accurate and precise quantitation of DNA is done when PCR 
amplification is still in the exponential phase that is in the log phase, which occurs earlier in 
the PCR reaction. Data is acquired from the threshold cycle (Ct), that is the cycle at which the 
reporter dye fluorescence intensity increases above the background noise. Ct is determined at 
the most exponential phase of the reaction and is more accurate than the end-point 
measurements. It should be noted that the Ct value is inversely proportional to the copy 
number of template DNA, that is the higher the Ct value, the lower the amount of template 
DNA. Thus, the Ct value is used in quantitation as well as in qualitative analysis as a pass/fail 
measure. The slope of the log-linear phase is a reflection of the amplification efficiency.  
 
SYBR Green I is a dye that when bound to double-stranded DNA fluoresces very brightly at a 
ratio that is much higher in the presence of double-stranded DNA than single-stranded DNA. 
It has an excitation and emission maxima of 494 nm and 594 nm respectively. Since SYBR 
Green I binds to amplified cDNA, the quantitation curve is the measure of increase in 
fluorescence as the dye binds to increasing amounts of DNA in the reaction tube. This DNA 
could be the PCR product but may also be any other DNA in the tube. In order to determine if 
the PCR product has been amplified and not any other DNA results can be analysed using a 
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melting curve. Thus, this is a means by which quality control can be maintained, as all 
products amplified with the same primers should have the same or similar melting 
temperature. Differences in this melting temperature may occur when there is contamination, 
mispriming, that is PCR products made due to the annealing of primers to complementary or 
partially complementary sequences on non-target DNA, or primer dimer formation. 
 
3.3.2. Relative Quantitative Real-Time Polymerase Chain Reaction 
Relative quantitative real-time PCR was done to determine level of expression of the PBR 
mRNA in various cancer tissues, namely lung normal tissue (MRC5), lung adenocarcinoma 
(A549), cervical carcinoma (HeLa) and liver hepatocellular carcinoma (HepG). This was 
achieved by extracting RNA from each cell line, reverse transcribing each cell line into cDNA 
using reverse transcriptase and oligo-(dT)15 after which each cell line underwent real-time 
PCR using PBR specific primers and SYBR Green I. Results were analysed using quantitation 
and melting curves using the Opticon 3.1 software (Bio-Rad Laboratories, Hercules, CA, 
USA) and agarose gel electrophoresis where real-time PCR products were run on a 1% 
agarose gel. 
 
3.3.2.1. Optimisation of the Concentration of Template DNA Required for Real-Time 
Polymerase Chain Reaction 
In order to determine the optimal concentration of cDNA required to perform this experiment, 
quantitative real-time PCR was conducted using serial dilutions of MRC5. Results were 
analysed using quantitation and melting curves. 
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Quantitation of the PCR product synthesised during the serial dilution of MRC5 is 
represented by a graph of fluorescence versus the cycle number, that is the amount of SYBR 
Green I that binds to double-stranded DNA at each cycle (Figure 3-65). The resultant graph 
for each of the serial dilutions is logarithmic, which eventually plateaus towards the end of the 
PCR reaction. Quantitation of the PCR product is determined where PCR amplification is still 
exponential, represented by linear part of the curve. The negative control that was used as a 
blank containing only sdH2O was subtracted from the other cell lines in order to remove the 
background noise. Further, the standard deviation was set at 0.002 in order to further remove 
background noise. Relatively, serial dilutions of MRC5 showed expression of PBR mRNA 
and the relationship in decreasing order of PBR mRNA expression is as follows: 1:1000 
dilution of MRC5 > 1:100 dilution of MRC5 > 1:10 dilution of MRC5 > 1:10000 dilution of 
MRC5 > undiluted MRC5. 
 
Ct values and efficiency of PCR was determined in comparison to the negative control 
containing only sdH2O (Table 3-2).  The efficiency of PCR should lie between 90-100%. 
However, in this study, only the 1:10000 dilution of MRC5 showed efficiency greater than 
100%, which indicates that the result obtained for this cell line is highly efficient. The other 
serial dilutions of MRC5 showed efficiencies that were lower than 90% ranging from 44% to 
81%. Reasons for low efficiency seen could include the length of the PCR product, secondary 
structure formation, primer quality and concentration of the product. Ct values should not lie 
higher than 40 because any value higher than this indicates that no amplification of PCR 
product occurs. In this case, all the Ct values lie below 40 with Ct values increasing as 
follows:  1:1000 dilution of MRC5 < 1:100 dilution of MRC5 < 1:10 dilution of MRC5 < 
1:10000 dilution of MRC5 < undiluted MRC5. This indicates that samples containing 
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template DNA increases as follows: 1:1000 dilution of MRC5 > 1:100 dilution of MRC5 > 
1:10 dilution of MRC5 > 1:10000 dilution of MRC5 > undiluted MRC5. 
 
 
 
Figure 3-65: Quantitative Curve of the Peripheral Benzodiazepine Receptor Gene in the 
Serial Dilution of the MRC5 Cell Line 
 
In order to determine if the PBR gene was amplified and not any other product, a melting 
curve was done. Results are represented as a graph of fluorescence, which is the relative 
fluorescence units over time (-dI/dTmax), versus temperature that peaks at the melting 
temperature (Tm) (Figure 3-66) and a table showing the melting temperature for each of the 
samples (Table 3-3). An additional column is the full width half maximum (FWHM), which 
represents the width in C˚ of the –dI/dTmax peak and thus describes the sharpness of the peak. 
In order to reduce background noise, the effect of the blank was subtracted from all five 
samples. It was found that all five samples had a major peak at 84 C˚. However, even after 
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subtracting the blank background noise could still be seen which indicates that the PCR 
product synthesised is probably not very pure and this could have occurred due to 
contamination. 
 
Table 3-2: Efficiency and Threshold Cycle Values of PCR Product Synthesised 
Sample Efficiency Threshold Cycle (Ct) 
Negative Control  - - 
Undiluted MRC5 80.85 23.42 
1:10 Diluted MRC5 64.01 22.31 
1:100 Diluted MRC5 44.93 20.32 
1:1000 Diluted MRC5 49.55 18.66 
1: 10000 Diluted MRC5 134.58 22.52 
 
It was found that the optimal concentration at which real-time PCR occurred most efficiently 
and precisely was when the cDNA production was diluted 10000 times that is when the 
concentration of MRC5 was 0.286 ng/l (For calculation refer to Appendix 7 Calculations of 
Concentrations cDNA, Volume Required for Real-Time PCR and Purity of cDNA). 
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Figure 3-66: Melting Curve of the Real-Time PCR Products Synthesised 
 
3.3.2.2. Determination of Expression of Peripheral Benzodiazepine Receptor mRNA in 
Various Cell Lines using Optimal Concentration of Template DNA 
The cDNA products for each of the cell lines were quantified to determine the concentration 
and purity of the cDNA for each. Determining the concentration of each cell line was required 
to determine what volume of each cell line was required to make a final concentration of 
0.216 ng/µl for real-time PCR. This was done spectrophotometrically by measuring the 
absorbance at 260 nm and 280 nm for each of the cell lines, which was blanked against sdH2O 
(Table 3-4). 260 nm is the wavelength at which nuclei absorbs light maximally while 280 nm 
is the wavelength at which protein absorbs light maximally. A pure DNA solution should 
result in a value greater than or equal to 1.8. The values obtained were lower than 1.8 for each 
of the cell lines, which may have occurred because the sample solutions were blanked against 
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sdH2O, while in actual fact the sample solutions also contained the reagents used in order to 
construct cDNA. 
 
Table 3-3: Calculation of Melting Temperatures for the PCR Product Synthesised in 
Serial Dilution of the MRC5 Cell Line 
Sample 
Full Width 
Half Maximum 
(FWHM)  
Relative Fluorescent 
Units over Time  
(-dI/dTmax) 
Melting 
Temperature 
(Tm) (˚C) 
Negative Control  0.000 0.00000 55 
Undiluted MRC5 6.681 0.007354 84 
1:10 Diluted MRC5 7.045 0.007429 84 
1:100 Diluted MRC5 3.571 0.010830 84 
1:1000 Diluted MRC5 3.945 0.017000 84 
1: 10000 Diluted MRC5 5.67 0.01154 84 
 
Concentration of each clone was determined using the formula: c = A260 x [A260dsDNA] x 
DF, where c is the concentration of the sample, [A260dsDNA] is the concentration of double-
stranded (ds) DNA where absorbance at 260 nm is 1.0, which is 50 g/ml and DF is the 
dilution factor, which was 100 and were as tabulated in Table 3-4.  The volume required to 
prepare a cDNA template of concentration 0.216 ng/l was determined using ratios and was 
found to be 0.8 l for MRC5, 1.0 l for A549, 0.34 l for HeLa and 1.0 l for HepG (For 
calculations see Appendix 7 Calculations of Concentrations cDNA, Volume Required for 
Real-Time PCR and Purity of cDNA). 
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Table 3-4: Absorbance, Purity and Concentration of Sense and Anti-Sense Probes 
Measured at 260 nm and 280 nm 
Sample A260 A280 A260:A280 
Concentration 
(g/ml) 1 
Concentration  
(ng/l)2 
MRC5 0.438 0.347 1.65 2860 0.286 
A549 0.438 0.270 1.62 2190 0.219 
HeLa 1.280 0.932 1.38 6430 0.643 
HepG 0.432 0.266 1.62 2160 0.216 
1. Concentration of each cell line was determined using the formula: c = A260 x [A260dsDNA] x DF 
2. Concentration of each cell line was determined by using a dilution factor of 10000 
 
Quantitation of the PCR product is represented by a graph of fluorescence versus the cycle 
number (Figure 3-67). The resultant graph for each of the cell lines is logarithmic, which 
eventually plateaus towards the end of the PCR reaction. Quantitation of the PCR product is 
determined where PCR amplification is still exponential and is represented by the linear part 
of the curve. The negative control that was used as a blank containing only sdH2O was 
subtracted from the other cell lines in order to remove the background noise. Further, the 
standard deviation was set at 0.004 in order to further remove background noise. Relatively, 
the normal MRC5 showed a higher concentration of PBR when compared to it cancerous cell 
line A549. When comparing the cancerous cell lines HepG showed the highest concentration 
of PBR while A549 showed the least concentration of PBR. 
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Figure 3-67: Quantitative Curve of the Peripheral Benzodiazepine Receptor Gene in 
Various Cell Lines 
 
Ct values and efficiency of PCR was determined in comparison to the negative control 
containing only sdH2O (Table 3-5).  The efficiency of PCR should lie between 90-100%. 
However, in this study, only HepG lies in this range, which indicates that the result obtained 
for this cell line is highly efficient while the other cell lines show efficiency that lies within 
72%-78% range. Reasons for low efficiency seen could include the length of the PCR 
product, secondary structure and primer quality. Ct values should not lie higher than 40 
because any value higher than this indicates that no amplification of PCR product occurs. In 
this study, all the Ct values lie below 40 with MRC5 having a lower Ct value when compared 
to A549, which indicates that MRC5 had a higher concentration of template PBR than A549. 
When the cancerous cell lines were compared to each other, it was found that the lowest Ct 
value was seen in HepG and the highest Ct value was seen in A549, which indicates that 
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HepG had the highest concentration of template PBR and A549 had the lowest concentration 
of template PBR. 
 
Table 3-5: Efficiency and Threshold Cycle Values of PCR Product Synthesised 
Sample Efficiency Threshold Cycle (Ct) 
Negative Control  - - 
MRC5 77.53 21.71 
A549 76.56 22.71 
HeLa 99.45 22.59 
HepG 72.18 22.12 
 
In order to determine the relative expression levels of PBR mRNA in absolute terms, the 
following formula to compare two cell lines were used: Relative Expression Level = 2Ct, 
where Ct is the difference in the Ct values for the two different cell lines been compared 
(Table 3-6 and Table 3-7, Figure 3-68 and Figure 3-69). Using this formula, the value 1, 
which the reference mRNA will have, serves as the base from which increase or decrease 
expression can be determined, that is any value greater than 1 shows that an increase in 
expression occurs with regard to the reference mRNA while any value lower than 1 shows 
that a decrease in expression occurs with regard to the reference mRNA. It was found that 
A549 had a half-fold decrease in PBR mRNA expression when compared to MRC5.  HeLa 
had a slight increase in PBR mRNA expression when compared to A549 and HepG had a 
half-fold increase in PBR mRNA when compared to A549 (for calculations refer to Appendix 
7 Calculations of the Relative Expression of the Peripheral Benzodiazepine Receptor mRNA 
in Absolute Terms). 
 
 203 
Table 3-6: Relative Expression Level of the Peripheral Benzodiazepine Receptor mRNA 
in Lung Adenocarcinoma when Compared Lung Normal in Absolute Terms 
Cell Line Threshold Cycle (Ct) Relative Expression Level1 
MRC5 21.71 1 
A549 22.71 0.5 
1. The relative expression level of PBR mRNA was determined using the following formula: Relative 
Expression Level = 2Ct. 
2. The relative expression level of PBR mRNA was determined using the following formula: Relative 
Expression Level = 2Ct. 
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Figure 3-68: Relative Expression Level of Lung Adenocarcinoma When Compared to its 
Normal Counterpart 
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Table 3-7: Relative Expression Level of the Peripheral Benzodiazepine Receptor mRNA 
in Various Cancers in Absolute Terms 
Cell Line Threshold Cycle (Ct) Relative Expression Level1 
A549 22.71 1 
HeLa 22.59 1.09 
HepG 22.12 1.51 
1. The relative expression level of PBR mRNA was determined using the following formula: Relative 
Expression Level = 2Ct. 
2. The relative expression level of PBR mRNA was determined using the following formula: Relative 
Expression Level = 2Ct. 
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Figure 3-69: Relative Expression Levels of Peripheral Benzodiazepine Receptor mRNA 
in Various Cancers 
 
In order to determine if the PBR gene was amplified and not any other product, a melting 
curve was done. Results are represented as a graph of fluorescence, which is the relative 
fluorescence units over time (-dI/dTmax), versus temperature that peaks at the melting 
temperature (Tm) (Figure 3-70) and a table showing the melting temperature for each of the 
samples (Table 3-8). An additional column is the full width half maximum (FWHM), which 
Key: 
A549 – Lung 
Adenocarcinoma Cell 
Line 
HeLa – Cervical 
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HepG – Hepatocellular 
Carcinoma Cell Line 
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represents the width in C˚ of the –dI/dTmax peak and thus describes the sharpness of the peak. 
In order to reduce background noise, the effect of the blank was subtracted from all four cell 
lines. It was found that all four cell lines had a major peak at 84 C˚. However, even after 
subtracting the blank background noise could still be seen which indicates that the PCR 
product synthesised is probably not very pure and this could have occurred due to 
contamination and also due to some DNA degradation. 
 
 
Figure 3-70: Melting Curve of the Real-Time PCR Products Synthesised 
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Table 3-8: Calculation of Melting Temperatures for the PCR Product Synthesised in 
each Cell Line 
Sample 
Full Width 
Half Maximum 
(FWHM)  
Relative Fluorescent 
Units over Time  
(-dI/dTmax) 
Melting 
Temperature 
(Tm) (˚C) 
Negative Control  0.000 0.00000 56 
MRC5 3.481 0.008731 84 
A549 3.753 0.007285 84 
HepG 3.535 0.011540 84 
HeLa 4.156 0.015670 84 
 
 
Since the efficiency for three of the cell lines were not high enough and the melting curve 
showed that the PCR product generated was not pure, the PCR product that was generated 
during real-time PCR for each of the cell lines was run on a 1% agarose gel in order to 
determine if the PCR product of 247 bp was the only product generated (Figure 3-71). All 
four cell lines showed the formation of a band of 247 bp (Lanes 3-6), which lies between the 
200 bp and 300 bp reference bands of Lane 1. The negative control containing only sdH2O 
showed no formation of bands (Lanes 2). However, smearing did occur, which indicates that 
PCR product may not be pure and contains contaminants or some DNA degradation may have 
occurred. 
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Figure 3-71: Amplification of Real-Time Polymerase Chain Reaction Product 
 
3.3.3. Summary 
Quantitative real-time PCR showed that the expression levels of PBR mRNA varied between 
lung adenocarcinoma and its normal counterpart and between the different cancer cell lines. It 
was found that the relative expression of PBR mRNA decreased half-fold in lung 
adenocarcinoma when compared to it normal counterpart seen by the decrease in 
concentration of template DNA for the two cell lines. In the case of the cancerous cell lines, 
the concentration of PBR mRNA increases as follows: liver hepatocellular carcinoma > 
cervical carcinoma  lung adenocarcinoma, with liver hepatocellular carcinoma showing a 
half-fold increase compared to lung adenocarcinoma and cervical carcinoma and lung 
adenocarcinoma showing a similar expression level. 
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3.4. Peripheral Benzodiazepine Receptor Protein Expression 
3.4.1. Introduction 
Since not many studies have focused on the effect of the Peripheral Benzodiazepine Receptor 
(PBR) protein specifically in various cancer tissues, it was thought that synthesis of this 
protein would prove valuable in determining the expression patterns of this protein in various 
cancer tissues as well as determining its role in cell proliferation and apoptosis. The PBR 
protein was synthesised by ligating the PBR insert into an expression vector, namely pGEX-
6P-2, which contains a GST domain and a lac promoter site. Thus, when the pGEX-6P-2 
expression vector is induced with IPTG, it results in the expression of a GST-tagged PBR 
protein, which after purification with gluthathione can be digested with PreScissionTM 
Protease in order to isolate the PBR protein, which can be used for further studies such as 
immunocytochemistry and TUNEL assays. 
 
3.4.2. Restriction Digestion of the Peripheral Benzodiazepine Receptor Insert and pGEX-
6P-2 Expression Vector 
In order to ensure that PBR fragment could be digested with BamHI and XhoI and to 
determine the size of the PBR fragment that would be digested from the pGEM-T Easy 
vector, the sequence of the PBR insert obtained from Inqaba Biotechnical Industries (Pty) 
Ltd, (Pretoria, Gauteng, South Africa) was digested using NEBCutter (NewEngland, BioLabs, 
Inc., Beverly, MA, USA) and the results were obtained as seen in Figure 3-72. Using 
NEBCutter confirmed that BamHI and XhoI could digest the PBR fragment and that the 
fragment size digested by these two enzymes was 520 bp. 
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Figure 3-72: Virtual Results for Peripheral Benzodiazepine Receptor Digested with 
BamHI and XhoI 
(A) is a schematic diagram showing that the PBR insert in the pGEM-T Easy vector can be digested with BamHI 
and XhoI. (B) shows the sizes of the fragments that will result when the PBR fragment in the pGEM-T Easy 
vector is digested by BamHI and XhoI. (C) is the virtual gel showing the relative positions of the bands that 
would result when the PBR insert in the pGEM-T Easy vector is digested with BamHI and XhoI. 
 
Since NEBCutter proved that the PBR insert in pGEM-T Easy vector could be digested with 
BamHI and XhoI, the pGEM-T Easy vector containing PBR and the pGEX-6P-2 expression 
vector, which has a multiple cloning site for these enzymes, were digested with these 
enzymes. Results were analysed by agarose gel electrophoresis where the digestions were run 
on a 1% agarose gel (Figure 3-73). Digestion of the pGEM-T Easy containing PBR with 
# Ends Coordinates Length (bp) 
 1 BamHI-XhoI 59-578 520 
  2 XhoI-(Right End) 579-825 247 
3 (Left End)-BamHI 1-58 58 
(A) 
(B) 
(C) 
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BamHI and XhoI resulted in the formation of two bands (Lane 5) one band forming at a level 
greater than the 1031 bp reference band (Lane 1) and the other occurring between the 500 bp 
and 600 bp reference band (Lane 1). This result is different from what was seen using 
NEBCutter, which showed the resultant of three bands. The two bands seen in the digestion is 
true as the larger band is the pGEM-T Easy vector while the smaller band is the PBR 
fragment while NEBCutter only digest with respect to the PBR insert sequence. Digestion of 
the pGEX-6P-2 expression vector with BamHI and XhoI resulted in the formation of a single 
band (Lane 9) at a level greater than the 1031 bp reference band (Lane 1). Expectant results 
were to see two bands but the resultant of one band is the indication of a really smaller second 
band forming that probably ran off the gel. Three controls used for the pGEM-T Easy 
containing PBR clone and the pGEX-6P-2 expression vector digestion included undigested 
clone, the clone digested with BamHI only and the clone digested with XhoI only. In both the 
pGEM-T Easy containing PBR clone and the pGEX-6P-2 expression vector case, the 
undigested clone resulted in the formation of three bands (Lanes 2 and 6), which is indicative 
of the different states in which the clone exists and digestion with BamHI or XhoI only 
resulted in the linearisation of the clones seen by the occurrence of one band (Lanes 3, 4, 7, 
and 8) at a level greater than the 1031 bp reference band (Lane 1).  
 
3.4.3. Purification of the Peripheral Benzodiazepine Receptor and pGEX-6P-2 Expression 
Vector 
The released PBR insert and the pGEX-6P-2 expression vector were then purified using the 
Wizard® SV Gel and PCR Clean-Up System (Promega Corporation, Madison, WI, USA) to 
remove excess salts and other contaminants. Results were analysed using agarose gel 
electrophoresis where the purified products were run on a 1% agarose gel (Figure 3-74). It 
was found that both the PBR insert and the pGEX-6P-2 expression vector were recovered as 
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is indicated by the formation of one band in each lane (Lanes 2 and 3). In the case of the PBR 
insert, the band was found between the 500 bp and 600 bp reference bands (Lane 1) while in 
the case of the pGEX-6P-2 expression vector the band lied at a level greater than the 1031 bp 
reference band (Lane 1). 
 
 
                      
Figure 3-73: Double Digestion of pGEM-T Easy Containing Peripheral Benzodiazepine 
Receptor Insert and pGEX-6P-2 Expression Vector 
 
3.4.4. Cloning 
The purified PBR fragment was ligated into the purified pGEX-6P-2 expression vector, which 
contains a multiple cloning site and an ampicillin resistant domain, using LigaFastTM Rapid 
Ligation System (Promega Corporation, Madison WI, USA) after which it was transformed 
into competent MC1061 Escherichia coli cells and grown on ampicillin-containing nutrient-
520 bp 
600 bp 
500 bp 
1    2     3     4     5    6     7    8      9 
1031 bp 
Key: 
Lane 1: 
GeneRulerTM 50 
bp DNA Ladder 
Lane 2+6: 
Undigested Clone 
Lane 3+7: BamHI 
Digested Clone 
Lane 4+8: XhoI 
Digested Clone 
Lane 5+9: BamHI + 
XhoI Digested 
Clone 
pGEM-T Easy + PBR PGEX-6P-2 
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rich agar plates. Thus, only those bacteria containing the ampicillin resistant gene will grow. 
A negative background control used was to allow the bacteria to grow in the absence of the 
vector and the insert. This control served the purpose of determining if the bacterial cells 
contained the ampicillin resistant gene. A positive control used was to grow bacteria in the 
presence of just the pGEX-6P-2 expression vector only. This control served the purpose of 
determining if the bacterial cells were competent. It was found that growth occurred on the 
ampicillin-positive plates where the bacterial cells contained the pGEX-6P-2 expression 
vector plus the insert or just the pGEX-6P-2 expression vector only while no growth occurred 
on ampicillin-positive plates where bacterial cells did not contain the pGEX-6P-2 expression 
vector and insert (Figure 3-75).  
 
                                    
Figure 3-74: Purification of the Peripheral Benzodiazepine Receptor Insert and pGEX-
6P-2 Expression Vector 
 
    1      2     3 
1031 bp 
600 bp 
500 bp 520 bp 
Key: 
Lane 1: GeneRulerTM 50 bp DNA 
Ladder 
Lane 2: Purified PBR Insert  
Lane 3: Purified pGEX-6P-2 Expression 
Vector 
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Figure 3-75: Cloning of the Peripheral Benzodiazepine Receptor Insert into pGEX-6P-2 
Expression Vector 
 
3.4.5. Colony Polymerase Chain Reaction  
Colony PCR was done to confirm that the bacterial cells that grew on the ampicillin plates 
contained the vector plus the insert. Taking the colonies at random that grew on the nutrient-
rich agar plates and amplifying the region of interest by PCR using PBR specific primers 
accomplished this. The results were analysed by agarose gel electrophoresis where the PCR 
product was run on a 1% agarose gel (Figure 3-76). It was found that the insert was amplified 
as is indicative by the bands (Lanes 3-10) that lied between 200 bp and 300 bp reference 
bands (Lane 1). A negative control run with the amplification of the recombinant DNA 
molecules was to perform PCR in the absence of any recombinant DNA by replacing it with 
nuclease free H2O, which resulted in no band formation (Lane 2). 
 
 
 
 
 
Negative Control PBR + pGEX-6P-2 Positive Control 
(A) (B) (C) 
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Figure 3-76: Amplification of the Peripheral Benzodiazepine Receptor via Colony 
Polymerase Chain Reaction 
 
3.4.6. Miniprep Analysis/Plasmid DNA Extraction 
The pGEX-6P-2 expression vector containing the insert was isolated from the bacterial cells 
and purified by plasmid DNA extraction using the WizardPlus® SV Miniprep Purification 
System (Promega Corporation, Madison, WI, USA). To determine if the clones were isolated, 
the results were analysed by agarose gel electrophoresis where the clones were run on a 1% 
agarose gel (Figure 3-77). The gel showed the formation of three bands greater than the 1031 
bp reference band (Lane 1), which indicates that the pGEX-6P-2 expression vector containing 
the insert was isolated (Lanes 2-6). The three bands that can be seen are indicative of the 
different states in which plasmid DNA occurs, namely it may range from supercoiled to 
completely relaxed. The most tightly supercoiled plasmid DNA will travel furthest in the gel 
while the most relaxed plasmid will travel the least on the gel. 
300 bp 
200 bp 
247 bp 
1    2   3   4    5    6    7    8    9   10
Key: 
Lane 1: GeneRulerTM 50 
bp DNA Ladder 
Lane 2: Negative 
Control 
Lanes 3-10: PCR 
Product 
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Figure 3-77: Isolation of Plasmid DNA via Miniprep Analysis 
 
3.4.7. Restriction Digestion 
The purified plasmid DNA was digested with BamHI and XhoI to determine the presence of 
the insert as well as if the correct size of the insert was present in the recombinant plasmid 
DNA. The results were analysed with agarose gel electrophoresis where the digestions were 
run on a 1% agarose gel (Figure 3-78). Four controls used in this experiment include the 
undigested clone (Lane 2), which resulted in the formation of three bands greater than the 
1031 bp reference band (Lane 1) that represents the different states of the plasmid DNA, the 
digestion of the recombinant plasmid DNA with either BamHI or XhoI (Lanes 3 and 4), which 
resulted in the formation of one band greater than the 1031 bp reference band (Lane 1) 
indicating that the recombinant plasmid DNA was linearised by each enzyme, and the colony 
PCR product (Lane 6) (used to show if the correct size of the insert is released), which 
showed the formation of a band between the 200 and 300 bp reference band (Lane 1). When 
1031 bp 
1   2   3   4   5   6 
Key: 
Lane 1: GeneRulerTM 50 bp DNA 
Ladder 
Lanes 2-6: Plasmid DNA (pGEX-6P-2 
+ PBR) 
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the recombinant plasmid DNA was double digested with BamHI and XhoI, it resulted in the 
formation of two bands (Lane 5), one band greater than the 1031 bp reference band (Lane 1) 
and the other band located between the 500 bp and 600 bp reference bands (Lane 1). The size 
of this fragment varies from the colony PCR product, that is from 247 bp to 520 bp but it is 
still correct as was indicated by NEBCutter. 
 
 
                          
              
Figure 3-78: Restriction Digestion of Plasmid DNA containing Peripheral 
Benzodiazepine Receptor Insert 
 
 
 
 
 
 1      2    3    4     5    6 
520 bp 
247 bp 
1031 bp 
600 bp 
500 bp 
300 bp 
200 bp 
Key: 
Lane 1: GeneRulerTM 100 bp 
DNA Ladder 
Lane 2: Undigested Clone 
Lane 3: BamHI Digested Clone 
Lane 4: XhoI Digested Clone 
Lane 5: BamHI and XhoI 
Digested Clone 
Lane 6: Colony PCR Product 
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3.4.8. Sequencing 
The purified recombinant clone containing the region of interest of the PBR gene was sent to 
Inqaba Biotechnical Industries (Pty) Ltd (Pretoria, Gauteng, South Africa) for sequencing to 
determine if the insert isolated was actually the PBR gene. The results were analysed using 
CHROMAS, version 1.62 and by comparing the PBR sequence obtained to that of the Homo 
sapiens benzodiazepine receptor (peripheral) mRNA reference sequence (Accession Number: 
BT006949) obtained from Nucleotide database at the NCBI. This was done using BLAST at 
NCBI where two sequences can be compared to each other (Figure 3-79). It was found that 
the PBR insert was 502 bp in size and that this size is almost the entire size of the original 
reference PBR sequence is 99% accurate to the reference sequence and lies in a 5’  to 3’  
orientation. 
 
The sequence of the PBR insert was than processed through DNAMAN, version 6.0 (Lynonn 
Corporation, Vaudreuil, Quebec, Canada) where the molecular composition of the insert 
(Table 3-9) and when translated the size of the protein synthesised determined. Further, the 
amino acid sequence was also determined and it was found that the PBR insert could be 
translated via three reading frames consisting of 166 or 167 amino acids (Figure 3-80 and 
Figure 3-81). In addition, Figure 3-80 shows that an additional reading frame exists that can 
be formed by the translation of the negative strand, that is the complementary strand in the 
plasmid DNA. Using the number of amino acids, the size of the PBR protein was calculated 
to be 17 kDa (for calculation see Appendix 7 Calculation of Size of the Peripheral 
Benzodiazepine Receptor Protein). 
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Score = 913 bits (475), Expect = 0.0 
Identities = 498/502 (99%), Gaps = 3/502 (0%) 
Strand = Plus / Plus 
 
 
 
                                                                        
Query: 10  ccctgggtg-cccgccatgggc-ttcacg-ctggcgcccagcctggggtgcttcgtgggc 66 
           ||||||||| ||| |||||||| |||||| |||||||||||||||||||||||||||||| 
Sbjct: 37  ccctgggtgtccccccatgggccttcacgtctggcgcccagcctggggtgcttcgtgggc 96 
 
                                                                        
Query: 67  tcccgctttgtccacggcgagggtctccgctggtacgccggcctgcagaagccctcgtgg 126 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 97  tcccgctttgtccacggcgagggtctccgctggtacgccggcctgcagaagccctcgtgg 156 
 
                                                                        
Query: 127 cacccgccccactgggtgctgggccctgtctggggcacgctctactcagccatggggtac 186 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 157 cacccgccccactgggtgctgggccctgtctggggcacgctctactcagccatggggtac 216 
 
                                                                        
Query: 187 ggctcctacctggtctggaaagagctgggaggcttcacagagaaggctgtggttcccctg 246 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 217 ggctcctacctggtctggaaagagctgggaggcttcacagagaaggctgtggttcccctg 276 
 
                                                                        
Query: 247 ggcctctacactgggcagctggccctgaactgggcatggccccccatcttctttggtgcc 306 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 277 ggcctctacactgggcagctggccctgaactgggcatggccccccatcttctttggtgcc 336 
 
                                                                        
Query: 307 cgacaaatgggctgggccttggtggatctcctgctggtcagtggggcggcggcagccact 366 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 337 cgacaaatgggctgggccttggtggatctcctgctggtcagtggggcggcggcagccact 396 
 
                                                                        
Query: 367 accgtggcctggtaccaggtgagcccgctggccgcccgcctgctctacccctacctggcc 426 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 397 accgtggcctggtaccaggtgagcccgctggccgcccgcctgctctacccctacctggcc 456 
 
                                                                        
Query: 427 tggctggccttcgcgaccacactcaactactgcgtatggcgggacaaccatggctggcat 486 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 457 tggctggccttcgcgaccacactcaactactgcgtatggcgggacaaccatggctggcat 516 
 
                                  
Query: 487 gggggacggcggctgccagagt 508 
           |||||||||||||||||||||| 
Sbjct: 517 gggggacggcggctgccagagt 538 
 
 
 
 
 
Figure 3-79: Alignment of the Peripheral Benzodiazepine Receptor (PBR) Gene  
(A) shows a graphic alignment of the two sequences. (B) shows a detailed alignment of the cloned PBR gene to 
the reference PBR gene.  
 
Key: 
Query: Reference Sequence (BT006949)                           – Binding site for PBR specific primers   
Subject: Purified Recombinant PBR Sequence                  – Original size of the PBR region of interest 
(A) 
(B) 
Reference Sequence 
Queried Sequence 
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Table 3-9: Molecular Composition of the Peripheral Benzodiazepine Receptor Insert 
Nucleotides Number of Bases Percentage of Bases (%) 
Adenines (A) 63 12.5 
Thymines (T) 99 19.7 
Guanines (G) 168 33.5 
Cytosines (C) 172 34.3 
 
DNAMAN1_Translation
Universal code
START
STOP
1 502100 150 200 251 301 351 401 451
Strand RF
 plus   1
 plus   2
 plus   3
 minus  1
 minus  2
 minus  3
 
Figure 3-80: Schematic Representation of the Reading Frames of the Peripheral 
Benzodiazepine Receptor Protein 
 
3.4.9. Optimisation of Glutathione-S-Transferase Fusion Protein using Isopropyl--D-
Thiogalactopyranoside 
In order to express the GST fusion protein, that is, GST fused with the PBR protein, the 
pGEX-6P-2 expression vector containing the PBR insert was transformed into competent BL-
2 Escherichia coli cells after which it was induced with different concentrations of IPTG. 
IPTG binds to the lac repressor, encoded by the lac Iq gene thus allowing for the transcription 
of all genes downstream of the tac promoter in the pGEX-6P-2 expression vector. 
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                  10        20        30        40        50        60 
1         CCCTGGGTGTCCCCCCATGGGCCTTCACGTCTGGCGCCCAGCCTGGGGTGCTTCGTGGGC 
1          P  W  V  S  P  H  G  P  S  R  L  A  P  S  L  G  C  F  V  G  
1           P  G  C  P  P  M  G  L  H  V  W  R  P  A  W  G  A  S  W  A 
1            L  G  V  P  P  W  A  F  T  S  G  A  Q  P  G  V  L  R  G   
 
                  70        80        90       100       110       120 
61        TCCCGCTTTGTCCACGGCGAGGGTCTCCGCTGGTACGCCGGCCTGCAGAAGCCCTCGTGG 
21         S  R  F  V  H  G  E  G  L  R  W  Y  A  G  L  Q  K  P  S  W   
21          P  A  L  S  T  A  R  V  S  A  G  T  P  A  C  R  S  P  R  G  
20        L  P  L  C  P  R  R  G  S  P  L  V  R  R  P  A  E  A  L  V    
 
                 130       140       150       160       170       180 
121       CACCCGCCCCACTGGGTGCTGGGCCCTGTCTGGGGCACGCTCTACTCAGCCATGGGGTAC 
41         H  P  P  H  W  V  L  G  P  V  W  G  T  L  Y  S  A  M  G  Y   
41          T  R  P  T  G  C  W  A  L  S  G  A  R  S  T  Q  P  W  G  T  
40        A  P  A  P  L  G  A  G  P  C  L  G  H  A  L  L  S  H  G  V    
 
                 190       200       210       220       230       240 
181       GGCTCCTACCTGGTCTGGAAAGAGCTGGGAGGCTTCACAGAGAAGGCTGTGGTTCCCCTG 
61         G  S  Y  L  V  W  K  E  L  G  G  F  T  E  K  A  V  V  P  L   
61          A  P  T  W  S  G  K  S  W  E  A  S  Q  R  R  L  W  F  P  W  
60        R  L  L  P  G  L  E  R  A  G  R  L  H  R  E  G  C  G  S  P    
 
                 250       260       270       280       290       300 
241       GGCCTCTACACTGGGCAGCTGGCCCTGAACTGGGCATGGCCCCCCATCTTCTTTGGTGCC 
81         G  L  Y  T  G  Q  L  A  L  N  W  A  W  P  P  I  F  F  G  A   
81          A  S  T  L  G  S  W  P  *  T  G  H  G  P  P  S  S  L  V  P  
80        G  P  L  H  W  A  A  G  P  E  L  G  M  A  P  H  L  L  W  C    
 
                 310       320       330       340       350       360 
301       CGACAAATGGGCTGGGCCTTGGTGGATCTCCTGCTGGTCAGTGGGGCGGCGGCAGCCACT 
101        R  Q  M  G  W  A  L  V  D  L  L  L  V  S  G  A  A  A  A  T   
101         D  K  W  A  G  P  W  W  I  S  C  W  S  V  G  R  R  Q  P  L  
100       P  T  N  G  L  G  L  G  G  S  P  A  G  Q  W  G  G  G  S  H    
 
                 370       380       390       400       410       420 
361       ACCGTGGCCTGGTACCAGGTGAGCCCGCTGGCCGCCCGCCTGCTCTACCCCTACCTGGCC 
121        T  V  A  W  Y  Q  V  S  P  L  A  A  R  L  L  Y  P  Y  L  A   
121         P  W  P  G  T  R  *  A  R  W  P  P  A  C  S  T  P  T  W  P  
120       Y  R  G  L  V  P  G  E  P  A  G  R  P  P  A  L  P  L  P  G    
 
                 430       440       450       460       470       480 
421       TGGCTGGCCTTCGCGACCACACTCAACTACTGCGTATGGCGGGACAACCATGGCTGGCAT 
141        W  L  A  F  A  T  T  L  N  Y  C  V  W  R  D  N  H  G  W  H   
141         G  W  P  S  R  P  H  S  T  T  A  Y  G  G  T  T  M  A  G  M  
140       L  A  G  L  R  D  H  T  Q  L  L  R  M  A  G  Q  P  W  L  A    
 
                 490       500 
481       GGGGGACGGCGGCTGCCAGAGT 
161        G  G  R  R  L  P  E                                          
161         G  D  G  G  C  Q  S                                         
160       W  G  T  A  A  A  R                                           
 
 
 
 
 
Figure 3-81: Translation of Peripheral Benzodiazepine Receptor (PBR) Insert  
 
 
 
 
Key: 
 – Nucleotide 
Sequence 
 – Amino Acid 
Sequence 
A – Alanine 
C – Cysteine 
D – Aspartic Acid 
E – Glutamic Acid 
F – Phenylalanine 
G – Glycine  
H – Histidine 
I – Isoleucine  
L – Leucine 
M - Methionine 
N - Asparagine 
P – Proline 
Q – Glutamine  
R – Arginine  
S – Serine 
T - Threonine 
V – Valine  
W – Tryptophan 
Y – Tyrosine  
* - Termination   
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The transformed Escherichia coli cells were plated on ampicillin-containing nutrient-rich agar 
plates (Figure 3-82). Thus, only those bacteria containing the ampicillin resistant gene will 
grow. To determine if the BL-2 Escherichia coli cells were competent; a background control 
used was to plate the cloning reactions on nutrient-rich agar plates not containing ampicillin. 
A negative background control used was to allow the bacteria to grow in the absence of the 
vector containing the insert. This control served the purpose of determining if the bacterial 
cells contained the ampicillin resistant gene. It was found that a lawn of growth occurred on 
ampicillin-negative plates that were plated with bacteria containing no pGEX-6P-2 expression 
vector or insert or when plated with bacteria containing pGEX-6P-2 expression vector 
containing the insert. When the bacteria containing no vector or insert were plated on 
ampicillin-positive plates no growth occurred while bacteria containing the pGEX-6P-2 
expression vector containing the insert showed growth in the form of colonies when plated on 
ampicillin-positive plates.  
 
In order to determine the optimal concentration of IPTG required to induce the GST-fusion 
protein, different concentrations of IPTG ranging from 0.1 mM to 0.9 mM was used to induce 
the GST-fusion protein and the results were analysed with SDS-PAGE (Figure 3-83). The 
negative control was to do protein expression in the absence of IPTG (Lane 7). It was found 
that these different concentrations of IPTG induced the GST-fusion protein seen by the bold 
band (Lane 2-6) that lies between the 40 kDa and 55 kDa reference bands (Lane 1). This is 
correct because it is the molecular weight of the GST protein, which is 26 kDa plus the PBR 
protein, which is 17 kDa, that is 43 kDa. Further, it was found that 0.7 mM IPTG induced the 
GST-fusion protein most optimally. 
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Figure 3-82: Transformation of the pGEX-6P-2 Expression Vector Containing the 
Peripheral Benzodiazepine Receptor Insert 
 
                                                           
                               
 
 
Figure 3-83: SDS-PAGE of Optimising the Concentration of IPTG Required to Induce 
Gluthathione-S-Transferase Fusion Protein 
 
 
Ampicillin-Negative 
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PBR + PGEX-6P-2 Negative Control 
(A) (B) 
(C) (D) 
55 kDa 
40 kDa 
   1       2       3      4      5       6          7                                                    Key: 
Lane 1: PageRulerTM Prestained 
Protein Ladder 
Lane 2: 0.1 mM IPTG 
Lane 3: 0.3 mM IPTG 
Lane 4: 0.5 mM IPTG 
Lane 5: 0.7 mM IPTG 
Lane 6: 0.9 mM IPTG 
Lane 7: Negative Control 
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3.4.10. Summary 
This study only showed preliminary expression of the GST-PBR protein in small 
concentrations. Thus, future study will have to focus on the expression of the GST-PBR 
protein with an optimal concentration of IPTG in order to generate a large concentration of 
the protein after which it can be purified and treated with PreScissionTM Protease to isolate the 
PBR protein. 
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APPENDIX 7: Calculations 
 
Calculations of Concentrations Linearised Clones, Volume Required to Synthesise 
Probes and Purity of Linearised Clones  
 
• Recombinant Plasmid DNA Digested with ApaI 
A260 = 0.070                                                        A280 = 0.065 
 
c = A260 x [A260dsDNA] x DF 
   = 0.070 x 50 g/ml x 100 
   = 350 g/ml 
 
If there is 350 g of linearised clone in 1000 l of DEPC-treated H2O 
Then there is 2 g of linearised clone in x l of DEPC-treated H2O 
                                                x  = 5.7 l 
 
Purity of Clone = A260 : A280  
                   
             = 0.070 : 0.065 
                         = 1.1 
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• Recombinant Plasmid DNA Digested with PstI 
A260 = 0.082                                                        A280 = 0.083 
 
c = A260 x [A260dsDNA] x DF 
   = 0.082 x 50 g/ml x 100 
   = 410 g/ml 
 
If there is 410 g of linearised clone in 1000 l of DEPC-treated H2O 
Then there is 2 g of linearised clone in x l of DEPC-treated H2O 
                                                x  = 4.9 l 
 
Purity of Clone = A260 : A280  
                   
             = 0.082 : 0.083 
                                = 1.0 
 
 
Calculations of Concentrations cDNA, Volume Required for Real-Time PCR and Purity 
of cDNA 
 
• MRC5 
A260 = 0.572                                                        A280 = 0.347 
 
c = A260 x [A260dsDNA] x DF                            If there is 2860 µg in 1000 µl of sdH2O 
   = 0.572 x 50 µg/ml x 100                                Then there is x µg in 1 µl of sdH2O             
   = 2860 µg/ml                                                                         x = 2.86 µg/µl                                        
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When the undiluted sample is diluted 1:10000, the concentration of cDNA is 2.86 x 10-4 
µg/µl = 0.286 ng/µl 
 
Thus, if there is 0.286 ng of cDNA in 1 µl of sdH2O 
Then there is 0.216 ng of cDNA in x µl of sdH2O 
                                                x  =  0.8 µl 
 
Purity of Clone = A260 : A280  
                   
             = 0.572 : 0.347 
                         = 1.65 
 
• A549 
A260 = 0.438                                                        A280 = 0.270 
 
c = A260 x [A260dsDNA] x DF                            If there is 2190 µg in 1000 µl of sdH2O 
   = 0.438 x 50 µg/ml x 100                                Then there is x µg in 1 µl of sdH2O             
   = 2190 µg/ml                                                                         x = 2.19 µg/µl                                        
 
When the undiluted sample is diluted 1:10000, the concentration of cDNA is 2.19 x 10-4 
µg/µl = 0.219 ng/µl 
 
Thus, if there is 0.219 ng of cDNA in 1 µl of sdH2O 
Then there is 0.216 ng of cDNA in x µl of sdH2O 
                                                x  =  1.0 µl 
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Purity of Clone = A260 : A280  
                   
             = 0.438 : 0.270 
                          = 1.62 
 
• HeLa 
A260 = 1.286                                                        A280 = 0.935 
 
c = A260 x [A260dsDNA] x DF                            If there is 6430 µg in 1000 µl of sdH2O 
   = 1.286 x 50 µg/ml x 100                                Then there is x µg in 1 µl of sdH2O             
   = 6430 µg/ml                                                                         x = 6.43 µg/µl                                        
 
When the undiluted sample is diluted 1:10000, the concentration of cDNA is 6.43 x 10-4 
µg/µl = 0.643 ng/µl 
 
Thus, if there is 0.643 ng of cDNA in 1 µl of sdH2O 
Then there is 0.216 ng of cDNA in x µl of sdH2O 
                                                x  =  0.3 µl 
 
Purity of Clone = A260 : A280  
                   
             = 1.286 : 0.935 
                          = 1.38 
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• HepG 
A260 = 0.432                                                        A280 = 0.266 
 
c = A260 x [A260dsDNA] x DF                            If there is 2160 µg in 1000 µl of sdH2O 
   = 0.432 x 50 µg/ml x 100                                Then there is x µg in 1 µl of sdH2O             
   = 2160 µg/ml                                                                         x = 2.16 µg/µl                                        
 
When the undiluted sample is diluted 1:10000, the concentration of cDNA is 2.16 x 10-4 
µg/µl = 0.216 ng/µl 
 
Thus, if there is 0.216 ng of cDNA in 1 µl of sdH2O 
Then there is 0.216 ng of cDNA in x µl of sdH2O 
                                                x  =  1.0 µl 
 
Purity of Clone = A260 : A280  
                   
             = 0.432 : 0.266 
                                = 1.62 
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Calculations of the Relative Expression of the Peripheral Benzodiazepine Receptor 
mRNA in Relative Terms 
 
• MRC5 and A549 
MRC5: Ct = 21.71                                                A549: Ct = 22.71 
 
In order to determine the relative expression of PBR mRNA, A549 was compared to 
MRC5 as follows: 
Relative Expression = 2 (MRC5 Ct – A549 Ct) 
                                                
 = 2 (21.71 – 22.71) 
                                                 
=
 
 0.5 
Therefore, A549 shows a half-fold decrease in the level of PBR mRNA expressed when 
compared to MRC5.   
 
• A549 and HeLa 
A549: Ct = 22.71                                                HeLa: Ct = 22.59 
 
In order to determine the relative expression of PBR mRNA, HeLa was compared to 
A549 as follows: 
Relative Expression = 2 (A549 Ct – HeLa Ct) 
                                                
 = 2 (22.71 – 22.59) 
                                                 
=
 
 1.09 
Therefore, HeLa shows a similar level of PBR mRNA expressed when compared to A549 
as it shows only a slight increase.   
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• A549 and HepG 
A549: Ct = 22.71                                                HepG: Ct = 22.12 
 
In order to determine the relative expression of PBR mRNA, HepG was compared to 
A549 as follows: 
Relative Expression = 2 (A549 Ct – HepG Ct) 
                                                
 = 2 (22.71 – 22.12) 
                                                 
=
 
 1.51 
Therefore, HeLa shows a half-fold increase of PBR mRNA expressed when compared to 
A549.   
 
 
Calculation of Size of the Peripheral Benzodiazepine Receptor Protein 
 
      If 333 amino acids of coding capacity = 3.4 x 104 Daltons  
Then 166 amino acids of coding capacity = x Daltons 
                     x = 16948 Daltons = 17 kDa 
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APPENDIX 8: Summary of PBR mRNA Localisation Studies 
 
Table 1: Expression of the Peripheral Benzodiazepine mRNA in Various Normal 
Human Tissues 
Localisation of PBR mRNA 
Organ 
Main 
Histological 
Components 
Main Cells 
Nuclear Cytoplasm 
Parenchyma Hepatocytes No Yes 
Endothelial Cells Yes Yes Liver 
Sinusoids 
Kupffer Cells Yes Yes 
Goblet Cells No Yes Crypts of 
Lieberkhün Absorptive Cells No Yes 
Plasma Cells No Yes 
Colon 
Lamina Propria 
Lymphocytes Yes Yes 
Adipose Tissue Adipose Cells No Yes 
Collagen Fibres No Yes Epiploon 
Stroma 
Fibroblasts Yes Yes 
Parietal Cells No Yes 
Chief Cells No Yes 
Surface Mucous Cells No Yes 
Gastric Glands 
Neck Mucous Cells No Yes 
Plasma Cells No Yes 
Macrophages No Yes 
Stomach 
Lamina Propria 
Collagen Fibres No Yes 
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  Lymphocytes Yes Yes 
Columnar Epithelial 
Cells 
No Yes 
Glands 
Cuboidal Endothelial 
Cells 
Yes Yes 
Collagen Fibres No Yes 
Elastic Fibres No Yes 
Prostate 
(Hyperplastic 
Tissue) 
Stroma 
Fibroblasts Yes Yes 
Cuboidal Epithelial 
Cells 
No Yes Terminal Ducts 
and Alveoli 
Myoepithelial Cells No Yes 
Collagen Fibres No Yes 
Lymphocytes Yes Yes 
Breast 
Intralobular 
Stroma 
Endothelial Cells Yes No 
Macrophages No Yes 
Plasma Cells No Yes 
Fibroblasts No Yes 
Stroma 
Lymphocytes Yes Yes 
Respiratory 
Bronchiole 
Cuboidal Epithelial 
Cells 
No Yes 
Smooth Muscle Fibres No Yes 
Lung 
Pulmonary 
Artery Endothelial Cells Yes Yes 
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Flattened Cells in 
Parietal Layer of 
Bowman’ s Capsule 
No Yes 
Renal Corpuscle 
Endothelial Cells of 
Glomerulus 
No Yes 
Proximal Convoluted 
Tubule 
No Yes 
Vasa Recta No Yes 
Thin Ascending and 
Descending Limbs 
No Yes 
Thick Ascending Limb No  Yes 
Distal Convoluted 
Tubule 
No Yes 
Collecting Tubule No Yes 
Kidney 
Renal Tubules 
Collecting Duct No Yes 
Pyramidal Cells No Yes 
Fusiform Cells No Yes Neurones 
Stellate Cells No Yes 
Oligodendrocytes No Yes 
Glial Cells 
Astrocytes No Yes 
Brain 
Fibrillary 
Network 
 No Yes 
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Table 2: Expression of the Peripheral Benzodiazepine Receptor mRNA in Various 
Human Cancer Tissues 
Localisation of PBR 
mRNA Organ Cancer Grade Cells 
Nuclear Cytoplasmic 
II Tumour Cells No Yes 
Liver 
Hepatocellular 
Carcinoma III Tumour Cells Yes Yes 
Tumour Cells No Yes 
I Fibromuscular 
Fibres 
No Yes 
II Tumour Cells No Yes 
Colon Adenocarcinoma 
III Tumour Cells No Yes 
Tumour Cells No Yes 
Stomach/Epiploon 
Squamous Cell 
Carcinoma 
III 
Collagen Fibres  No Yes 
Cuboidal to 
Columnar 
Epithelial Cells 
No Yes 
Collagen Fibres No Yes 
Lymphocytes Yes Yes 
II 
Endothelial Cells Yes Yes 
Prostate 
Adenocarcinoma 
of the Peripheral 
Duct and Acini 
III Tumour Cells No Yes 
Tumour Cells No Yes 
Collagen Fibres  No Yes Breast 
Invasive Ductal 
Carcinoma (No 
Special Type) 
III 
Lymphocytes Yes Yes 
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Tumour Cells Yes Yes 
Adenocarcinoma III 
Collagen Fibres No Yes 
Squamous Cell 
Carcinoma 
III Tumour Cells Yes Yes Lung 
Small Cell 
Carcinoma 
 Tumour Cells Yes Yes 
Chromophobe 
Renal Cell 
Carcinoma 
 Tumour Cells Yes Yes 
Tumour Cells Yes Yes 
Kidney 
Renal Clear Cell 
Carcinoma 
 Branching 
Vasculature 
No Yes 
Tumour Cells No Yes 
Stellate Cells No Yes 
Oligodendrocytes No Yes 
Astrocytic 
Process 
No Yes 
Microglia Yes No 
Diffuse Fibrillary 
Astrocytoma 
II 
Fusiform Cells Yes Yes 
Tumour Cells No Yes 
Oligodendrocytes No Yes 
Astrocytes Yes Yes 
Microglia Yes Yes 
Brain 
Primary Central 
Nervous System 
Lymphoma 
 
Fusiform Cells Yes Yes 
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 Tumour Cells Yes Yes 
 
Fibrillary 
Processes 
No Yes 
 
Ependymoma 
 Lymphocytes Yes Yes 
 
Table 3: Variation in Expression Levels of PBR mRNA in the Various Normal Tissues of 
the Human Body 
Organ Intensity of Staining1 
Liver + 
Colon ++ 
Stomach ++ 
Epiploon ++-+++ 
Prostate (Hyperplastic Tissue) ++-+++ 
Breast +++ 
Lung +++ 
Kidney + 
Brain: Grey Matter + 
Brain: White Matter + 
1. 0 – No Staining                   + - Low Staining                ++ - Intermediate Staining             +++ - High Staining 
 
 
 
 
 
 237 
Table 4: Variation in Expression Levels of PBR mRNA in the Various Cancer Tissues 
Organ Type of Cancer Grade 
Intensity of 
Staining1 
II ++ 
Liver Hepatocellular Carcinoma 
III + 
I ++ 
II 0-+ Colon Adenocarcinoma 
III +-++ 
Stomach/Epiploon Squamous Cell Carcinoma III +++ 
II ++-+++ 
Prostate 
Adenocarcinoma of the Peripheral Duct 
and Acini III +++ 
Breast Invasive Carcinoma (No Specific Type) III +++ 
Adenocarcinoma III ++ 
Squamous Cell Carcinoma III ++-+++ Lung 
Small Cell Carcinoma - 0-+ 
Chromophobe Renal Cell Carcinoma - +++ 
Kidney 
Clear Cell Renal Cell Carcinoma - ++-+++ 
Diffuse Fibrillary Astrocytoma II +-++ 
Primary Central Nervous System 
Lymphoma 
- 0-+ Brain 
Ependymoma - + 
1. 0 – No Staining                   + - Low Staining                ++ - Intermediate Staining             +++ - High Staining 
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Table 5: Summary of Expression Pattern of Peripheral Benzodiazepine Receptor mRNA 
in Various Cancerous Tissues when Compared to its Normal Counterpart  
Organ Regions of the Human Body 
Intensity of 
Staining1 
Liver 
Normal 
Hepatocellular Carcinoma 
Grade II 
Grade III 
+ 
 
+++ 
++ 
Colon 
Normal 
Colonic Adenocarcinoma 
Grade I 
Grade II 
Grade III 
++ 
 
+++ 
0-+ 
+ 
Epiploon and 
Stomach 
Normal Epiploon 
Normal Stomach 
Squamous Cell Carcinoma 
Grade III 
++-+++ 
++ 
 
+++ 
Prostate 
Hyperplastic Tissue 
Adenocarcinoma of the Peripheral Duct and 
Acini 
Grade II 
Grade III 
++ 
 
 
++-+++ 
+++ 
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Breast 
Normal 
Invasive Carcinoma (NST) 
Grade III 
++ 
 
+++ 
Lung 
Normal 
Adenocarcinoma 
Grade III 
Squamous Cell Carcinoma 
Grade III 
Small Cell Carcinoma 
++ 
 
+ 
 
+++ 
0-+ 
Kidney 
Normal 
Chromophobe Renal Cell Carcinoma 
Clear Cell Renal Cell Carcinoma 
+-++ 
+++ 
++ 
Brain 
Normal 
White Matter 
Grey Matter 
Diffuse Fibrillary Astrocytoma 
Grade II 
Primary Central Nervous System Lymphoma 
Ependymoma 
 
+ 
+-++ 
 
+++ 
+-++ 
++ 
1. 0 – No Staining                   + - Low Staining                ++ - Intermediate Staining             +++ - High Staining
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4. DISCUSSION 
 
4.1. Cancer 
Cancer occurs as a result of an out of control growth of abnormal cells (American Cancer 
Society, 2006). In a normal body, cells grow, divide and die in an orderly fashion while in 
cancer, cells continue to grow and divide and instead of dying, outlive normal cells and 
continue to form new abnormal cells. Cancer cells occurs arise from normal cells that have 
undergone DNA damage, which is normally repaired in the normal cell, not been repaired 
(American Cancer Society, 2006). 
 
Cancer is the second leading cause of death in the United States with nearly half of all men 
and a little over one third of all women in the United States likely to develop cancer during 
their lifetimes (American Cancer Society, 2006).  In South Africa one in six men and one in 
seven women are likely to develop cancer in their lifetimes (Cancer Association of South 
Africa, 2006). 
 
Cancer is measured using three factors: incidence, mortality and prevalence. Incidence is the 
number of new cases occurring that is expressed as an absolute number of cases per year or as 
a rate per 100000 persons per year. Mortality is the number of deaths occurring and the 
mortality rate is the number of death occurring per 100000 persons per year. Prevalence is the 
number of persons alive at a particular point in time with the disease of interest and is 
presented as the number of persons alive after a given number years following diagnosis 
(Parkin, et al., 2005). 
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4.1.1. Liver Cancer 
Liver cancer is the sixth most common cancer that occurs worldwide accounting for 5.7 % of 
all new cancer cases.  The rate of incidence and mortality for this cancer can be seen in 
developing countries such as sub-Saharan Africa, eastern and south eastern Asia and 
Melanesia while it is low in developed countries, with the exception of southern Europe, Latin 
America and south central Asia (Parkin, et al., 2005). It is a disease that is more common in 
men than in women having an overall sex ration of 2.4 (Parkin, et al., 2005).  
 
The prognosis is poor and accounts for almost the same amount of deaths as incidence and 
thus forms the third most common cause of death from cancer. Cancer registries worldwide 
have shown that survival rates are between 3 to 5% (Parkin, et al., 2005). 
 
4.1.2. Colon Cancer 
Colon cancer is the fourth most common cancer occurring in men and the third most common 
cancer occurring in women and it occurs at a rate of 1.2:1 when compared between men and 
women. It is the second most common cancer occurring worldwide (Maaser, et al., 2002) with 
1 million new cases been reported in 2002. It has a relatively good prognosis with a mortality 
rate half that of the incidence rate (Parkin, et al., 2005). The highest rate of incidence has been 
reported in North America, Australia/New Zealand, Western Europe and Japan, intermediate 
in South America and low in Africa and Asia. The rate of incidence is still increasing rapidly 
in geographical regions where the overall risk was formerly low while gradual increase has 
been seen in countries where incidence was already high with North America the only region 
showing a decrease (Parkin, et al., 2005). 
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In South Africa, colon cancer accounts for 3.6% of all female cancers and 3.7% of all male 
cancers. The highest rate of incidence occurs in the coloured and white population accounting 
for 4.8% of all female cancers and 4.2% of all male cancers in this population group and is the 
third leading cause of cancer for this population group in females and the fourth leading cause 
of cancer for this population group in males. Intermediate rate of incidence occurs in Asians 
where it accounts for 6% of all colon cancer cases in males and females and is the third 
leading cause of cancer for this population group in females and the fourth leading cause of 
cancer for this population group in males while the black population had the lowest rate of 
incidence (Sitas, et al., 1998). 
 
4.1.3. Stomach Cancer 
Stomach cancer is the fourth most common cancer worldwide accounting for an estimated 
934000 new cases been reported in 2002. It is the second most common cause of cancer death 
accounting for 700000 deaths reported in 2002 (American Cancer Society, 2006, Parkin, et 
al., 2005). A high rate of incidence, that is almost two-thirds of this type of cancer occurs in 
developing countries with 42% of cases been reported in China alone. Stomach cancer is 
twice as common in males than in females (American Cancer Society, 2006). A high rate of 
incidence for men is seen in East Asia such as China and Japan, Eastern Europe and parts of 
Central and South America while a low rate of incidence for men is seen in Southern Asia, 
North and East Africa, North America, Australia and New Zealand. The pattern of incidence 
is similar for women with a slightly increased risk seen in Central Africa and Eastern Europe 
(Parkin, et al., 2005).  
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Rate of survival is moderately good in Japan accounting for a 52% survival rate, 40% in 
North America, 27% in Western Europe and 6% in sub-Saharan Africa. Differences in 
survival rate is determined by screening for this disease because the earlier this type of cancer 
is detected the better the prognosis and survival rate (Parkin, et al., 2005). 
 
4.1.4. Prostate Cancer 
Prostate cancer is the fifth most common cancer in the world and the second most common 
cancer in men forming 11.7% of all new cancers reported. In 2002, 679 000 new cases of 
prostate cancer were reported worldwide. The rate of incidence is 19% in developed countries 
and 5.3% in developing countries. The rate of incidence is high in the United States, Northern 
and Western Europe and in Australia/New Zealand (Parkin, et al., 2005). However, the 
mortality rate is a much better guide in monitoring this cancer as its shows the risk of invasive 
prostate cancer in different populations. It was found that mortality rates were high in the 
Caribbean, Southern and Central Africa, North and West Europe, Australia/New Zealand, and 
North and South America and low in Asia and North Africa and is still thought to be 
increasing (Parkin, et al., 2005). Prognosis of this cancer is relatively good as the mortality 
rate through this cancer is 5.8% in men and accounts for 3.3% of all cancer deaths in men 
(Parkin, et al., 2005).  
 
In South Africa, prostate cancer is the leading cause of cancer in males, which comprised 
12.6% of all male cancers. The highest rate of incidence occurs in the coloured and white 
population group followed by the Asian population group with the lowest rate of incidence 
seen in the Black population group (Sitas, et al., 1998). 
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4.1.5. Breast Cancer 
Breast cancer is the most common cancer in women forming 23% of all cancers and having 
an estimated 1.15 million new cases occurring in 2002 and accounts for 3% of women’ s 
death. It is ranked the second most common cancer occurring worldwide when both sexes are 
considered together. Most cases have been observed in industrialised countries such as those 
found in Europe (27.3% reported cancer cases in women) and North America (31.3% reported 
cancer cases in women), with North America having the highest rate in the world (American 
Cancer Society, 2006). The rate of incidence is moderate in Eastern Europe, South America, 
Southern Africa, except South Africa, and Western Asia while it is low in most of Africa and 
Asia. However, it is still the most common cancer in women in these geographic regions and 
is still increasing in most countries (Parkin, et al., 2005). It should be noted that breast cancer 
also occurs in men (American Cancer Society, 2006).   
 
In South Africa, the incidence of breast cancer occurring in women is 16.4% with breast 
cancer been the leading form of cancer in Asians, accounting for 6.8% of all female breast 
cancers, coloureds and whites and been the second most common form of cancer in Black 
females in 1997 (Sitas, et al., 1998). 
 
Prognosis of breast cancer is good with 73% survival rate recorded in developed countries and 
57% reported in developing countries. Breast cancer has been ranked as the fifth most 
common cause of death from cancer overall, even though it still remains the leading cause of 
cancer mortality in women (14% of female cancer deaths) (Parkin, et al., 2005). However, 
because of it high incidence and relatively good prognosis, breast cancer is the most prevalent 
form of cancer in the world today (Parkin, et al., 2005). 
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4.1.6. Lung Cancer 
Lung cancer is the most common form of cancer worldwide (Hashimoto, et al., 2000) 
accounting for 12.4% of all new cancers with 1.35 million new cases been reported in 2002. It 
also forms the most common cause of death by cancer for both men and women accounting 
for 17.6% of all deaths occurring by cancer worldwide with 1.18 million cases been reported 
in 2002 as more people die from this form of cancer than those that will die from colon, breast 
and prostate cancer combined (American Cancer Society, 2006). Nearly 60% of people 
diagnosed with lung cancer will die within the first year from diagnosis and nearly 75% of 
people diagnosed with lung cancer will die within two years and this statistic has not 
improved in the last ten years (American Cancer Society, 2006). 
 
Almost half of the cases of lung cancer occur in developing countries. It is the most common 
form of cancer in men accounting 35.5% of all new cancers reported in men with the highest 
rates of incidence seen in North America and Eastern Europe and moderately high rates seen 
Australia/New Zealand and eastern Asia such as China and Japan. In women the rate of 
incidence of lung cancer is lower accounting for 12.1% of all new cancers reported in women 
with the highest rate of incidence seen in North America and Northern Europe (Parkin, et al., 
2005). To date, lung cancer still remains a highly lethal disease with the United States 
reporting a 15% survival rate, Europe reporting a 10% survival rate and developing countries 
reporting a 8.9% survival rate (Parkin, et al., 2005). The overall rate of incidence and 
mortality of lung cancer is still on the increase worldwide in both men and women while 
when looking at certain countries specifically, the rate of incidence has reached its peak and is 
now declining in both men and women (Parkin, et al., 2005). 
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In South Africa, lung cancer comprises 2.8% of all female cancers and 6.7% of all male 
cancers. The highest rate of lung cancer is found in the coloured and white population 
combined comprising 4% of all male cancers in this population group, thus forming the third 
leading cause of cancer in this male population group, and 3% of all female cancers in this 
population group, thus forming the fifth leading cause of cancer in this female population 
group. Intermediate rates of lung cancer occurs in the Asian population group where it formed 
the second leading cause of cancer in Asian males comprising 10.6% and the seventh leading 
cause of cancer in Asian female comprising 2.7%. The black population group showed the 
lowest rate of incidence for developing lung cancer (Sitas, et al., 1998). 
  
4.1.7. Kidney Cancer 
Kidney cancer accounts for 1.9% of the total cancers worldwide with 208000 new cases and 
102000 deaths been reported in 2002. The rate of incidence is highest in North America, 
Australia/New Zealand and western, eastern and northern Europe while it is lowest in Africa, 
and Asia with the exception of Japanese males and the Pacific Islands (Parkin, et al., 2005). 
 
4.1.8. Brain Cancer 
Cancers of the brain accounts for 1.7% of all new cases and 2.1% of all deaths caused by 
cancer been reported worldwide with 189 000 new cases and 142 000 deaths been reported in 
2002. The highest rates of incident occurs in developed countries such as Australia/New 
Zealand, Europe and North America while it is lowest in Africa and the Pacific Islands. 
However, the estimates are thought to be underdeveloped in many countries because of the 
poor availability of diagnostic facilities. Furthermore, the mortality rates tend to be unreliable 
because of the confusion that exists between primary and metastatic cancers (Parkin, et al., 
2005). 
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4.1.9. Cervical Cancer 
Cervical cancer is the second most common cancer in women with an estimated 493000 new 
cases reported and 274000 deaths occurring in 2002. It is the seventh most common cancer 
worldwide when both sexes are considered together. It is much more common in developing 
countries accounting for 15% of all female cancers while in developed countries it accounts 
for 3.6% of all new female cancers reported. The highest rates of incidence have been 
reported in sub-Saharan Africa, Melanesia, Latin America and the Caribbean, south central 
Asia and south east Asia while the rate of incidence is generally low in developed countries 
today such as the United States due to the introduction of screening programs, China and 
Western Asia. Incidence of cervical cancer occurring has declined in developed countries, 
however developing countries have also showed decline such as seen in China and now only 
sub-Saharan Africa, central America, south central Asia and Melanesia show a high rate of 
incidence (Parkin, et al., 2005). The ratio of mortality to incidence is 55% and survival rate 
vary between regions with quite good prognosis seen in low risk regions (Parkin, et al., 2005).  
 
Cervical cancer is the leading cause of cancer among South African women accounting for 
18.2% of all cancers reported. It is the leading cause of cancer amongst black females 
accounting for 85% of all cancers reported followed by 14% seen in coloured and white 
females combined with the least rate of incidence seen in Asians. This may be in part due to 
the lower socio-economic status that has been associated with a higher risk of developing 
cervical cancer and is in part due to lack of access to good health care and Papanicolaou 
(Papsmear) tests. However, the rate of incidence can be decreased with the implementation of 
screening programmes (Sitas, et al., 1998). 
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4.2. Expression of the Peripheral Benzodiazepine Receptor mRNA in Various Normal 
and Cancer Tissues 
4.2.1. Tissue Microarrays 
The use of tissue microarrays is a powerful technology that efficiently and economically 
assesses the expression of proteins or genes across large sets of tissue specimens assembled 
onto a single microscope slide (Chen, et al., 2004). Advantages of using tissue microarrays 
include: (i) allows for the amplification of limited tissue resources by providing the means by 
which a large number of small core biopsies rather than a single section, (ii) each tissue 
specimen on the microarray is treated in an identical manner such that reagent concentrations, 
incubation times, temperatures and washing conditions are consistent across discs on each 
tissue microarray slide (Chen, et al., 2004). 
 
As mentioned above, the use of tissue arrays in this study provided an efficient way in 
analysing multiple cancers. However, the disadvantage that arose through the use of this 
particular tissue array was that many cancers had only one disc (dot), that is one specimen of 
a particular type of cancer and so generalization and trends in a particular expression pattern 
were difficult to make. To compensate for this colorimetric and fluorescent in situ 
hybridisation was done on 3 tissue array slides respectively. Thus, future studies should be 
done using tissue arrays that are specific for a particular type of cancer, which will allow for 
more generalised results to be obtained for a particular type of cancer and not specific results 
as was obtained in this study. 
 
 
 
 
 249 
4.2.2. In Situ Hybridisation 
The expression pattern of PBR mRNA in normal human tissues and cancerous human tissues 
was determined by in situ hybridisation. It looked at the expression of PBR mRNA in some 
tissues for which current information on expression of PBR mRNA is still sparse. Further, it 
should be noted that very few to no studies have used in situ hybridisation to determine the 
expression pattern of PBR mRNA in various tissues.  
 
In situ hybridisation is a qualitative or semi-quantitative technique by which mRNA of 
interest in the cytoplasm or DNA of interest in the nucleus can be localised through the 
hybridisation of the sequence of interest to the complimentary strand of a nucleotide probe. 
The sensitivity of this technique is such that the threshold levels of detection in the region of 
10 to 20 copies of mRNA or DNA per cell. This technique provides considerable information 
regarding the structure and function of the cell within pathological means (Lanlani, et al., 
1997). 
 
In order to conduct in situ hybridisation anti-sense probes complementary to the PBR mRNA 
had to be synthesised. This was done by the isolation of the PBR region of interest from 
mRNA in normal kidney tissue. The use of mRNA is advantageous as it contains only the 
functional regions known as the exons, which are required for translation to synthesise the 
protein. The PBR region of interest was isolated and multiple copies generated using gene-
specific primers during PCR after which the PBR fragments were ligated into pGEM-T Easy 
cloning vector and transformed into Escherichia coli in order to generate stable complexes. 
After cloning, the recombinant DNA was purified and linearised in preparation for probe 
synthesis. Both sense- and anti-sense RNA probes were generated by in vitro transcription. 
The use of RNA probes in in situ hybridisation is advantageous because RNA probes are 
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already single-stranded and thus there is no need for the denaturation step and RNA-RNA 
hybrids are very thermostable and resistant to digestion by RNases. However, the 
disadvantage of using RNA probes includes their instability and the difficulty that exists to 
inactivate RNases. 
 
 
The reason for the use of both the colorimetric and fluorescent detection methods for in situ 
hybridisation was because fluorescent detection offers several advantages. These include the 
fact that it is simple, far more accurate than colorimetric detection as it reduces a lot of the 
background staining and thus is more reliable and requires a shorter time period for 
performing the technique before which results can be viewed (Lanlani, et al., 1997). 
However, several disadvantages for the use of fluorescent detection also occur including the 
fact that it is far more expensive and have a short time period in which results can be viewed, 
in this case approximately three days. The advantage of using colorimetric detection is that it 
is cheaper while the disadvantage of using colorimetric detection is the higher background 
staining making it more difficult to determine if localisation occurred. High background 
staining occurs as a result of the intermediates that form during the NBT/BCIP reaction, 
which is relatively slow, diffusing away into the medium making it difficult to localise the site 
of hybridisation and reducing the hybridisation signal. 
 
It was found that the expression pattern of PBR mRNA was uniform in most tissues studied 
with the exception been epiploon normal tissue, which showed intermediate expression in 
50% of cases and high expression in 50% of cases and lung small cell carcinoma, which 
showed low expression in 50% of cases and no expression in 50% of cases. 
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4.2.2.1.  Localisation of the Peripheral Benzodiazepine Receptor mRNA in Various Normal 
Tissues 
This study focused on determining the expression pattern of PBR mRNA in liver, colon, 
epiploon, stomach, prostate, breast, lung, kidney and brain. To my knowledge, this is the first 
time that the expression pattern of PBR mRNA has been determined in epiploon. 
 
The PBR mRNA was expressed in all normal human tissues studied. From the results 
obtained it is clear that the PBR mRNA is expressed mainly in the cytoplasm. This is 
understandable since the PBR protein is synthesised in the ribosomes and is located mainly in 
the outer mitochondrial membrane (Hans, et al., 2005, Kletsas, et al., 2004, Lacapère, et al., 
2003). However, nuclear localisation of PBR mRNA were observed, which further suggest as 
previous studies that the PBR protein is involved in the transport of cholesterol from the 
cytoplasm into the nucleus where it affects genes involved in the cell cycle (Corsi, et al., 
2005) or it could be as a result of the PBR mRNA been just transcribed in the nucleus and still 
having not been transferred to the cytoplasm for translation or as a result of PBR anti-sense 
probe binding with DNA in the nucleus.  
 
The results obtained in this study are similar to those obtained by Bribes et al., who looked at 
the expression pattern of the PBR protein through the use of a monoclonal antibody specific 
for PBR. However this study looked at additional tissues including kidney, brain and epiploon 
and showed expression in some cells, which Bribes, et al. did not show (Bribes, et al., 2004). 
Previous studies have also shown that PBR is expressed mainly in the glial cells (Jordà, et al., 
2005, Kassiou, et al., 2004, Veenman, et al., 2004), however, this study clearly showed that 
PBR is expressed in neurones and in the fibrillary network. 
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The level of expression within a given organ varies. In normal tissue, high expression levels 
of PBR mRNA were seen in epiploon, prostate, breast and lung, intermediate expression 
levels were seen in colon and stomach and low expression levels were seen in liver, kidney 
and brain with white matter showing a higher level of expression than grey matter. The level 
of expression seen in this study for PBR mRNA is similar to those seen previously for the 
PBR protein, with the exception been lung, which previously was reported to show 
intermediate expression and in this study shows high expression. These results have mainly 
been confirmed in other species but not in human (Bribes, et al., 2004, Casellas, et al., 2002). 
 
4.2.2.2. Localisation of the Peripheral Benzodiazepine Receptor mRNA in Various Human 
Cancer Tissues 
In order to determine if the level of expression of PBR mRNA increased or decreased in the 
cancerous state, cancerous tissues were compared to its normal counterpart. It was found that 
that expression of PBR mRNA increased in Grade II and Grade III liver hepatocellular 
carcinoma, Grade I colonic adenocarcinoma, Grade III stomach squamous cell carcinoma, 
Grade II and Grade III prostate adenocarcinoma of the peripheral duct and acini, Grade III 
breast invasive ductal carcinoma (NST), Grade III lung squamous cell carcinoma, kidney 
chromophobe renal cell carcinoma, kidney clear cell carcinoma, Grade II brain diffuse 
fibrillary astrocytoma, brain PCNSL and brain ependymoma while the expression of PBR 
mRNA decreased in Grade II and Grade III colonic adenocarcinoma, Grade III lung 
adenocarcinoma and lung small cell carcinoma. Similar patterns have been observed in 
previous studies for some cancers including hepatocellular carcinoma, colonic 
adenocarcinoma, breast invasive ductal carcinoma (NST), prostate adenocarcinoma, diffuse 
fibrillary astrocytoma and ependymoma (Allenfall, et al., 1995, Gavish, et al., 1999, 
Hardwick, et al., 2002, Miettinen, et al., 1995, Venturini, et al., 1998), however a previous 
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study conducted in renal clear cell carcinoma showed an absence of PBR binding sites, which 
appears contradictory to those obtained in this study (Katz, et al., 1989). It should be noted 
that they were looking at the PBR protein while this study focused on the PBR mRNA. To my 
knowledge it was the first time that stomach Grade III squamous cell carcinoma, lung Grade 
III adenocarcinoma, lung Grade III squamous cell carcinoma, lung small cell carcinoma, 
chromophobe renal carcinoma and brain PCNSL were studied.  
 
The level of PBR mRNA varies also with tumour malignancy grade. In hepatocellular 
carcinoma the level of PBR mRNA decreased as tumour invasion increased while in prostate 
adenocarcinoma of the peripheral duct and acini PBR mRNA level increased as tumour 
invasion increased. This suggests that PBR may serve as a prognostic marker in these 
diseases. A previous study has shown that the expression of PBR varies with tumour 
malignancy grade for hepatocellular carcinoma (Venturini, et al., 1998). In colon 
adenocarcinoma expression of PBR mRNA decreased from Grade I to Grade II and Grade III 
colonic adenocarcinoma. However, Grade III colonic adenocarcinoma had a higher PBR 
mRNA expression level than Grade II colonic adenocarcinoma. However, this is not the same 
as what was found in a previous study where the expression of PBR mRNA decreased as 
tumour malignancy increased (Maaser, et al., 2002). 
 
The level of expression of PBR mRNA varies for the different cancers, which was determined 
by comparing the different tissues. High expression levels were seen in epiploon Grade III 
squamous cell carcinoma, Grade II and Grade III prostate adenocarcinoma of the peripheral 
duct and acini, with Grade II showing a lower expression than Grade III, breast Grade III 
invasive ductal carcinoma (NST), lung Grade III squamous cell carcinoma, chromophobe 
renal cell carcinoma and renal clear cell carcinoma with chromophobe renal cell carcinoma 
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showing the highest expression level, intermediate expression levels were seen in Grade II 
hepatocellular carcinoma, Grade I and Grade III colon adenocarcinoma, lung Grade III 
adenocarcinoma, brain Grade II diffuse fibrillary astrocytoma and low expression levels were 
seen in Grade III hepatocellular carcinoma, Grade II colonic adenocarcinoma, lung small cell 
carcinoma, brain PCNSL and brain ependymoma with highest expression level seen in 
ependymoma and lowest expression level seen in PCNSL. 
 
The expression of PBR mRNA was clearly seen in all cancerous tissues studied. From the 
results obtained it is clear that the PBR mRNA is expressed mainly in the cytoplasm with 
some nuclear localisation also seen. The expression of PBR mRNA in the nucleus is thought 
to be essential in the regulation of cell proliferation and thus ultimately may function in the 
development and progression of the disease (Galiègue, et al., 2004). 
 
From this study, it can be concluded that the PBR may serve as a prognostic marker in cancer 
tissues where the expression level of PBR mRNA varies with tumour malignancy grade and 
that this receptor may play an important role in the development of cancer. It should be noted 
that this study provided specific results for the different cancer types and further studies will 
have to be done to determine generalized trends for the expression of PBR mRNA in the 
various types of cancers focused on in this study. This may be achieved by getting a higher 
number of patients for each type of cancer that is by using tissue microarrays having only one 
type of cancer. Also future studies should focus on looking at the different grades for a 
specific type of cancer, which will allow one to see if the expression of PBR mRNA is 
uniform as tumour malignancy increases. 
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4.2.3. Expression Levels of Peripheral Benzodiazepine Receptor mRNA in Human 
Normal and Various Cancer Cell Lines 
4.2.3.1.  Quantitative Real-Time Reverse-Transcriptase Polymerase Chain Reaction 
The relative expression levels of the PBR mRNA in normal lung and various human cancer 
cell lines were determined in absolute terms by quantitative real-time RT-PCR. Quantitative 
real-time RT-PCR is a technique used to rapidly measure the quantity of PCR product 
synthesised and thus indirectly functions in quantitatively determining the amounts of DNA, 
cDNA or RNA. The amount of RNA or more specifically mRNA used as the starting material 
correlates with the amount of protein that will be synthesised by the cell eventually. Thus, it is 
a commonly used molecular biology tool to determine quantification of gene expression 
levels in a particular cell or tissue as only minute amounts of sample is required. Very few to 
no studies have focused on determining the expression level of PBR mRNA in this manner. 
 
4.2.3.2.  Relative Expression Levels of the Peripheral Benzodiazepine Receptor mRNA in 
Normal and Various Cancer Cell Lines 
The normal cell line studied was the lung normal (MRC5) and cancers studied include lung 
adenocarcinoma (A549), cervical carcinoma (HeLa) and liver hepatocellular carcinoma 
(HepG). RNA was extracted from each of the confluent cell lines after which they were 
reverse transcribed using reverse transcriptase and oligo-(dT)15 primers to synthesise cDNA 
after which real-time PCR was performed using PBR-specific primers and SYBR Green 1. In 
order to determine the relative expression levels of the lung normal and cancers, the same 
concentration (216 ng/l) of each of the cDNA were used. Thus, any variation that occurred 
in the amount of PCR product synthesised would indicate the difference in expression levels 
for the normal cell line and each of the cancer cell lines and thus ultimately which cell line 
had the most starting product as each cell line was subjected to the same starting conditions. 
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4.2.3.2.1. Quantitative Real RT-PCR Versus Conventional PCR 
The use of quantitative real-time PCR offers several advantages including: (i) conventional 
PCR is measured at the end-point while real-time PCR is measured during the exponential 
growth phase, (ii) the increase in reporter fluorescence signal is directly proportional to the 
number of PCR products generated, (iii) the cleaved probe provides a permanent record of 
amplification of the PCR product, (iv) the increased dynamic range of detection, (v) the need 
for a thousand-fold less RNA than that is required in conventional PCR, (vi) no post-PCR 
processing due to its closed system, thus no need for electrophoresis, (vii) the PCR product is 
detected down to a two-fold change and (viii) small PCR products result in increase 
amplification efficiency. One major disadvantage of quantitative real-time PCR is because of 
its sensitivity; the introduction of any contaminants to the samples dramatically affects the 
final results. 
 
Conventional PCR requires the use of agarose gel electrophoresis in order to analyse results. 
The results analysed by agarose gel electrophoresis is measured at the end-point of the PCR 
reaction, based on size discrimination, which is not very precise and is time consuming. In 
addition, the resolution of the agarose gel is very poor at around ten-fold. Thus, the 
disadvantages of end-point detection include poor precision, low sensitivity, a short dynamic 
range of less than two logs, low resolution, non-automated processing, PCR products are 
discriminated by size only, results via ethidium bromide staining is not very quantitative and 
post-PCR processing. 
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4.2.3.2.2. Expression Levels of Peripheral Benzodiazepine Receptor mRNA 
Efficiency of the reactions should lie within 90% to 100%. However, in this study the 
efficiency was lower than this for three cell lines, which could have occurred as a result of 
secondary structure and primer quality. Thus, in order to increase this efficiency, primers 
more sensitive than the ones used should be designed.  
 
The most important value to determine the success of the reaction was to determine the Ct 
values for each of the reactions. The Ct value is the threshold cycle at which the system begins 
to detect the increase in signal associated with an exponential growth of the PCR products 
during the log-linear phase of PCR. Ct values should not lie higher than 40 because any value 
higher than this indicates that no amplification of PCR product occurs. In this study, all the Ct 
values lie below 40 with MRC5 having a lower Ct value when compared to A549, which 
indicates that MRC5 had a higher concentration of template PBR than A549. When the 
cancerous cell lines were compared to each other, it was found that the lowest Ct value was 
seen in HepG and the highest Ct value was seen in A549, which indicates that HepG had the 
highest concentration of template PBR and A549 had the lowest concentration of template 
PBR. 
 
The expression levels of PBR mRNA varied between lung adenocarcinoma and its normal 
counterpart and between the different cancer cell lines. It was found that the relative 
expression of PBR mRNA decreased half-fold in lung adenocarcinoma when compared to it 
normal counterpart seen by the decrease in concentration of template DNA for the two cell 
lines. The results serve to confirm the results via in situ hybridisation, which showed a 
decrease in PBR mRNA expression in Grade III lung adenocarcinoma when compared to its 
normal counterpart. In the case of the cancerous cell lines, the concentration of PBR mRNA 
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increases as follows: liver hepatocellular carcinoma > cervical carcinoma  lung 
adenocarcinoma, with liver hepatocellular carcinoma showing a half-fold increase compared 
to lung adenocarcinoma and cervical carcinoma and lung adenocarcinoma showing a similar 
expression level. 
 
This study shows preliminary results of expression levels in human normal and various cancer 
cell lines. In order to obtain much better efficiency future studies should focus on designing 
primers that are more sensitive and specific for the PBR mRNA. Future studies should also 
include a reference or standard gene such as glyceraldehydes-3-phospahte-dehydrogenase 
mRNA or -actin mRNA, which serves as an internal standard to which experimental 
variables may be compared to allow for a more efficient and accurate result to be obtained. In 
addition, future studies will have to focus on determining the changes in expression levels 
between various normal and cancerous cell lines. 
 
Expression of PBR mRNA in the different cancers suggests that PBR may play a role in 
cancer progression probably through the induction of cell proliferation. However, in the case 
of lung adenocarcinoma where a decrease in expression of PBR mRNA is seen, it could 
further play a role in suppressing apoptosis. 
 
4.2.4. In Situ Hybridisation Versus Quantitative Reverse Transcriptase Real-Time 
Polymerase Chain Reaction 
In situ hybridisation is the technique by which nucleic acids are fixed in situ instead of being 
extracted thus permitting the localisation of the hybridising probe within a cell or tissue 
(Harvey, 2002). It has the advantage of requiring only small amounts of tissues and tolerates 
the degradation of target nucleic acids due to formalin fixation (Biedermann, et al., 2004). 
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Disadvantages of this technique include: (i) maintaining the morphology and structure of the 
cells introduces more potentially inhibitory elements and thus in order to make the nucleic 
acids accessible for hybridisation, protease pre-treatment has to be performed, (ii) it cannot 
quantify mRNA or DNA in a prognostic-diagnostic significant manner and (iii) the chance of 
false-positives increases during RNA analysis because of the spliced nature and abundance of 
RNA (Biedermann, et al., 2004, Harvey, 2002). 
 
Real-time quantitative PCR is a timesaving high throughput analysis technique by which 
mRNA or DNA can be detected and quantified in a prognostic-diagnostic significant manner. 
This technique is more sensitive in detecting the sequence of interest than in situ 
hybridisation. Disadvantages of real-time PCR include: (i) the detection of false-positives due 
to unspecific signals and (ii) it is an expensive technique to conduct. The detection of false-
positives increases through the use of SYBR Green, which has the disadvantage of binding to 
double-stranded DNA of any sequence, thus making accurate product detection more 
difficult. Further, it is difficult to decipher specific peaks from unspecific peaks during 
melting curve analysis. Thus, the more accurate the probe is the better because it will 
overcome the problem of non-specificity and thus permit more accurate quantification 
(Biedermann, et al., 2004).  
 
4.3. Peripheral Benzodiazepine Receptor Protein Expression 
This study focused on the preliminary steps required to isolate the PBR protein.  PBR protein 
isolation involves a number of steps including, (i) cloning, where the protein sequence of 
interest (PBR) is ligated into an expression vector such as pGEX-6P-2, which contains a lac 
repressor gene and a GST gene that functions as an affinity tag when transformed into 
Escherichia coli cells, (ii) bacterial colonies containing the expression vector are selected and 
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grown, (iii) Escherichia coli cells are induced by IPTG in the case of pGEX-6P-2 to express 
the recombinant protein and harvested, (iv) the recombinant protein is purified using 
gluthathione in the case of GST via affinity chromatography and (v) digestion with a 
proteases such as PreScissionTM protease in the case of GST allows for the isolation of the 
protein of interest. 
 
The PBR protein was isolated via the expression of recombinant proteins in Escherichia coli 
(in this case GST fused to the PBR protein (GST-PBR)), which enables the production of 
large amounts of proteins from relatively small amounts of biomass and later simplifies its 
purification and detailed characterisation. Producing recombinant proteins is advantageous 
because purifying protein from native sources requires large amounts of starting material to 
yield small amounts of protein. Furthermore, the purifying step for non-recombinant proteins 
is a multi-step process where at each step a proportion of the target protein is lost. However, 
in the case of recombinant proteins, a standardised affinity chromatography procedure (in this 
case GST-PBR can be purified and isolated in the presence of gluthathione) is only required 
in order to purify the protein obtained at a high level of purity eliminating the need to develop 
a protein-specific purification procedure for each new target protein. 
 
The efficient and controlled expression of the GST-PBR in Escherichia coli cells is regulated 
by the presence of the lac repressor protein. The lac repressor protein binds to the operator 
sequences on the pGEX-6P-2 expression vector during normal cell growth and prevents GST-
PBR expression. However, when the Escherichia coli cells are treated with IPTG, it induces 
GST-PBR expression as it binds to the lac repressor protein and inactivates it, thus allowing 
the host cell’ s RNA polymerase to transcribe the sequences downstream from the promoter, 
which are then translated to form the recombinant protein. This tightly controlled expression 
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of recombinant protein is advantageous as it allows for the almost exclusive production of the 
recombinant protein and proteins that may have adverse effects on the growing cells are not 
expressed. 
 
This study only showed preliminary expression of the GST-PBR protein in small 
concentrations. Thus, future study requires the expression of the GST-PBR protein with an 
optimal concentration of IPTG in order to generate a large concentration of the protein after 
which it can be purified and treated with PreScissionTM Protease to isolate the PBR protein. 
The isolation of the PBR protein will allow for antibodies to be raised, which can be used in 
future studies that will determine the expression pattern of the PBR protein in different types 
of human normal and cancerous tissues. 
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5. CONCLUSION 
 
Localisation of PBR mRNA was determined by in situ hybridisation. It was found that PBR 
mRNA is expressed in both normal and cancerous human tissues studied. Subcellularly, it 
was found that PBR mRNA was expressed in the cytoplasm of most cells, however, nuclear 
localisation have been seen in some cells. Cytoplasmic localisation is conclusive of what 
previous studies have suggested that PBR is located mainly on the outer mitochondrial 
membrane and that the PBR protein is synthesised in the ribosomes that are also located in the 
cytoplasm. The nuclear localisation of PBR is thought to function in the transport of 
cholesterol into the nucleus it affects genes involved in the cell cycle and in promoting 
aberrant mitogenic activity and thus malignancy. Thus, expression of PBR mRNA in the 
nucleus is thought to be essential in the regulation of cell proliferation and thus ultimately 
may function in the development and progression of the disease. 
 
PBR mRNA expression determined by in situ hybridisation showed that the expression levels 
vary between the normal and the cancerous state, with an increase expression of PBR mRNA 
seen in most cases. Increase levels of PBR mRNA were seen in Grade II and Grade III liver 
hepatocellular carcinoma, Grade I colonic adenocarcinoma, Grade III stomach squamous cell 
carcinoma, Grade II and Grade III prostate adenocarcinoma of the peripheral duct and acini, 
Grade III breast invasive ductal carcinoma (NST), Grade III lung squamous cell carcinoma, 
kidney chromophobe renal cell carcinoma, kidney clear cell carcinoma, Grade II brain diffuse 
fibrillary astrocytoma, brain primary central nervous system lymphoma and brain 
ependymoma while the expression of PBR mRNA decreased in Grade II and Grade III 
colonic adenocarcinoma, Grade III lung adenocarcinoma and lung small cell carcinoma. 
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The level of PBR mRNA varies also with tumour malignancy grade. In hepatocellular 
carcinoma the level of PBR mRNA decreased as tumour invasion increased while in prostate 
adenocarcinoma of the peripheral duct and acini PBR mRNA level increased as tumour 
invasion increased. This suggests that PBR may serve as a prognostic marker in these 
diseases. In colon adenocarcinoma expression of PBR mRNA decreased from Grade I to 
Grade II and Grade III colonic adenocarcinoma. However, Grade III colonic adenocarcinoma 
had a higher PBR mRNA expression level than Grade II colonic adenocarcinoma.  
 
In situ hybridisation studies showed that the level of expression of PBR mRNA varies for the 
different cancers. High expression levels were seen in epiploon Grade III squamous cell 
carcinoma, Grade II and Grade III prostate adenocarcinoma of the peripheral duct and acini, 
with Grade II showing a lower expression than Grade III, breast Grade III invasive ductal 
carcinoma (NST), lung Grade III squamous cell carcinoma, chromophobe renal cell 
carcinoma and renal clear cell carcinoma with chromophobe renal cell carcinoma showing the 
highest expression level, intermediate expression levels were seen in Grade II hepatocellular 
carcinoma, Grade I and Grade III colon adenocarcinoma, lung Grade III adenocarcinoma, 
brain Grade II diffuse fibrillary astrocytoma and low expression levels were seen in Grade III 
hepatocellular carcinoma, Grade II colonic adenocarcinoma, lung small cell carcinoma,  brain 
PCNSL and brain ependymoma with highest expression level seen in ependymoma and 
lowest expression level seen in PCNSL. 
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In situ hybridisation studies showed that the level of expression of PBR mRNA varies for the 
different normal tissues. High expression levels of PBR mRNA were seen in epiploon, 
prostate, breast and lung, intermediate expression levels were seen in colon and stomach and 
low expression levels were seen in liver, kidney and brain with white matter showing a higher 
level of expression than grey matter. 
 
Relative quantitative real-time PCR was done to determine the expression levels of PBR 
mRNA in human normal and various cancer cell lines. The expression levels of PBR mRNA 
varied between lung adenocarcinoma and its normal counterpart and between the different 
cancer cell lines. It was found that the relative expression of PBR mRNA decreased one-fold 
in lung adenocarcinoma when compared to it normal counterpart seen by the decrease in 
concentration of template DNA for the two cell lines. In the case of the cancerous cell lines, 
the concentration of PBR mRNA increases as follows: liver hepatocellular carcinoma > 
cervical carcinoma  lung adenocarcinoma, with liver hepatocellular carcinoma showing a 
half-fold increase compared to lung adenocarcinoma and cervical carcinoma and lung 
adenocarcinoma showing a similar expression level. 
 
The steps involving the isolation of the PBR protein was only obtained in the preliminary 
stages, that is only small concentrations of the GST-PBR protein was isolated using various 
concentrations of IPTG. Thus, future studies requires the expression of the GST-PBR protein 
with an optimal concentration of IPTG in order to generate a large concentration of the GST-
PBR protein after which it can be purified and treated with PreScissionTM Protease to isolate 
the PBR protein. The isolation of the PBR protein will allow for antibodies to be raised, 
which can be used in future studies that will determine the expression pattern of the PBR 
protein in different types of human normal and cancerous tissues. 
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Determination of the PBR mRNA expression in many cancer tissues is still in the preliminary 
stages and further studies will have to be done to determine and confirm its expression. 
However, from previous studies and this one, it is clear that PBR may play a role in cancer 
progression, serves as a biochemical marker or prognostic factor in the development of cancer 
and correlates with tumour malignancy. Determining the role of PBR in cancer may lead to 
the discovery of new therapies for the treatment of cancer. 
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